Oral Communications
Platelet Signaling I 8:00–9:30 Room C-1
Chairpersons: Bernhard Nieswandt (DE) and Mauro Torti (IT)
DISCOVERY OF A NEW SIGNALING COMPLEX BASED ON SPINOPHILIN THAT REGULATES PLATELET ACTIVATION IN VITRO AND IN VIVO O-MO-001
Peisong Ma, Aleksandra Cierniewska, Rachel Signarvic, Andrew Sinnamon, Marcin Cieslak, Timothy Stalker, Richard Neubig, Lawrence Brass
CLP36 IS A NEGATIVE REGULATOR OF GPVI SIGNALING IN PLATELETS O-MO-002
Shuchi Gupta, Attila Braun, Martina Morowski, Zoltan Nagy, Bernhard Nieswandt
SEVERE GPVI DEFICIENCY AND MACROTHROMBOCYTOPENIA IN MICE LACKING G6B-B O-MO-003
Ying-Jie Wang, Alexandra Mazharian, Jun Mori, Danai Bem, Brenda Finney, Silke Heising, Paul Gissen, Michael Douglas, James G. White, Neel G. Benjamin, R. Duncan Campbell, Steve P. Watson, Yotis A. Senis
THE PLATELET SURFACE THIOL ISOMERASE ERP57 IS REQUIRED FOR PLATELET FUNCTION O-MO-004
Ronald Geoffrey Stanley, Lisa-Marie Holbrook, Parvathy Sasikumar, Jonathan Gibbins
ELUCIDATING THE ROLE OF THE INTRINSIC APOPTOSIS PATHWAY IN PLATELET FUNCTION O-MO-005
Emma Charlotte Josefsson, Michael J. White, Simone M. Schoenwaelder, Kate Jarman, Katya J. Henley, Rachael M. Lane, Shaun P. Jackson, Benjamin T. Kile
PAR1, PAR4 AND GPIB FORM FUNCTIONAL INTERDEPENDENT UNITS IN A RECEPTOR COMPLEX MEDIATING PLATELET ACTIVATION BY THROMBIN O-MO-006
Lars Faxalv, Niklas Boknas, Tomas L. Lindahl
Fibrinolysis 8:00–9:30 Room C-2
Chairpersons: Paul J. Declerck (BE) and Koji Yamamoto (JP)
RED BLOOD CELLS CONFER LYTIC RESISTANCE TO FIBRIN O-MO-007
Nikolett Wohner, Laszlo Szabo, Raymund Machovich, Marta Silva, Colin Longstaff, Krasimir Kolev
THE INVOLVEMENT OF FACTOR XIII IN THE IMPAIRED FIBRINOLYSIS OF PATIENTS WITH FACTOR V LEIDEN MUTATION O-MO-008
Zsuzsa Bagoly, Zsuzsa Koncz, Zoltan Andras Mezei, Zsolt Olah, Robert A.S. Ariens, Laszlo Muszbek
FIBRIN CLOTS CONTAIN FUNCTIONALLY ACTIVE ALPHA-1-ANTITRYPSIN O-MO-009
Dick C. Rijken, Simone Talens, Joyce J.M.C. Malfliet, Frank W.G. Leebeek
DNA STABILISES FIBRIN CLOTS AND MODULATES THE ACTIVITY OF STREPTOKINASE O-MO-010
Colin Longstaff, Craig Thelwell
ALTERATIONS OF COAGULATION AND FIBRINOLYSIS IN PATIENTS WITH ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY: THE INVOLVEMENT OF THROMBOMODULIN O-MO-011
Mark van Geffen, Massimo Cugno, Paul Lap, Arnoud Loof, Marco Cicardi, Waander van Heerde
A NEW APPROACH FOR MEASUREMENT OF MP-ASSOCIATED PLASMIN GENERATION O-MO-012
Romaric Lacroix, Philippe Poncelet, Tarik Bouriche, Coralie Judicone, Karim Harti Souab, Sebastien Bordon, Genevieve Contant, Florence Sabatier, Jose Sampol, Eduardo Angles-Cano, Francoise Dignat-George
Protein S and GAS6 8:00–9:30 Room D
Chairpersons: Bjorn Dahlback (SE) and Tatsuya Hayashi (JP)
HDL FRESHLY ISOLATED BY ULTRACENTRIFUGATION FROM PLASMA IS A COFACTOR FOR ACTIVATED PROTEIN C(APC)/PROTEIN S ANTICOAGULANT ACTIVITY: CONTROVERSY AND REEVALUATION O-MO-013
John H. Griffin, Jose A. Fernandez, Natalie Pecheniuk, Subramanian Yegneswaran, Carole L. Banka, Hiroshi Deguchi
ACTIVATED PROTEIN S COFACTOR FUNCTION OF PROTEIN S: A NOVEL FUNCTION FOR A γ-CARBOXYGLUTAMIC ACID RESIDUE O-MO-014
Josefin Ahnstrom, Helena M. Andersson, Kevin Canis, Eva Norstrom, Yao Yu, Bjorn Dahlback, Maria Panico, Howard R. Morris, James TB Crawley, David A. Lane
GROWTH ARREST-SPECIFIC GENE 6 (GAS6) AS AN INTRA-HOSPITAL MORTALITY PREDICTOR FOR PATIENTS IN SEPTIC SHOCK O-MO-015
Gregoire Stalder, Christophe Kosinski, Frederik Delodder, Beatrice Ternon, Thierry Roger, Thierry Calandra, Michel A. Duchosal, Philippe Eggimann, Anne Angelillo-Scherrer, Lausanne The Lausanne Sepsis Study Group
COMPOUND HETEROZYGOUS PROTEIN S DEFICIENCY IN A HEALTHY WOMAN O-MO-016
Carolina Pintao, Kristien Winckers, Herm-Jan M. Brinkman, Elisabetta Castoldi, Tilman M. Hackeng, Pieter H. Reitsma
DOWNREGULATION OF PROTEIN S BY MICRO-RIBONUCLEIC ACID 494 (MIR-494) O-MO-017
Giuliana Romeo, Quintin Hughes, Ross Baker
PHOSPHORYLATION OF PROTEIN S (PS) BY PLATELET KINASES ENHANCES ITS DIRECT ANTICOAGULANT ACTIVITY O-MO-018
Fabian Stavenuiter, Mary-Jo Heeb
Antiplatelet Therapy 8:00–9:30 Room E
Chairpersons: Tsukasa Ohmori (JP) and Christopher Morice Ward (AU)
DEVELOPMENT OF REFERENCE METHODS FOR EVALUATING THE EFFECT OF ASPIRIN AND FOR COMPARISON WITH ROUTINELY USED METHODS; THE LACK OF ASPIRIN RESISTANCE IN HEALTHY VOLUNTEERS O-MO-019
Eva Katona, Emese Gyongyver Kovacs, Zsuzsanna Bereczky, Laszlo Balogh, Nora Homorodi, Gizella Haramura, Eszter Toth, Judit Csapo, Istvan Edes, Laszlo Muszbek
PLATELET REACTIVITY AND RECURRENT CARDIOVASCULAR EVENTS IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE USING ASPIRIN: A HEAD-TO-HEAD COMPARISON OF DIFFERENT TESTS O-MO-020
Jaapjan D. Snoep, Jeroen CJ Eikenboom, Jaap Jan Zwaginga, Mark Roest, Carlo Patrono, Bianca Rocca, Giovanna Petrucci, Frits R. Rosendaal, Johanna G. van der Bom
ACETYLSALICYLIC ACID INHIBITS THROMBOXANE A2 PRODUCTION AND THROMBOXANE A2-DEPENDENT PLATELET FUNCTION EQUALLY WELL IN DIABETIC AND NON-DIABETIC SUBJECTS O-MO-021
Marco Cattaneo, Eti Alessandra Femia, Mariateresa Pugliano, Gian Marco Podda, Klodiana Dosti, Cristina Razzari
HIGH ON-TREATMENT PLATELET REACTIVITY BY VARIOUS PLATELET FUNCTION TESTS: IS THE CURRENTLY REPORTED VASP PRI CUTOFF TOO LOW? O-MO-022
Paul Alfred Gurbel, Jeong Young-Hoon, Kevin P. Bliden, Mark J. Antonino, Udaya S. Tantry
EV-077-3201-2TBS, A TP ANTAGONIST AND TS INHIBITOR, REDUCES PLATELET AGGREGATION IN WHOLE BLOOD OF TYPE 2 DIABETICS WITH CORONARY ARTERY DISEASE ON CHRONIC ASPIRIN THERAPY O-MO-023
Kjell S. Sakariassen, E. Femia, R.P. Rothlin, G.-M. Podda, C. Razzari, M.-T. Pugliano, F.M. Daray, A.E. Errasti, A.R. Armesto, W. Novak, P. Alberts, R. Hermosilla, J.-P. Meyer, M. Cattaneo, A. Santana Sorensen
ARC15105 A POTENT ANTAGONIST OF VON WILLEBRAND FACTOR (VWF) PLATELET ACTIVATION AND ADHESION O-MO-024
Jolanta M. Siller-Matula, Yahye Merhi, Jean-Francois Tanguay, Daniel Duerschmied, Kathleen E. McGinness, Shannon P. Pendergrast, Denisa D. Wagner, Robert G. Schaub, Bernd Jilma
Inherited Coagulation Disorders 8:00–9:30 Sakura
Chairpersons: Kathelijn Fischer (NL) and Eriko Morishita (JP)
A ZEBRAFISH MODEL FOR HUMAN FIBRINOGEN DISORDERS O-MO-025
Richard J. Fish, Silja Vorjohann, Alexandre Fort, Corinne DiSanza, Franck Bontems, Frederique Bena, Roland Dosch, Marguerite Neerman-Arbez
THE FVII R402X NONSENSE MUTATION, ASSOCIATED WITH AN ASYMPTOMATIC PHENOTYPE, IS RESPONSIBLE FOR SMALL AMOUNTS OF CIRCULATING PROTEIN WITH IMPROVED COAGULANT ACTIVITY O-MO-026
Alessio Branchini, Lara Rizzotto, Alessandro Canella, Rosella Mari, Mario Lapecorella, Marisanta Napolitano, Guglielmo Mariani, Mirko Pinotti, Francesco Bernardi
“COMPENSATORY” ABERRANT SPLICING SUPPORTS RESIDUAL EXPRESSION LEVELS IN SEVERE COAGULATION FACTOR VII DEFICIENCY O-MO-027
Nicola Cavallari, Dario Balestra, Lara Rizzotto, Alessio Branchini, Iva Maestri, Ampaiwan Chuansumrit, Werasak Sasanakul, Guglielmo Mariani, Franco Pagani, Francesco Bernardi, Mirko Pinotti
EFFICACY OF PROPHYLAXIS AND GENOTYPE-PHENOTYPE CORRELATION IN PATIENTS WITH SEVERE FACTOR X DEFICIENCY IN IRAN O-MO-028
Mehran Karimi, Armaghan Vafafar, Sezaneh Haghpanah, Mehrdad Payandeh, Peyman Eshghi, Hamid Hoofar, Abdolreza Afrasiabi, Javad Gerdabi, Rezvan Ardeshiri, Marzia Menegatti, Flora Peyvandi
A RECURRENT P.GLY43ASP SUBSTITUTION OF COAGULATION FACTOR X (FX) IMPAIRS INTRACELLULAR TRAFFICKING AND FUNCTIONAL ACTIVITY CAUSING A SEVERE FX DEFICIENCY IN FOUR PATIENTS O-MO-029
Marzia Menegatti, Roberta Palla, Mehran Karimi, Rossella Bader, Raimondo De Cristofaro, Flora Peyvandi
PHENOTYPE-GENOTYPE CORRELATION OF 181 PATIENTS WITH HEREDITARY COAGULATION FACTOR XIII DEFICIENCY O-MO-030
Vytautas Ivaskevicius, Arijit Biswas, Anne Thomas, Rainer Seitz, Seifried Erhard, Johannes Oldenburg
Late Breaking Clinical Trials 8:00–9:45 Room A
Chairpersons: Kenneth Alan Bauer (US) and Takenori Yamaguchi (JP)
APIXABAN FOR PREVENTION OF ACUTE ISCHEMIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROMES O-MO-031
Stefan Karl James, John H. Alexander, Puneet Mohan, Lars Wallentin, Robert A. Harrington
J-ROCKET AF: THE SAFETY AND EFFICACY OF RIVAROXABAN FOR PREVENTION OF STROKE IN JAPANESE PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION O-MO-032
Masatsugu Hori, Masayasu Matsumoto, Norio Tanahashi, Shin-ichi Momomura, Shinichiro Uchiyama, Shinya Goto, Tohru Izumi, Yukihiro Koretsune, on behalf of the J-ROCKET AF Study Investigators
IDRABIOTAPARINUX FOR ACUTE SYMPTOMATIC PULMONARY EMBOLISM O-MO-033
Harry R. Buller, Alex S. Gallus, Gerard Pillion, Martin H. Prins, Gary E. Raskob
RIVAROXABAN VERSUS ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS: MAGELLAN SUBGROUP ANALYSES O-MO-034
Alexander Thomas Cohen, Theodore Erich Spiro, Harry Roger Buller, Lloyd Haskell, Dayi Hu, Russell Hull, Alexandre Mebazaa, Geno Merli, Sebastian Schellong, Alex Spyropoulos, Victor Tapson
TREATMENT-RELATED RISK FACTORS OF INHIBITOR DEVELOPMENT IN PATIENTS WITH SEVERE HEMOPHILIA A: THE RODIN STUDY O-MO-035
Samantha C. Gouw, H. Marijke van den Berg, Johanna G. van der Bom, On behalf of the PedNet Study group, and the RODIN Study Group
THE IMPACT OF LOW-MOLECULAR-WEIGHT HEPARIN PROPHYLAXIS ON MORTALITY IN ACUTELY ILL MEDICAL PATIENTS: THE LIFENOX STUDY O-MO-036
Ajay Kakkar, Claudio Cimminiello, Samuel Z. Goldhaber, Rajiv Parakh, Chen Wang, Jean-Francois Bergmann, on behalf of the LIFENOX Investigators
DABIGATRAN VERSUS PLACEBO FOR EXTENDED MAINTENANCE THERAPY OF VENOUS THROMBOEMBOLISM O-MO-037
Sam Schulman, D. Baanstra, H. Eriksson, S. Goldhaber, A. Kakkar, C. Kearon, P. Mismetti, S. Schellong, J. Schnee, the RE-SONATE Study Group
VTE: Risk Factors I 8:00–9:30 Room B-1
Chairpersons: Masataka Ikeda (JP) and Richard H. White (US)
THE OPTIMAL DURATION OF ANTICOAGULANT THERAPY IN PATIENTS WITH CANCER-RELATED DEEP VEIN THROMBOSIS: THE ADVANTAGE OF USING RESIDUAL VEIN THROMBOSIS (THE CANCER-DACUS STUDY) O-MO-038
Alessandra Malato, Sergio Siragusa
MELISSE, A LARGE MULTICENTRIC OBSERVATIONAL STUDY TO DETERMINE RISK FACTORS OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IMMUNOMODULATOR DRUGS O-MO-039
Xavier Leleu, L. Daley, P. Rodon, C. Hulin, C. Dauriac, M. Hacini, O. Decaux, JC Eisemann, O. Fitoussi, B. Lioure, L. Voillat, B. Slama, A. Al Jijakli, C. Chaleteix, R. Costello, A. Lamblin, P. Natta, JP Fermand, P. Moreau
A SIMPLE NON-INVASIVE DIAGNOSTIC ALGORITHM FOR RULING OUT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION IN PATIENTS AFTER ACUTE PULMONARY EMBOLISM O-MO-040
Frederikus A. Klok, Sulaiman Surie, Tibor Kempf, Jeroen Eikenboom, Jan van Stralen, Klaas van Kralingen, Arie van Dijk, Hubert Vliegen, Paul Bresser, Kai Wollert, Menno Huisman
INSULIN RESISTANCE AND RISK OF VENOUS THROMBOEMBOLISM O-MO-041
Inge M. van Schouwenburg, Bakhtawar K. Mahmoodi, Nic JGM Veeger, Karina Meijer, Stephan JL Bakker, Hanneke C. Kluin-Nelemans, Ron T. Gansevoort
IMPACT OF DIETARY PATTERNS ON THE RISK OF MYOCARDIAL INFARCTION AND VENOUS THROMBOEMBOLISM. THE TROMSO STUDY 1994-2005 O-MO-042
Ida Johanne Hansen-Krone, John-Bjarne Hansen, Kristin Enga, Sigrid Braekkan
INCIDENCE AND RISK FACTORS FOR POST-DISCHARGE VTE AMONG MEDICALLY ILL PATIENTS HOSPITALIZED IN THE UNITED STATES: 2005-2009 O-MO-043
Alex C. Spyropoulos, Maxine Fisher, Charles Mahan, Larry E. Fields, Roger Mills, Judith J. Stephenson, Tom Wasser, An-Chen Fu, Winslow Klaskala
Thrombotic Thrombocytopenic Purpura 8:00–9:30 Room B-2
Chairpersons: Karl Desch (US) and Masanori Matsumoto (JP)
STRAIN-SPECIFIC MODIFIER GENE(S) FOR THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) SUSCEPTIBILITY IN THE MOUSE O-MO-044
Yosef Y. Kalish, David Siemieniak, Karl Desch, David Ginsburg
SPLEEN-DERIVED ANTI-ADAMTS13 B-CELLS IN RELAPSING TTP PATIENTS USE THE SAME RESTRICTED GENES BUT DIFFERENT IGG SUBCLASS DISTRIBUTION WHEN TREATED WITH OR WITHOUT RITUXIMAB O-MO-045
Monica Maria Schaller, Karin Sprecher, Irmela Sulzer, Monique Vogel, Beda Stadler, Kent Kentouche, Bernhard Laemmle, Johanna Anna Kremer Hovinga
PRECLINICAL EFFICACY TESTING OF BAXTER’S RECOMBINANT ADAMTS13 IN A MOUSE MODEL OF TTP O-MO-046
Alexandra Schiviz, John Philip Lawo, Kuno Wuersch, Hartmut Ehrlich, Friedrich Scheiflinger, Hans-Peter Schwarz, Werner Hoellriegl, Eva-Maria Muchitsch
AAV LIVER-SPECIFIC EXPRESSION OF A C-TERMINAL TRUNCATED ADAMTS13 VARIANT CORRECTS THROMBOTIC THROMBOCYTOPENIC PURPURA IN A MURINE MODEL O-MO-047
Sheng-Yu Jin, Juan (Jenny) Xiao, Fraser J. Wright, X. Long Zheng
RESIDUAL PLASMATIC ACTIVITY OF ADAMTS13 IN CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA AND ITS CORRELATION WITH DISEASE PHENOTYPE O-MO-048
Luca A. Lotta, Haifeng M. Wu, Ian J. Mackie, Marina Noris, Agnes Veyradier, Samuel J. Machin, Giuseppe Remuzzi, Paul Coppo, Marie A. Scully, Roberta Donadelli, Chantal Loirat, Richard A. Gibbs, April Horne, Shangbin Yang, Roberta Palla, Flora Peyvandi
PLASMA MODIFIERS OF VWF CLEAVAGE BY ADAMTS13 O-MO-049
Han-Mou Tsai, Wenhua Zhou
Inflammatory Cells and Cytokines 13:30–15:00 Room C-1
Chairpersons: Satoshi Fujii (JP) and David George Motto (US)
SURFACE PROTEIN DISULFIDE ISOMERASE PLAYS AN IMPORTANT ROLE IN BETA2 INTEGRIN-MEDIATED NEUTROPHIL ADHESION TO THE ACTIVATED ENDOTHELIUM UNDER VASCULAR INFLAMMATION O-MO-050
Jaehyung Cho, Eunsil Hahm, Stella Huh, Melissa Geyer, Snezna Rogelj
COMPLEMENT MBL-ASSOCIATED SERINE PROTEASE-1 (MASP-1) INTERACTS WITH PLASMA CLOT FORMATION - A NOVEL LINK BETWEEN INFLAMMATION AND THROMBOSIS? O-MO-051
Verena Schroeder, Katharina Hess, Jozsef Dobo, Peter Gal, Ramzi Ajjan
PLATELETS REGULATE CD4+ T CELL DIFFERENTIATION VIA MULTIPLE CHEMOKINES O-MO-052
Linjing Zhu, Norbert Gerdes, Maria Ersoy, Andreas Hermansson, Maud Daleskog, Ragnhild Stalesen, Paul Hjemdahl, Hu Hu, Goran Hansson, Nailin Li
PLASMIN AND CPB CLEAVAGE OF CHEMERIN IS NECESSARY FOR ACTIVATION TO THE ACTIVE FORM, CHEM157S, THAT FUNCTIONS AS A SIGNALING MOLECULE IN GLIOBLASTOMA O-MO-053
Yasuto Yamaguchi, Xiao-yan Du, Zhao Lei, John Morser, Lawrence L.K. Leung
LACK OF P2X1 ION CHANNELS INCREASES ENDOTOXEMIA-ASSOCIATED COAGULATION AND ORGAN DAMAGE THROUGH NEUTROPHIL HYPERRESPONSIVENESS O-MO-054
Christelle Lecut, Celine Faccinetto, Richard J. Evans, Vincent Bours, Cecile Oury
Structures of Coagulation Factors 13:30–15:00 Room C-2
Chairpersons: James Andrew Huntington (UK) and Weikai Li (US)
STRUCTURAL CHARACTERIZATION OF THE THROMBIN ACTIVATION OF COAGULATION FACTOR VIII STUDIED BY HYDROGEN-DEUTERIUM EXCHANGE MASS SPECTROMETRY O-MO-056
Johan Henrik Faber, Anders Svensson, Mette Dahl Andersen, Ole Hvilsted Olsen, Henning Stennicke
PEPTIDES BINDING TO KUNITZ DOMAIN 1 OF TISSUE FACTOR PATHWAY INHIBITOR INHIBIT THE INTERACTION WITH FACTOR XA O-MO-057
Michael Dockal, M. Fries, J. Brandstetter, M. Ludwiczek, G. Kontaxis, K. Prohaska, A. Hofbauer, W. Kammlander, R. Hartmann, H. Ehrlich, Fritz Scheiflinger
THROMBIN ALLOSTERY: EFFECT OF EXOSITE-1 AND EXOSITE-2 BINDERS ON THE ENZYME MOLECULAR RECOGNITION AND CATALYSIS O-MO-058
Vincenzo De Filippis, Nicola Pozzi, Roberta Frasson, Laura Acquasaliente, Davide Zaramella
A DYNAMICAL, ATOMIC-DETAILED VIEW OF COMPLEX FORMATION BETWEEN FACTOR VIIA, TISSUE FACTOR, AND FACTOR X ON THE SURFACE OF THE MEMBRANE O-MO-059
Y. Zenmei Ohkubo, Emad Tajkhorshid
RESIDUES 1967-1968 AT THE A1-A2-A3 DOMAIN INTERFACE ARE PART OF A FUNCTIONAL REGION THAT EXPOSES UPON ACTIVATION OF FACTOR VIII O-MO-060
Esther Bloem, Henriet Meems, Maartje van den Biggelaar, Carmen van der Zwaan, Koen Mertens, Alexander B. Meijer
IDENTIFICATION OF THE FACTOR XII SEQUENCE THAT MEDIATES CONTACT ACTIVATION IN VITRO AND IN VIVO O-MO-061
Felicitas E. Mueller, Daniela Urlaub, Christoph Kleinschnitz, Thomas Renne
Pathway of Coagulation Factor VIII 13:30–15:00 Room D
Chairpersons: Kagehiro Amano (JP) and Peter Collins (UK)
PROLONGED OSCILLATORY SHEAR STRESS INDUCES FVIII EXPRESSION IN ENDOTHELIAL PROGENITOR CELLS O-MO-062
Jonathan Jacob Riches, Barbara Vidal, Christine Brown, Colleen Notley, Christine Hough, David Lillicrap
INCREASED FACTOR VIII LEVELS IN PATIENTS TREATED FOR VENOUS THROMBOSIS O-MO-063
Vladimir Tichelaar, Andre B. Mulder, Hanneke C. Kluin-Nelemans, Karina Meijer
C1 DOMAIN RESIDUES LYS 2092 AND PHE 2093 ARE OF MAJOR IMPORTANCE FOR THE ENDOCYTIC UPTAKE OF COAGULATION FACTOR VIII O-MO-064
Alexander B. Meijer, Henriet Meems, Maartje van den Biggelaar, Mariska Rondaij, Carmen van der Zwaan, Koen Mertens
THE ROLE OF PROTEOLYSIS AT INDIVIDUAL CLEAVAGE SITES IN THE EXPRESSION OF FVIIIA COFACTOR ACTIVITY O-MO-065
Mettine H.A. Bos, Lacramioara Ivanciu, Raffaella Toso, Hua Zhu, Rodney M. Camire
MUTATION OF ALA108ILE IN THE FACTOR VIII A1 DOMAIN ENHANCES AFFINITY FOR LIGHT CHAIN VIA INTERACTION WITH THE C2 DOMAIN AND CONTRIBUTES TO INCREASED FACTOR VIII STABILITY O-MO-066
Hironao Wakabayashi, Amy E. Griffiths, Masahiro Takeyama, Philip J. Fay
THE GAP JUNCTION PROTEIN CONNEXIN37 REGULATES FVIII PLASMATIC ACTIVITY O-MO-067
Laurent Burnier, Pierre Fontana, Brenda R. Kwak, Anne Angelillo-Scherrer
Megakaryopoiesis and Platelet Production 13:30–15:00 Room E
Chairpersons: Benjamin Kile (AU) and Mortimer Poncz (US)
REGULATOR OF G PROTEIN SIGNALING 18 REGULATES MEGAKARYOPOIESIS AND THE CILIA-MEDIATED VERTEBRATE MECHANOSENSORY SYSTEM O-MO-068
Kathleen - Freson, Sophie Louwette, Chantal Thys, Chantal Wittevrongel, Veerle Labarque, Rik Gijsbers, Zeger Debyser, Jef Arnout, Chris Van Geet
EXPRESSION AND FUNCTION OF LINE-1 DURING MEGAKARYOPOIESIS AND ITS ROLE IN HUMAN PLATELET PROGENY FORMATION O-MO-069
Hansjorg Schwertz, Larry W. Kraiss, Andrew S. Weyrich
SEVERE MACROTHROMBOCYTOPENIA AND ABNORMAL MEGAKARYOCYTE DEVELOPMENT IN MICE LACKING SHP1 AND SHP2 O-MO-070
Alexandra Mazharian, Ying-Jie Wang, Jun Mori, Silke Heising, Benjamin G. Neel, Steve P. Watson, Yotis A. Senis
SILENCING OF RHOA NUCLEOTIDE EXCHANGE FACTOR, ARHGEF3, REVEALS ITS ROLE IN THROMBOPOIESIS AND IRON UPTAKE O-MO-071
Kathleen Freson, Jovana Serbanovic-Canic, Ana Cvejic, Nicole Soranzo, Derek Stemple, Willem Ouwehand
GENETIC TARGETING IN MICE REVEALS THE IMPORTANCE OF RHOA FOR PLATELET FUNCTION IN VITRO AND IN VIVO O-MO-072
Irina Pleines, Ina Hagedorn, Shuchi Gupta, Frauke May, Lidija Chakarova, Jolanda van Hengel, Georg Krohne, Cord Brakebusch, Bernhard Nieswandt
REDUNDANT FUNCTIONS OF RHOA AND CDC42 IN PLATELET BIOGENESIS AND ACTIVATION O-MO-073
Lidija Chakarova, Irina Pleines, Johanna Andersson, Xunwei Wu, Jolanda van Hengel, Georg Krohne, Cord Brakebusch, Bernhard Nieswandt
Hemophilia: Clinical Aspects 13:30–15:00 Sakura
Chairpersons: Amy D. Shapiro (US) and Renchi Yang (CN)
IS THERE A NEED FOR A NEW STRATEGY IN GENOTYPING HAEMOPHILIA A FAMILIES? O-MO-074
Shirin Ravanbod, Maryam Rassoulzadegan, Farzaneh Nassirinejad, Ghasem Rastegar Lari, Said Enayat, Fereydoun Ala
XQ28 LARGE DELETIONS DETECTED BY OLIGONUCLEOTIDE ARRAY CGH IN PATIENTS WITH HAEMOPHILIA B AND MENTAL RETARDATION O-MO-075
Christine Vinciguerra, Marie-Laure Carage, Audrey Labalme, Dorothee Pellecchia, Mathilde Fretigny, Christophe Zawadzki, Claude Negrier, Damien Sanlaville
OUTCOME IN MODERATE HAEMOPHILIA O-MO-076
Ingrid den Uijl, Douwe Biesma, Diederick Grobbee, Kathelijn Fischer
NOT MILD AT ALL: VIRAL INFECTIONS (HIV, HBV, HCV) ARE PRESENT IN OVER ONE THIRD OF 2600 MILD AND MODERATE HEMOPHILIA A PATIENTS AND CAUSE 24% OF THE OBSERVED 30-YEAR MORTALITY O-MO-077
Corien Eckhardt, Alice S. van Velzen, Marjolein Peters, Kathelijne Peerlinck, Jan Astermark, Rainer Schwaab, Charles R.M. Hay, Pieter-Willem Kamphuisen, Maria Elisa Mancuso, Johanna G. van der Bom, Karin Fijnvandraat
HEALTH-RELATED QUALITY OF LIFE IN RELATION TO BONE MINERAL DENSITY IN ADULT PATIENTS WITH SEVERE HAEMOPHILIA O-MO-078
Sylvia von Mackensen, Mohammed Khawaji, Jan Astermark, Kristina Akesson, Erik Berntorp
OBESITY-RELATED HEMOSTATIC CHANGES IN HEMOPHILIA PATIENTS O-MO-079
Attie Tuinenburg, Sara Biere-Rafi, Marjolein Peters, Peter Verhamme, Kathelijne Peerlinck, Marieke J.H.A. Kruip, Britta A.P. Laros-van Gorkom, Joost C.M. Meijers, Pieter W. Kamphuisen, Roger E.G. Schutgens
Malignancy and Thrombosis I 13:30–15:00 Room A
Chairpersons: Beverley J. Hunt (UK) and Amir K. Jaffer (US)
SURVIVAL IN CANCER PATIENTS WITH AND WITHOUT VTE IN A PROSPECTIVE CASE-CONTROL STUDY: THE MASTER-ONCOLOGY PROJECT O-MO-080
Giancarlo Agnelli, Roberto LaBianca, Claudio Cimminiello, Giovanni Di Minno, Paolo Prandoni, Melina Verso
YOUNG SUBJECTS WITH OVERT CANCER HAVE SIGNIFICANTLY HIGHER RISK OF VENOUS THROMBOEMBOLISM. THE TROMSO STUDY 1994-2007 O-MO-081
Kristine Blix, Sigrid K. Braekkan, Finn E. Skjeldestad, John-Bjarne Hansen
OCCURRENCE OF MYOCARDIAL INFARCTION, ISCHEMIC STROKE AND PULMONARY EMBOLISM IN LUNG CANCER PATIENTS O-MO-082
PW Kamphuisen, Myrthe Van Herk-Sukel, Sumitra Shantakumar, Christof Majoor, Lucy Overbeek, Fennie Penning-van Beest, Ron Herings
INCIDENCE AND RISK FACTORS FOR DEVELOPING VENOUS THROMBOEMBOLISM (VTE) IN JAPANESE PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) O-MO-083
Kenji Yokoyama, Mitsuru Murata, Yasuo Ikeda, Shinichiro Okamoto
A WORLDWIDE SURVEY TO ASSESS THE CURRENT APPROACH TO THE TREATMENT OF PATIENTS WITH CANCER AND VENOUS THROMBOEMBOLISM O-MO-084
Ankie Kleinjan, Pieter W. Kamphuisen, Frederick R. Rickles, Charles Faselis, Dalia Mobarek, Harry R. Buller
TUMOR GRADE IS ASSOCIATED WITH VENOUS THROMBOEMBOLISM IN CANCER PATIENTS: RESULTS FROM THE VIENNA CANCER AND THROMBOSIS STUDY (CATS) O-MO-085
Jonas Ahlbrecht, Boris Dickmann, Cihan Ay, Daniela Dunkler, Johannes Thaler, Manuela Schmidinger, Peter Quehenberger, Andrea Haitel, Christoph Zielinski, Ingrid Pabinger
Thrombotic Disorders: Clinical I 13:30–15:00 Room B-1
Chairpersons: Valder Arruda (US) and Mashio Nakamura (JP)
DABIGATRAN DOES NOT INTERACT WITH PF4 OR PF4 BINDING TO PLATELETS AND MIGHT BE USED AS AN ALTERNATIVE ANTICOAGULANT IN HEPARIN-INDUCED THROMBOCYTOPENIA O-MO-086
Krystin Krauel, Christine Hackbarth, Birgitt Fuerll, Andreas Greinacher
RIVAROXABAN AS A POTENTIAL ALTERNATIVE ANTICOAGULANT IN PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA O-MO-088
Krystin Krauel, Christine Hackbarth, Birgitt Fuerll, Andreas Greinacher
VISUALIZING THE ENDOTHELIAL INVOLVEMENT IN THE PATHOGENESIS OF HEPARIN INDUCED THROMBOCYTOPENIA O-MO-089
Lubica Rauova, Vincent M. Hayes, Douglas B. Cines, Mortimer Poncz
EXTENDED FOLLOW-UP OF THE MULTI-CENTER PROSPECTIVE COHORT THAT DERIVED THE “MEN CONTINUE AND HERDOO2” CLINICAL DECISION RULE IDENTIFYING LOW RISK UNPROVOKED PATIENTS O-MO-090
Marc Alan Rodger, Marc Rodger, Mike Kovacs, Gregoire Le Gal, Susan Kahn, David Anderson, Isabelle Chagnon, Philip Wells, Marc Carrier, Mark Crowther, Richard White, Susan Solymoss, Arnaud Perrier
EXTRACELLULAR CHROMATIN IS AN IMPORTANT MEDIATOR OF ISCHEMIC STROKE O-MO-091
Simon F. De Meyer, Tobias A. Fuchs, Georgette L. Suidan, Alex Brill, Daphne Schatzberg, Marc Monestier, Markus Napirei, Hans G. Mannherz, Denisa D. Wagner
VTE: Epidemiology 13:30–15:00 Room B-2
Chairpersons: Samuel Goldhaber (US) and Saskia Middeldorp (NL)
PREVALENCE OF CHRONIC THROMBO-EMBOLIC PULMONARY HYPERTENSION AFTER ACUTE PULMONARY EMBOLISM : A PROSPECTIVE MULTICENTER STUDY O-MO-092
Olivier Sanchez, Laurent Guerin, Francis Couturaud, Florence Parent, Florence Gillaizeau, Gerald Simonneau, Guy Meyer
YEAR-LONG, REAL-TIME AUDIT OF HOSPITAL ACQUIRED (HAT) VENOUS THROMBOEMBOLIC EVENTS (VTE), FROM RADIOLOGICAL INVESTIGATIONS IN AN EXEMPLAR CENTRE O-MO-094
Huw Raymond Rowswell, Timothy Nokes, Kathy Clarke
INCIDENCE OF VENOUS THROMBOEMBOLISM (VTE) IN THE GENERAL POPULATION - VTE EPIDEMIOLOGY GROUP (VEG) STUDY O-MO-095
Carlos Martinez, Stephen Rietbrock, Luke Bamber, Alexander T. Cohen
INCIDENCE OF VENOUS THROMBOEMBOLISM (VTE) IN THE MEDICALLY-ILL POPULATION - VTE EPIDEMIOLOGY GROUP (VEG) STUDY O-MO-096
Alexander T. Cohen, Stephen Rietbrock, Carlos Martinez
RECURRENT VENOUS THROMBOSIS: INCIDENCE AND CHARACTERISTICS IN A LARGE COHORT OF VT PATIENTS (MEGA STUDY) O-MO-097
Linda E. Flinterman, Astrid Hylckama Vlieg, Suzanne C. Cannegieter, Frits R. Rosendaal
Platelet Receptors 15:30–17:00 Room C-1
Chairpersons: Stephanie M. Jung (UK) and Steve P. Watson (UK)
COMPARISON OF GENETIC AND ANTIBODY-INDUCED GPVI DEFICIENCY IN DIFFERENT MURINE ARTERIAL THROMBOSIS MODELS O-MO-098
Ina Hagedorn, Markus Bender, Bernhard Nieswandt
SEVERELY DEFECTIVE HEMOSTASIS AND ARTERIAL THROMBUS FORMATION IN GPVI/CLEC-2 DOUBLE-DEPLETED MICE O-MO-099
Frauke May, Markus Bender, Ina Hagedorn, Attila Braun, Bernhard Nieswandt
A ROLE OF PLATELET C-TYPE LECTIN LIKE RECEPTOR-2 (CLEC-2) IN THROMBUS FORMATION IN VIVO O-MO-100
Osamu Inoue, Kazuo Hokamura, Kazuo Umemura, Kinta Hatakeyama, Yujiro Asada, Yukio Ozaki, Katsue Suzuki-Inoue
CLEC-2 REGULATES LYMPHANGIOGENESIS BY INHIBITING PROLIFERATION, MIGRATION, AND TUBE FORMATION OF LYMPHATIC ENDOTHELIAL CELLS O-MO-101
Makoto Osada, Osamu Inoue, Guo Ding, Masanori Hirashima, Yukio Ozaki, Katsue Suzuki-Inoue
A NOVEL SPLICE VARIANT OF THE MER RECEPTOR TYROSINE KINASE FUNCTIONS AS AN INHIBITOR OF THE GAS6/TAM SIGNALING PATHWAY AND DECREASES PLATELET ACTIVATION RESPONSES O-MO-102
Brian R. Branchford, Susan Sather, Gary Brodsky, Tara White-Adams, Deborah DeRyckere, Keith Neeves, Douglas Graham, Jorge Di Paola
PLATELET NMDA RECEPTORS AS MEDIATORS OF GLUTAMATE EFFECTS ON PLATELET FUNCTION O-MO-103
Maggie L. Kalev-Zylinska, Marie-Christine Morel-Kopp, Paul Sun, Deborah Young, Matthew J. During, Christopher M. Ward
Laboratory Tests for Coagulopathy 15:30–17:00 Room C-2
Chairpersons: Anne Angelillo-Scherrer (CH) and Masashi Taki (JP)
SEVERITY OF CLINICAL PHENOTYPE IN PEDIATRIC HEMOPHILIA A SUBJECTS IS INVERSELY CORRELATED WITH TISSUE FACTOR-BEARING MICROPARTICLE LEVELS AND ACTIVITY O-MO-104
Mona D. Shah, Angela L. Bergeron, Molly Behymer, Noha Eyada, Swapan K. Dasgupta, Perumal Thiagarajan, Jing-fei Dong
FVIII-SPECIFIC CD4+ T CELLS ARE IMPORTANT REGULATORS OF FVIII INHIBITOR DEVELOPMENT IN PATIENTS WITH SEVERE HEMOPHILIA A O-MO-105
Christoph Hofbauer, Eva Altinger, Peter Allacher, Johannes Oldenburg, Jerzy Windyga, Hans Peter Schwarz, Birgit Maria Reipert
ENOXAPARIN DOWN REGULATES INFLAMMATORY AND THROMBOTIC MEDIATORS IN CANCER PATIENTS AS STUDIED USING PROTEIN AND BIOCHIP ARRAY APPROACHES O-MO-106
Debra A. Hoppensteadt, Evangelos Litinas, Hussein Khan, Josephine Cunanan, Indermohan Thethi, Jawed Fareed
PROCOAGULANT AND INFLAMMATORY MEDIATORS IN SMALL CELL LUNG CARCINOMA: POTENTIAL ROLE IN THROMBOEMBOLIC COMPLICATIONS O-MO-107
Indermohan Thethi, Debra Hoppensteadt, Hussein Kahn, Muzzafer Demir, Cafer Adiguzel, Evangelos Litinas, Jawed Fareed
ADAPTATION OF THE CALIBRATED AUTOMATED THROMBOGRAPHY ASSAY FOR ACCURATE PK/PD MEASUREMENT OF BAY 86-6150 FVIIA THERAPY IN CLINICAL TESTING FOR HEMOPHILIA A O-MO-108
Timothy Myles, Ji-Yun Kim, Claus Bornaes, Juliang Pan, John E. Murphy, Jesper Haaning
SIGNIFICANT IMPROVEMENT OF THE BETWEEN-LABORATORY VARIATION OF FVIII INHIBTOR TESTING: RESULTS OF A WORKSHOP O-MO-109
Bert Verbruggen, Myriam Dardikh, Robert Polenewen, Clint van Duren, Piet Meijer
Tissue Factor and Tissue Factor Pathway Inhibitor 15:30–17:00 Room D
Chairpersons: Esteban C. Gabazza (JP) and Henri H. Versteeg (NL)
TISSUE FACTOR-DEPENDENT CHEMOKINE PRODUCTION AGGRAVATES EXPERIMENTAL COLITIS O-MO-110
Karla CS Queiroz, Cornelis van't Veer, Yascha van den Berg, Jan Willem Duitman, Henri H. Versteeg, Hella L. Aberson, Angelique P. Groot, Marlen I. Verstege, Joris J.T.H. Roelofs, Anje A. te Velde, C. Arnold Spek
TISSUE FACTOR DEENCRYPTION IS REQUIRED FOR NORMAL DEVELOPMENT AND HEMOSTASIS O-MO-111
Susanna HM Sluka, Alexander Akhmedov, Giovanni G. Camici, Thomas F. Luscher, Felix C. Tanner
INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR (TFPI) BY SMALL PEPTIDES PROTECTS FXA AND ENHANCES FXA AND THROMBIN FORMATION IN MODEL SYSTEMS AND IN PLASMA O-MO-112
Michael Dockal, M. C.L.G.D. Thomassen, A. C.A. Heinzmann, C. Duckers, R. Hartmann, F. Scheiflinger, J. Rosing
INHIBITION OF TISSUE FACTOR ATTENUATES COAGULATION AND INFLAMMATION IN A MOUSE MODEL OF SICKLE CELL DISEASE O-MO-113
Pichika Chantrathammachart, Nigel S. Key, Daniel Kirchhofer, Nigel Mackman, Rafal Pawlinski
TISSUE FACTOR PATHWAY INHIBITOR APTAMER AS A POTENTIAL DRUG FOR HEMOPHILIA TREATMENT O-MO-114
Saulius Butenas, Matthew Gissel, Thomas Orfeo, Kenneth G. Mann
TISSUE FACTOR PATHWAY INHIBITOR (TFPI) AND TISSUE FACTOR (TF) CO-LOCALIZE IN LIPID RAFTS OF PLATELET MEMBRANES: MECHANISM TO INHIBIT PLATELET PROCOAGULANT (PCA) ACTIVITY? O-MO-115
Panes Olga, Cesar Gonzalez, Valeria Matus, Jaime Pereira, Diego Mezzano
P2Y12 Antagonists 15:30–17:00 Room E
Chairpersons: Stan Heptinstall (UK) and Kazuo Umemura (JP)
DETECTION OF CLOPIDOGREL RESISTANCE: COMPARISON OF A NEW, P2Y12 RECEPTOR SPECIFIC PLATELET AGGREGATION TEST AND OTHER LABORATORY METHODS IN PATIENTS ON CLOPIDOGREL MONOTHERAPY O-MO-116
Zsuzsa Bagoly, Ferenc Sarkady, Tunde Magyar, Endre Pongracz, Janos Kappelmayer, Laszlo Csiba, Laszlo Muszbek
BENEFIT OF TAILORED THERAPY WITH HIGH CLOPIDOGREL MAINTENANCE DOSE ACCORDING TO CYP2C19 GENOTYPES IN CLOPIDOGREL NON RESPONDERS UNDERGOING CORONARY STENTING FOR ACS O-MO-117
Marie-Christine Alessi, Thomas Cuisset, Jacques Quilici, William Cohen, Laurent Fourcade, Charlotte Grosdidier, Noemie Saut, Benedicte Gaborit, Mathieu Pankert, Laurent Molines, Pierre-Emmanuel Morange, Jean Louis Bonnet
PLATELET INHIBITION BY ADJUNCTIVE CILOSTAZOL VERSUS HIGH MAINTENANCE-DOSE CLOPIDOGREL IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION ACCORDING TO CYTOCHROME P450 2C19 GENOTYPE O-MO-118
Young-Hoon Jeong, In-Suk Kim, Yongwhi Park, Seong-Eun Yun
IS THERE A “REBOUND” AFTER CESSION OF ANTIPLATELET THERAPY?FIRST COMPARISON OF IRREVERSIBLE VERSUS REVERSIBLE P2Y12 RECEPTOR BLOCKER O-MO-119
Paul Alfred Gurbel, Kevin P. Bliden, Mark J. Antonino, Martin Gesheff, Young-Hoon Jeong, Udaya S. Tantry
ROLE OF NEWLY FORMED PLATELETS IN THROMBUS FORMATION AFTER CLOPIDOGREL TREATMENT: COMPARISON TO THE REVERSIBLY BINDING P2Y12 ANTAGONIST TICAGRELOR O-MO-120
Marijke J.E. Kuijpers, Remco T.A. Megens, Elham Nikookhesal, Marion A.H. Feijge, Mirjam G.A. oude Egbrink, Jo G.R. De Mey, J. J.J. van Giezen, Johan W.M. Heemskerk
BF061, A NOVEL ANTIPLATELET AND ANTITHROMBOTIC AGENT TARGETING P2Y12 AND PDE O-MO-121
Liang Hu, Zhichao Fan, Hongguang Du, Ran Ni, Si Zhang, Kanhua Yin, Jianqin Ye, Yan Zhang, Xunbing Wei, Xiaohui Zhang, Peter Gross, Satya P. Kunapul, Zhongren Ding
Acquired Coagulation Disorders 15:30–17:00 Sakura
Chairpersons: Paul Edward Monahan (US) and Kenji Niiya (JP)
BIOCHEMICAL CHARACTERIZATION OF ANTI-FACTOR XIII AUTOANTIBODIES IN PATIENTS WITH HEMORRHAGIC ACQUIRED FACTOR XIII DEFICIENCY O-MO-122
Masayoshi Souri, Hiroki Iwata, Wei Guang Zhang, Akitada Ichinose
ROTATIONAL THROMBOELASTOMETRY IN CIRRHOSIS: HYPERCOAGULABLE AND HYPERFIBRINOLYTIC O-MO-123
Paul Harrison, Vipil Jairath, Simon Stanworth, Amber Raja, Jane Collier, Mike Murphy, Ellie Barnes
LEFT VENTRICULAR ASSIST DEVICES CAUSE LOSS OF VON WILLEBRAND FACTOR ACTIVITY BY PROMOTING ITS PROTEOLYTIC CLEAVAGE O-MO-124
Han-Mou Tsai, William J. Weiss, Evan Leibner, Branka Lukic, Wenhua Zhou, Gerson Rosenberg
FACTOR SEVEN ACTIVATING PROTEASE (FSAP) IS ACTIVATED MASSIVELY IN MULTIPLE TRAUMA PATIENTS AND IN TURN ACTIVATES COMPLEMENT FACTORS O-MO-125
Sandip M. Kanse, Andrea Gallenmueller, Marcus Krueger, Markus Huber-Lang
POST CARDIAC COAGULOPATHY; A 48 HOURS LONGITUDINAL DESCRIPTIVE STUDY BASED ON WHOLE BLOOD CLOT FORMATION AND THROMBIN GENERATION O-MO-126
Mariann Tang, Per Wierup, Kirsten Christiansen, Jacob Greisen, Benny Soerensen
ACTIVATED PROTEIN C IS A PRINCIPLE MEDIATOR OF ACUTE TRAUMATIC COAGULOPATHY O-MO-127
Ross Davenport, Claire Rourke, Joanna Manson, Henry De'Ath, Sean Platton, Amy Coates, Daniel Hart, Pasi Pearse, John Pasi, Simon Stanworth, Karim Brohi
Malignancy and Thrombosis II 15:30–17:00 Room A
Chairpersons: Sigrid Kufaas Braekkan (NO) and Janusz Rak (CA)
VENOUS THROMBOEMBOLISM IN CANCER PATIENTS: REGIONAL LYMPH NODE METASTASIS AS A RISK FACTOR O-MO-128
Boris Dickmann, Jonas Ahlbrecht, Cihan Ay, Daniela Dunkler, Johannes Thaler, Roman Kanz, Werner Scheithauer, Peter Quehenberger, Christoph Zielinski, Ingrid Pabinger
INCIDENTAL AND SYMPTOMATIC VENOUS THROMBOEMBOLIC EVENTS ARE ASSOCIATED WITH INCREASED MORTALITY IN LUNG CANCER PATIENTS O-MO-129
Gregory Clayton Connolly, Laurel Menapace, Tarek Sousou, Saman Safadjou, Khorana Alok
MALIGNANCIES AND RISK OF RECURRENT VENOUS THROMBOSIS O-MO-130
Jasmijn F. Timp, Linda E. Flinterman, Astrid van Hylckama Vlieg, Frits R. Rosendaal, Suzanne C. Cannegieter
VENOUS THROMBOEMBOLISM (VTE) IN THE CANCER OUTPATIENT SETTING: CONTEMPORARY RATES AND PREDICTORS IN THE U.S. O-MO-131
Alok A. Khorana, Mehul Dalal, Jay Lin, Gregory Connolly
CELL FREE DNA AS A NOVEL PROCOAGULANT STIMULUS IN BREAST CANCER CHEMOTHERAPY O-MO-132
Laura Swystun, Patricia C. Liaw
MICROPARTICLE-ASSOCIATED TISSUE FACTOR ACTIVITY AND OCCURRENCE OF VENOUS THROMBOEMBOLISM IN BRAIN, GASTROINTESTINAL AND PANCREATIC CANCER O-MO-133
Cihan Ay, Nigel Mackman, Nigel S. Key, Alexandra Kaider, Johannes Thaler, Christine Marosi, Christoph Zielinski, Ingrid Pabinger
von Willebrand Disease 15:30–17:00 Room B-1
Chairpersons: Ulrich Budde (DE) and Jeroen CJ Eikenboom (NL)
CHARACTERIZATION OF BLOOD OUTGROWTH ENDOTHELIAL CELLS DERIVED FROM VON WILLEBRAND DISEASE PATIENTS O-MO-134
Jiong-Wei Wang, Eveline Bouwens, Carolina Pintao, Jan Voorberg, Karine M. Valentijn, Hetty C. de Boer, Pieter H. Reitsma, Jeroen Eikenboom
GENETIC VARIATIONS IN SNARE PROTEIN GENES DETERMINE VON WILLEBRAND FACTOR PLASMA LEVELS IN PATIENTS WITH TYPE I VON WILLEBRAND DISEASE O-MO-135
Janine E. van Loon, Eva M. de Wee, Yvonne V. Sanders, Moniek P.M. de Maat, Frank W.G. Leebeek
AN L1278P VON WILLEBRAND FACTOR (VWF) MUTATION IDENTIFIED IN A TYPE 1 VWD PATIENT CAUSES REDUCED VWF SECRETION AND INCREASED VWF CLEARANCE O-MO-136
Sandra Haberichter, Jocelyn A. Schroeder, Paula M. Jacobi, Ashley L. Gehrand, Kenneth D. Friedman, Donna DiMichele, Robert R. Montgomery
GENETIC VARIABILITY OF THE CLEC4M ENDOTHELIAL LECTIN RECEPTOR IN TYPE 1 VON WILLEBRAND DISEASE O-MO-137
Natalia Rydz, B. Boonyawat, J. J. Riches, W. Hopman, A. Paterson, R. Montgomery, D. Lillicrap, P. D. James, For the ZPMCB-VWD Study Group
COPY NUMBER VARIATION IS A SIGNIFICANT CONTRIBUTOR TO TYPE 1 VWD PATHOGENESIS IN THE EU MCMDM-1VWD COHORT O-MO-138
Daniel J. Hampshire, Ashley Cartwright, Lisa D. Bloomer, Ahlam M. Al-Buhairan, Raymon N.C.P. Vijzelaar, David Habart, Frank G.H. Hill, Francesco Rodeghiero, Ulrich Budde, Jeroen C.J. Eikenboom, Ian R. Peake, Anne C. Goodeve, on behalf of the EU-VWD and ZPMCB-VWD Study Groups
CLASSIFICATION OF A LARGE COHORT OF PATIENTS WITH VON WILLEBRAND DISEASE BETWEEN 2004 AND 2010 O-MO-139
Ulrich Budde, Sonja Schneppenheim, Rita Dittmer, Reinhard Schneppenheim
Thrombotic Disorders: Experimental Models 15:30–17:00 Room B-2
Chairpersons: Nobuo Nagai (JP) and Alvin Harold Schmaier (US)
NON-HUMAN PRIMATE MODEL OF HEMOLYTIC UREMIC SYNDROME AND THERAPEUTIC TESTING O-MO-140
Shinichiro Kurosawa, Deborah J. Stearns-Kurosawa
CD36 PARTICIPATES IN A SIGNALING PATHWAY THAT REGULATES ROS FORMATION AND CONTRIBUTES TO THROMBOSIS AND NEOINTIMAL HYPERPLASIA O-MO-141
Wei Li, Roy L. Silverstein
IDENTIFICATION OF ENU-INDUCED AND STRAIN MODIFIER GENES FOR FACTOR V LEIDEN DEPENDENT THROMBOSIS IN THE MOUSE O-MO-142
Randal J. Westrick, Guojing Zhu, Sara L. Manning, Angela Y. Yang, Audrey C.A. Cleuren, David R. Siemieniak, David Ginsburg
EARLY DEATH OF FACTOR V LEIDEN HEMIZYGOUS MICE: A FATAL ABSENCE OF WILD TYPE FV ANTICOAGULANT FUNCTION O-MO-143
Audrey CA Cleuren, Hongmin Sun, Guojing Zhu, Bart JM van Vlijmen, Pieter H. Reitsma, David Ginsburg, Randal J. Westrick
REGULATION OF VKORC1 EXPRESSION BY MICRORNAS AND ITS POTENTIAL EFFECT ON ACENOCOUMAROL REQUIREMENTS O-MO-144
Virginia Perez-Andreu, Raul Teruel, Rocio Gonzalez-Conejero, Javier Corral, Vanessa Roldan, Nuria Garcia-Barbera, Maria Jose Gomez-Lechon, Vicente Vicente-Garcia, Constantino Martinez
ADMINISTRATION OF THE ANTI-FXI ANTIBODY, 14E11, IMPROVES NEUROLOGICAL FUNCTION IN A MOUSE MODEL OF STROKE O-MO-145
Owen J. McCarty, Sawan Hurst, Norah Verbout, Erik I. Tucker, David Gailani, Michelle A. Berny-Lang, Andras Gruber
Poster Presentations
Signal Transduction of Platelet Activation
REGULATION OF RAP1B LOCALIZATION AND FUNCTION BY PROSTAGLANDIN E1 (PGE1) P-MO-001
Jaclyn A. Porath, Jenny H. Petkova, Gilbert C. White, II
PLATELET REACTIVITY INCREASED BY ADVANCE GLYCATED HEMOGLOBIN P-MO-002
Bahram Alamdary Badlou, M. Bakhti, M. Habibi-Rezaei, A.A. Moosavi-Movahedi, SMR. Tabatabai, M. Asadifar, M. Ahmadinejad
PLATELET ACTIVATORS (VWF, THROMBIN, COLLAGEN) INITIATE NOVEL INHIBITORY PATHWAYS INVOLVING NO-INDEPENDENT ACTIVATION OF PKG AND CAMP-INDEPENDENT ACTIVATION OF PKA P-MO-003
Stepan Gambaryan, Anna Kobsar, Sabine Herterich, Suzanne M. Lohmann, Ulrich Walter
PEAR1 PROMOTES STABILIZATION OF PLATELET AGGREGATES VIA A PI3K PATHWAY P-MO-004
Alexandre Kauskot, Serena Loyen, Chantal Thys, Peter Verhamme, Marc Florimond Hoylaerts
THE ALZHEIMER’S DISEASE ASSOCIATED AMYLOID β-PEPTIDE SUPPORTS PLATELET ADHESION AND ACTIVATION P-MO-005
Ilaria Canobbio, Silvia Catricala, Gianni Guidetti, Lina Cipolla, Alessandra Consonni, Cesare Balduini, Mauro Torti
SYNAPTOTAGMIN-LIKE PROTEIN 4 REGULATES PLATELET GRANULE SECRETION P-MO-006
Ashling Hampson, Olga Neumuller, Kristina Gegenbauer, Albert Smolenski
12-LIPOXYGENASE MEDIATES PRO- AND ANTI-THROMBOTIC EFFECTS IN HUMAN PLATELETS VIA METABOLISM OF ARACHIDONIC ACID AND DGLA TO 12(S)-HETE AND 12(S)-HETRE, RESPECTIVELY P-MO-007
Michael Holinstat, Jennifer Yeung, Patrick L. Apopa, Joanne Vesci, Theodore R. Holman
REGULATOR OF G-PROTEIN SIGNALLING PROTEIN 18 (RGS18) IS A TARGET OF CYCLIC NUCLEOTIDE MEDIATED PLATELET INHIBITION P-MO-008
Kristina Gegenbauer, Giuliano Elia, Alfonso Blanco, Albert Smolenski
PHOSPHOLIPASE D1, BUT NOT PLD2, IS ESSENTIAL FOR EFFICIENT GPIB-DEPENDENT αIIBβ3 ACTIVATION P-MO-009
David Stegner, Ina Thielmann, Ina Hagedorn, Christoph Kleinschnitz, Attila Braun, Johan W.M. Heemskerk, Guido Stoll, Bernhard Nieswandt
AGONIST INDUCED αIIBβ3 ACTIVATION IN GENETICALLY ENGINEERED HUMAN MEGAKARYOBLASTIC CELL LINE, CMK P-MO-010
Tsuyoshi Nakazawa, Tsuyoshi Kamae, Kazunobu Kiyomizu, Seiji Tadokoro, Shigenori Honda, Hirokazu Kashiwagi, Yuzuru Kanakura, Yoshiaki Tomiyama
Biology of Platelets
DIFFERENTIAL REGULATION OF PLATELET CONTACT AND SPREADING MONITORED BY REFLECTION INTERFERENCE CONTRAST MICROSCOPY P-MO-012
Dooyoung Lee, Karen P. Fong, Lawrence F. Brass, Daniel A. Hammer
PLATELET REACTIVITY IS A STABLE AND GLOBAL PHENOMENON IN ASPIRIN-TREATED CARDIOVASCULAR PATIENTS P-MO-013
Anne Zufferey, Jean-Luc Reny, Christophe Combescure, Philippe de Moerloose, Jean-Charles Sanchez, Pierre Fontana
THE RESTRICTED DELETION OF THE PODOCALYXIN GENE IN MEGAKARYOCYTES PERTURBS THE CONTROL OF HEMOSTASIA P-MO-014
Matilde S. Ayuso, Miguel Pericacho, Sonia Alonso-Martin, Susana Larrucea, Consuelo Gonzalez-Manchon, Dario Fernandez, Roberto Parrilla
MEASUREMENT OF PROCOAGULANT MICROVESICLES GENERATED WITHIN AGEING PLATELET CONCENTRATES P-MO-015
Abdulmajeed Abdullah Albanyan, Abdulmajeed Albanyan, B. Curry, R. Dragovic, C. Gardiner, J. Biggerstaff, M. Murphy, P. Harrison
BCL-XL INHIBITORY BH3 MIMETICS CAN INDUCE A TRANSIENT THROMBOCYTOPATHY THAT UNDERMINES THE HEMOSTATIC FUNCTION OF PLATELETS P-MO-016
Simone Marianne Schoenwaelder, Kate Jarman, Elizabeth Gardiner, JianLin Qiao, Michael J. White, Emma C. Josefsson, Imala Alwis, Robert K. Andrews, Kylie D. Mason, Hatem H. Salem, David C.S. Huang, Benjamin T. Kile, Andrew W. Roberts, Shaun P. Jackson
DETECTION OF THE AMINOPHOSPHOLIPID TRANSLOCASE ATP8A1 IN HUMAN PLATELETS AND ITS CLEAVAGE WHEN CALPAIN IS ACTIVATED P-MO-017
Hong Wang, Adam M. Gwozdz, KW Annie Bang, Marian A. Packham, Margaret L. Rand
POTENTIALITY TO NEGATIVE-REGULATE BDNF EXPRESSION VIA FORMING SENSE/ANTISENSE DOUBLE STRAND RNA IN MEGAKARYOCYTIC CELL LINE, MEG-01 P-MO-018
Shogo Tamura, Tetsuya Tsunematsu, Masanao Hatase, Kazuhiko Matsuno, Seiichi Kobayashi, Takanori Moriyama
HYPERTHERMIA INHIBITS PLATELET HAEMOSTATIC FUNCTIONS AND SELECTIVELY REGULATES THE RELEASE OF α-GRANULE PROTEINS P-MO-019
Soledad Negrotto, Julia Etulain, Maria J. Lapponi, Santiago J. Patrucchi, Maria A. Romaniuk, Agostina Carestia, Giannoula L. Klement, Mirta Schattner
Integrins and Other Glycoproteins
MOLECULAR BASIS FOR FIBRIN BINDING BY PLATELET INTEGRIN αIIBβ3 P-MO-020
Nataly Podolnikova, Valentin P. Yakubenko, Tatiana P. Ugarova
THE PDZ PROTEIN SYNTENIN-1 ASSOCIATES WITH TETRASPANINS CD63 AND CD9 IN ACTIVATED PLATELETS P-MO-021
Sara J. Israels, Eileen M. McMillan-Ward
STAPHYLOCOCCUS AUREUS IRON REGULATED SURFACE PROTEIN (ISDB) DIRECTLY BINDS TO PLATELET INTEGRIN GPIIB/IIIA P-MO-022
Marta Anna Zapotoczna, Timothy J. Foster
COATED PLATELETS FORM AGGREGATES WITH NON-COATED ONES, BUT DO NOT AGGREGATE WITH EACH OTHER P-MO-023
Alena O. Yakimenko, Yana N. Kotova, Fazoil I. Ataullakhanov, Mikhail A. Panteleev
GLANZMANN’S THROMBASTHENIA: IDENTIFICATION OF 25 NEW MUTATIONS IN 25 PATIENTS P-MO-024
Qingya Cui, Ziqiang Yu, Jian Su, Xia Bai, Wei Zhang, Mingqing Zhu, Wenhong Shen, Li Chen, Changgeng Ruan
APPLICATION OF αIIBβ3 NANODISCS TO DIRECTLY ASSESS EXTENSION OF αIIBβ3 INDUCED BY αIIBβ3 ANTAGONISTS BY ELECTRON MICROSCOPY P-MO-025
Won-Seok Choi, Barry S. Coller
GPIIBIIIA-MEDIATED PLATELET APOPTOSIS P-MO-026
Asuman Mutlu, Armen V. Gyulkhandanyan, Sergiy Mykhaylov, David J. Allen, Elena Lyubimov, Anna Chavlovski, Alan Lazarus, John Freedman, Valery Leytin
THROMBIN-INDUCED INTERACTION BETWEEN HUMAN PLATELETS AND FIBRINOGEN γ-CHAIN DODECAPEPTIDE-MODIFIED LIPOSOMES AS A SYNTHETIC PLATELET SUBSTITUTE P-MO-027
Hidenori Suzuki, Yosuke Okamura, Yasuo Ikeda, Shinji Takeoka, Makoto Handa
A MUTATION IN THE β3 CYTOPLASMIC TAIL WHICH CAUSES VARIANT GLANZMANN THROMBASTENIA ABROGATES THE TRANSITION OF αIIBβ3 TO THE ACTIVE STATE P-MO-028
Hagit Hauschner, Ronit Mor-Cohen, Uri Seligsohn, Nurit Rosenberg
DIFFERENT STRUCTURAL AND FUNCTIONAL ROLES FOR INTEGRIN UNIQUE DISULFIDE BONDS IN THE β3 SUBUNIT OF αIIBβ3 AND αVβ3 P-MO-029
Ronit Mor-Cohen, Nurit Rosenberg, Yulia Einav, Ehud Zelzion, Wissam Mansour, Yulia Averbukh, Uri Seligsohn
GPVI DIMER, WHICH RECOGNIZES A HIGHER ORDER STRUCTURE IN COLLAGEN, IS MARKEDLY INCREASED UPON PLATELET ACTIVATION P-MO-030
Stephanie May Jung, Masaaki Moroi, Kenji Soejima, Tomohiro Nakagaki, Michael Berndt, Elizabeth Gardiner, Steve P. Watson, Richard W. Farndale
Platelet Receptors
LXR AS AN ANTI-THROMBOTIC TARGET P-MO-031
Michael Spyridon, Leonardo A. Moraes, Chris I. Jones, Tanya Sage, Parvathy Sasikumar, Jonathan M. Gibbins
THE INTRACELLULAR COLLAGEN CHAPERONE HSP47 IS A COLLAGEN ADHESION PROTEIN ON THE SURFACE OF PLATELETS REQUIRED FOR NORMAL THROMBOSIS AND HAEMOSTASIS P-MO-032
Jonathan Gibbins, William J. Kaiser, Parvathy Sasikumar, Tanya Sage, Laura Dobson, Nicholas Pugh, Lisa Holbrook
RECIPROCAL REGULATION OF PLATELET FUNCTION BY ENDOGENOUS PROSTAGLANDINS - EXPERIMENTAL DATA AND MATHEMATICAL MODELING P-MO-033
Jorg Geiger, Katharina Hubertus, Maxime Moulard, Marcel Mischnik, Jens Timmer, Ulrich Walter
PECAM-1 CLUSTERING REDUCES SURFACE EXPRESSION OF GPIB ON PLATELETS WHICH IMPAIRS THE BINDING OF THROMBIN AND DIMINISHES PLATELET ACTIVATION P-MO-034
Chris Ian Jones, Leonardo A. Moraes, Kirk Taylor, Emily Knight, Jonathan M. Gibbins
SIGNALING ROLE OF CD36 IN PLATELET ADHESION AND SPREADING P-MO-035
Reyhan Nergiz-Unal, Moniek M.E. Lamers, Roger van Kruchten, Judith M.E.M. Cosemans, Joost Luiken, Jan F.C. Glatz, Marijke J.E. Kuijpers, Johan W.M. Heemskerk
TRANSMEMBRANE DOMAINS ARE CRITICAL TO THE INTERACTION BETWEEN PLATELET GLYCOPROTEIN V AND GLYCOPROTEIN IB-IX COMPLEX P-MO-036
Xi Mo, Jose A. Lopez, Renhao Li
KAINATE RECEPTOR INHIBITOR UBP-302 REDUCES HOMOCYSTEINE- ENHANCED PLATELET AGGREGATION P-MO-037
Cezary W. Watala, Kamil Karolczak
PAR4 MEDIATES THROMBIN-INDUCED PRO-COAGULANT ACTIVITY IN HUMAN PLATELETS P-MO-038
Hannah Lee, Cheryl Berndt, Elizabeth E. Gardiner, Robert K. Andrews, Shaun P. Jackson, Justin R. Hamilton
PAI-1 SECRETION, RE-SYNTHESIZING and THE ROLE OF THROMBIN RECEPTORS IN PLATELETS P-MO-039
Martina Nylander, Emma Lofgren, Anders Larsson, Tomas L. Lindahl
Megakaryocytes and Thrombopoiesis
PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) IMPAIRS APOPTOSIS DURING MEGAKARYOPOIESIS BY ACTIVATING NF-κB: A PROTEOMIC STUDY P-MO-040
Michela Di Michele, Karen Peeters, Serena Loyen, Etienne Waelkens, Lutgart Overbergh, Marc Hoylaerts, Chris Van Geet, Kathleen Freson
DIFFERENTIATION OF OP9 BONE MARROW STROMA CELLS INTO MEGAKARYOCYTES AND PLATELETS VIA A P45NF-E2-MEDIATED MECHANISM P-MO-041
Yumiko Matsubara, Yukako Ono, Hidenori Suzuki, Fumio Arai, Toshio Suda, Mitsuru Murata, Yasuo Ikeda
SILK FIBROIN ENGINEERED 3D SYSTEM FOR THE STUDY OF MEGAKARYOCYTES AND FUNCTIONAL PLATELET PRODUCTION P-MO-042
Isabella Pallotta, Michael Lovett, David L. Kaplan, Alessandra Balduini
STUDY OF MEGAKARYOPOIESIS AND PROPLATELET FORMATION IN MYELOPROLIFERATIVE DISORDERS P-MO-043
Stefania Badalucco, Mariateresa Pugliano, Vittorio Rosti, Marco Cattaneo, Giovanni Barosi, Alessandra Balduini
EXPRESSION OF TYPE I INTERFERON RECEPTOR IN MEGAKARYOPOIESIS P-MO-044
Soledad Negrotto, Carolina Jaquenod de Giusti, Maria J. Lapponi, Julia Etulain, Agostina Carestia, Ricardo M. Gomez, Mirta Schattner
ULTRASTRUCTURAL INDICATIONS FOR AN ENDOGENOUS ORIGIN OF THE DEMARCATION MEMBRANE SYSTEM IN MURINE MEGAKARYOCYTES P-MO-045
Anita Eckly, Fabienne Proamer, Jean-Yves Rinckel, Francois Lanza, Christian Gachet
FACTOR V SUGAR MOIETIES ARE ESSENTIAL FOR BINDING TO THE SURFACE OF MEGAKARYOCYTES P-MO-046
Claudia Zappelli, Carmen van der Zwaan, Koen Mertens, Alexander B. Meijer
THE ABNORMAL PROPLATELET FORMATION OBSERVED IN PATIENTS WITH MYH9-RELATED SYNDROME RESULTS FROM AN INCREASE OF PMLC2 P-MO-047
Yolande Chen, Siham Boukour, Paquita Nurden, Ababakar Seye, Olivier Bluteau, Yunhua Chang, Larissa Lordier, Remi Favier, Beatrice Saposnik, Nicole Schlegel, Anne Galy, Alan Nurden, Hana Raslova, William Vainchenker, Najet Debili
CRUCIAL ROLE FOR ENDOPLASMIC RETICULUM STRESS DURING THROMBOPOIESIS P-MO-048
Jose Javier Lopez, Najet Debili, Chiraz Chaabane, Evelyne Polidano, Saoussen Dally, Elisabeth Corvazier, Paquita Nurden, Jocelyne Enouf, Regis Bobe
THE INTERACTION OF ADENOSINE DIPHOSPHATE WITH P2Y13 REGULATES IN VITRO PROPLATELET FORMATION FROM HUMAN MEGAKARYOCYTES P-MO-049
Christian Di Buduo, Alessandro Malara, Isabella Pallotta, Anna Lecchi, Alessandra Balduini, Marco Cattaneo
Platelets as Drug Targets
EVALUATION OF PLATELET AGONISTS AND ANTAGONISTS BY A NOVEL ELISA-BASED VASP ASSAY AND COMPATIBILITY WITH WHOLE BLOOD SAMPLES FROM SEVERAL ANIMAL SPECIES P-MO-050
Daniele Boulay-Moine, Nicolas Bourguet, Sylvie Miet, Maxime Moulard
THE EFFECT OF THE ORAL DIRECT FACTOR XA INHIBITOR RIVAROXABAN ON TISSUE FACTOR MEDIATED IN VITRO PLATELET AGGREGATION IS ENHANCED BY A P2Y12 RECEPTOR BLOCKER P-MO-051
Elisabeth Perzborn, M. Harwardt, S. Heitmeier, V. Laux
PROTEIN KINASE C REGULATES AGONIST-MEDIATED PLATELET ACTIVATION DOWNSTREAM OF 12-LIPOXYGENASE IN HUMAN PLATELETS P-MO-052
Patrick L. Apopa, Joanne Vesci, Jennifer Yeung, Michael Holinstat
ASPIRIN IS LESS EFFICIENT FOR THROMBOXANE A2 INHIBITION IN ACTIVATED PLATELETS P-MO-053
Juana Valles, Antonio Moscardo, Isabel Madrid, Maria Angeles Dasi, Belen Cortina, Ana Maria LaTorre, Maria Teresa Santos
ASPIRIN TREATMENT IS RESPONSIBLE FOR AN MRP4 OVER-EXPRESSION IN HUMAN PLATELETS P-MO-054
Fabio M. Pulcinelli, Isabella Massimi, Elisabetta Trifiro', Lavinia Vittoria Lotti
INCREASED VASCULAR NO & PROSTACYCLIN PROTECTS B2R KO MICE FROM THROMBOSIS BY AN ACQUIRED PLATELET GLYCOPROTEIN VI ACTIVATION AND SPREADING DEFECT P-MO-055
Chao Fang, Evi Stavrou, Alec Schmaier, Andrew Chen, Marvin Nieman, Gregory Adams, Gretchen LaRusch, Yihua Zhou, Matthew Bilodeau, Fakhri Mahdi, Mark Warnock, Douglas Tollefsen, Alvin Schmaier
THE INFLUENCE OF GENETIC POLYMORPHISM AND DRUG-DRUG INTERACTION ON ANTIPLATELET EFFECT IN PATIENTS TREATED WITH LONG-TERM DUAL ANTIPLATELET THERAPY P-MO-056
Young-Hoon Jeong, Park Yongwhi, Kim In-Suk, Jung Kwon Tae, Hwang Jin-Yong
FIRST VALIDATION OF ADJUNCTIVE CILOSTAZOL LOADING EFFECT AND DOSAGE ON PLATELET INHIBITION: RESULTS OF THE ACCEL-LOADING STUDY P-MO-057
Young-Hoon Jeong, Kim In-Suk, Yun Seong-Eun, Park Yongwhi, Jung Kwon Tae
FIRST COMPARISON OF PLATELET INHIBITION BY CILOSTAZOL VERSUS CLOPIDOGREL IN PATIENTS WITH CYTOCHROME 2C19 LOSS-OF-FUNCTION ALLELE: RESULTS OF THE ACCEL-SWITCH STUDY P-MO-058
Young-Hoon Jeong, Yongwhi Park, In-Suk Kim, Seong-Eun Yun, Kwon Tae Jung
CONSENSUS DEFINITION-BASED CUTOFFS OF HIGH ON-TREATMENT PLATELET REACTIVITY: VALIDATION BETWEEN LIGHT TRANSMITTANCE AND MULTIPLE ELECTRODE AGGREGOMETRIES P-MO-059
Young-Hoon Jeong, Yongwhi Park, In-Suk Kim, Seong-Eun Yun
Molecular Basis of Inherited or Acquired Platelet Disorders
MUTATION SCREENING IN GLANZMANN THROMBASTHENIA: IDENTIFICATION OF FOUR NOVEL MUTATIONS IN THE ITGA2B AND ITGB3 GENES P-MO-060
Bimal D.M. Theophilus, Andrea M. Guilliatt, Lesley M. Baugh, Jayashree Motwani, Michael D. Williams
IDENTIFICATION OF TWO NOVEL TMEM16F MUTATIONS IN A PATIENT WITH SCOTT SYNDROME P-MO-061
Elisabetta Castoldi, Peter W. Collins, Patrick L. Williamson, Edouard M. Bevers
PLATELET FUNCTION ABNORMALITIES IN GAUCHER DISEASE: ETIOLOGY AND EFFECT OF ENZYME REPLACEMENT THERAPY P-MO-062
Mirjana Miroslav Mitrovic, Darko A. Antic, Ivo I. Elezovic, Dragana D. Janic, Predrag P. Miljic, Sumarac Z. Zorica, Tanja T. Nikolic, Nada N. Suvajdzic
BLEEDING PHENOTYPE IN A PATIENT WITH MDS IN THE ABSENCE OF THROMBOCYTOPENIA IS CAUSED BY A PROFOUND DYSREGULATION OF THE SIGNALING PROTEIN, SYK P-MO-063
Elizabeth E. Gardiner, Jian L. Qiao, Jane F. Arthur, Amanda K. Davis, Margaret Collecutt, Yang Shen, Fi-Tjen Mu, Robert K. Andrews
THROMBOCYTOPENIA IN MICE LACKING SPHINGOMYELIN SYNTHASE 1 P-MO-064
Takahiro Fujii, Akira Hayashi, Yuwna Yakura, Makoto Taniguchi, Ken Watanabe, Kazuyuki Kitatani, Toshiro Okazaki, Hiroyuki Takeya
PLATELET MITOCHONDRIAL DYSFUNCTION IN PATIENTS WITH SEPTIC SHOCK P-MO-065
Andrea Artoni, Anna Lecchi, Alessandro Protti, Giovanna Motta, Giovanni Mistraletti, Francesca Pagan, Sergio De Chiara, Luciano Gattinoni
Heparin-induced Thrombocytopenia
EVALUATION OF A FAST ELISA ASSAY FOR MEASURING HIT IGG ANTIBODIES P-MO-066
Lieselotte Wagner, Sabine Geiter, Markus Graf, Helga Vetr, Annelie Siegemund
USEFULNESS OF 4TS SCORING SYSTEM FOR HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) IN THE FIELD OF HEMODIALYSIS P-MO-067
Keiko Wanaka, Kumiko Miyashita, Chieko Kaneko, Jeanine M. Walenga, Margaret Prechel, Vicki Escalante, Miyako Matsuo, Reiko Asada
GERMAN REGISTRY FOR THE USE OF FONDAPARINUX IN HIT OR SUSPECTED HIT P-MO-068
Marc Schindewolf, Julia Scheuermann, Jan Beyer-Westendorf, Sebastian Schellong, Pascal Dohmen, Johannes Brachmann, Katharina Madlener, Bernd Poetzsch, Robert Klamroth, Johannes Hankowitz, Stefan Kropff, Norbert Banik, Sabine Eberle, Markus Michael Mueller, Edelgard Lindhoff-Last
DEVELOPMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) IN SIX PATIENTS WITH HEPARIN LOCK (OR FLUSH) IN THE EARLY PHASE OF HEMODIALYSIS P-MO-069
Kumiko Miyashita, Keiko Wanaka, Chieko Kaneko, Yoshihiko Nakajima, Jeanine M. Walenga, Vicki Escalante, Miyako Matsuo
HEPARIN-INDUCED THROMBOCYTOPENIA DIAGNOSIS WITH MULTIPLE ELECTRODE AGGREGOMETRY P-MO-070
Ludek Slavik, Jana Ulehlova, Vera Krcova, Antonin Hlusi, Jana Prochazkova
COMPARISON OF DIAGNOSTIC PERFORMANCE OF HEPARIN EXPERT PROBABILITY (HEP) AND 4T’S SCORES IN SCREENING FOR HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) P-MO-071
Noppacharn Uaprasert, Ponlapat Rojnuckarin, Benjaporn Akkawat
COMPARISON OF CLINICAL PERFORMANCES OF TWO ELISA ASSAYS: ASSERACHROM HPIA-IGG AND PF4 IGG FOR HEPARIN INDUCED THROMBOCYTOPENIA DIAGNOSIS P-MO-072
Sylvie Langlet, Christine Bahuon, Claire Maurel, Stephane Le Floch, Ismael Elalamy, Pierre Emmanuel Morange, William Cohen
SIMPLE SCORING SYSTEM FOR EARLY MANAGEMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA P-MO-073
Harry Messmore, Nanacy Fabbrini, Mary Bird, Abdul Choudhury, Miguel Cerejo, Margaret Prechel, Walter Jeske, Arshea Siddiqui, Thethi Indermohan, William Wehrmacher, Jeanine Walenga
IMMUNOLOGIC DIFFERENTIATION OF GENERIC LOW MOLECULAR WEIGHT HEPARINS P-MO-074
Jeanine Walenga, Margaret Prechel, Vicki Escalante, Walter Jeske, Mamdouh Bakhos
NON-PATHOGENIC ANTI-HEPARIN/PF4 ANTIBODIES GENERATED BY LOW MOLECULAR WEIGHT HEPARINS MEDIATE PROCOAGULANT EFFECTS P-MO-075
Jeanine Walenga, Debra Hoppensteadt, Evangelos Litinas, Harry Messmore, Bruce Lewis, Gundu Rao, Russell Hull, Jawed Fareed, Mamdouh Bakhos
RAPID DIAGNOSIS OF HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) BY WHOLE BLOOD IMPEDANCE AGGREGOMETRY: RESULTS OF THE AUSTRALIAN MULTI CENTRE STUDY P-MO-076
Marie-Christine Morel-Kopp, Chee Wee Tan, Tim Brighton, Simon McRae, Huyen Tran, Peter Mollee, Geoff Kershaw, Joanne Joseph, Luke Coyle, Chris Ward
Antiplatelet Therapy
ANTIPLATELET THERAPY EFFECTIVELY REDUCES PLASMA PLASMINOGEN ACTIVATOR INHIBITOR-1 LEVELS P-MO-077
Toshiyuki Sakata, Kazuomi Kario
VASODILATOR-STIMULATED PHOSPHOPROTEIN (VASP) PHOSPHORYLATION ASSAY FOR PLATELET RESPONSE TO CILOSTAZOL P-MO-078
Jun Yamanouchi, Takaaki Hato, Toshiyuki Niiya, Masaki Yasukawa
GLYCOPROTEIN IIB-IIIA CONTENT, MEAN PLATELET VOLUME AND PLATELET AGGREGATION IN PATIENTS WITH ACUTE CORONARY SYNDROME P-MO-079
Alexey V. Mazurov, Ilia T. Zyuryaev, Vladimir V. Yakushkin, Svetlana G. Khaspekova, Mikhail Ya Ruda
PLATELET HYPERCOAGULANT ACTIVITY DUE TO REDUCED AMINOPHOSPHOLIPID TRANSLOCASE ACTIVITY IN T2DM IS AMELIORATED BY GPIIB/IIIA BLOCKADE P-MO-081
Wei Zhang, Zhangsen Huang, Paul Hjemdahl, Nailin Li
ESSENTIAL THROMBOCYTHAEMIA TREATMENT OF A PATIENT UNDER 12 MONTHS- A CASE REPORT P-MO-082
Pawel Laguna, Michal Romiszewski, Anna Klukowska, Michal Matysiak
CLINICAL OUTCOME AND PLATELET FUNCTION OF ACUTE STROKE BY GLOBAL THROMBOSIS TEST (GTT) AFTER T-PA THERAPY P-MO-083
Katsushi Taomoto, Hideyuki Ohnishi, Yoshihiro Kuga, Kazuya Nakashima, Yuji Kodama, Hisashi Kubota, Takashi Tominaga, Makoto Hayashi, Shiro Miyata, Junichiro Yamamoto
CILOSTAZOL, A PLATELET INHIBITOR, IN TREATING INTERMITTENT CLAUDICATION. A SYSTEMATIC REVIEW P-MO-084
David Bergqvist, Olov Rolandsson, Juliette Sawe
FEATURES OF TREATMENT AND PROGNOSIS OF NON-ST ELEVATION ACUTE CORONARY SYNDROME IN PATIENTS WITH IRON DEFICIENCY ANEMIA P-MO-085
Anton Skotnikov, Arcady Vertkin, Fedor Vilkoviskii
CHARACTERIZATION OF THE ANTIPLATELET EFFECT OF ASPIRIN AT ENROLLMENT AND AFTER A 2-YEAR FOLLOW-UP IN THE REAL CLINICAL SETTING IN JAPAN P-MO-086
Keiichiro Yamane, Tomoyuki Ikeda, Ryoji Taniguchi, Toru Kita, Takeshi Kimura, Hisanori Horiuchi
100 MG OF ASPIRIN IS SUFFICIENT TO SUPPRESS PLATELET ACTIVITY IN TYPE 2 DIABETES, IRRESPECTIVE OF GLYCEMIC CONTROL P-MO-087
Bregtje Annelieke Lemkes, Pieter W. Kamphuisen, Lonneke Bahler, An K. Stroobants, Erik J. Van den Dool, Joost B.L. Hoekstra, Rienk Nieuwland, Victor E.A. Gerdes, Frits Holleman
CLOPIDOGREL AND ASPIRIN PHARMACODYNAMIC RESPONSE IN ELDERLY INPATIENTS: A PILOT STUDY P-MO-088
Tiphaine Belleville, Pascale Gaussem, Eric Pautas, Christilla Bachelot-Loza, Jean-Louis Golmard, Laure Raymond, Jean Szymezak, Emilie Gaillaud, Marie-Antoinette Catrix, Virginie Siguret, Isabelle Gouin-Thibault
EFFECTS OF TANSHINONEIIA ON INFLAMMATORY CYTOKINES AND GMP-140 IN THE PATIENT WITH KAWASAKI DISEASES P-MO-089
Xiaojing Li, Qing Zhang, Ming Zhou
MORE RAPID AND GREATER PHARMACODYNAMIC EFFECTS OF PRASUGREL IN JAPANESE PATIENTS WITH STABLE CORONARY ARTERY DISEASE (CAD) UNDERGOING ELECTIVE PCI P-MO-090
Hisanori Horiuchi, Hiroyoshi Yokoi, Takeshi Kimura, Takaaki Isshiki, Hisao Ogawa, Yasuo Ikeda
Inherited and Acquired Platelet Disorders
FEATURES OF PLATELET FUNCTION IN PATIENTS WITH PORTAL HYPERTENSION SECONDARY CHRONIC MYELOPROLIFERATIVE NEOPLASMS P-MO-091
Viola Maria I. Popov, Ana Maria Vladareanu, Horia Bumbea, Eugenia Kovacs, Tudor Savopol, Adrian Tase, Minodora Onisai, Marilena Miulescu, Anca Maria Ilea, Camelia Dobrea
PLATELET DYSFUNCTION IN PATIENTS WITH PULMONARY HYPERTENSION ON SILDENAFIL P-MO-092
Edmond S.K. Ma, Elaine M.C. Chau, Katherine Fan
CAUSES OF PLATELETS DISFUNCION IN MULTIPLE MYELOMA P-MO-093
Irena Djunic, Ivo Elezovic, Vesna Ilic, Dragica Tomin, Nada Suvajdzic-Vukovic, Jelena Bila, Darko Antic, Ana Vidovic, Nadezda Milosevic-Jovcic
FOUNDER EFFECT AND PHENOTYPIC SEVERITY OF THE FRENCH GYPSY MUTATION IN GLANZMANN THROMBASTHENIA P-MO-094
Mathieu Fiore, Frederic Austerlitz, Xavier Pillois, Nadia Firah, Paquita Nurden, Alan T. Nurden
A CASE OF ESSENTIAL THROMBOCYTHEMIA AND VERSION OF HEREDITARY THROMBOPHILIA - MTHFR MUTATION P-MO-095
Sandra Lejniece, Viktorija Dunska-Petersone, Anna Toma, Aiivars Lejnieks
MACROTHROMBOCYTOPENIA AND HEMOLYSIS ASSOCIATED WITH PHYTOSTEROLEMIA: A POTENTIAL NEW PLATELET DISORDER P-MO-096
Zhaoyue Wang, Gaifeng Wang, Lijuan Cao, Minghua Jiang, Xia Bai, Changgeng Ruan
THROMBOTIC THROMBOCYTOPENIC PURPURA CONCOMITANT WITH AUTOIMMUNE THYROIDITIS P-MO-097
Ali Bay, Ali Seckin Yalcin, Goksel Leblebisatan, Enes Coskun, Hatice Uygun, Mehmet Yilmaz
PLATELET TRANSFUSION REQUIREMENTS INVERSELY CORRELATE WITH ENDOGENOUS PF4 LEVELS IN PATIENTS WITH STANDARD RISK ACUTE LYMPHOBLASTIC LEUKEMIA P-MO-098
Michele Puszkarczuk Lambert, Alisa Reznikov, Liqing Xiao, Yvonne Nguyen, Lubica Rauova, Mortimer Poncz
ADOLESCENTS WITH DIABETES MELLITUS HAVE EVIDENCE OF IN VIVO PLATELET ACTIVATION P-MO-099
Sara J. Israels, Heather J. Dean, Elizabeth A.C. Sellers, Fabrice Cognasse, Archie McNicol
RFVIIA IS AS EFFECTIVE AS PLATELETS IN GLANZMANN THROMBASTHENIA (GT) WITH OR WITHOUT PLATELET ANTIBODIES AND/OR REFRACTORINESS (PA/PR): DATA FROM GT REGISTRY (GTR) P-MO-100
Man-Chiu Poon, Giovanni di Minno, Rainer Zotz, Roseline dOiron
Laboratory Tests: Platelets
INCREASED PLATELET AND LEUKOCYTE ACTIVATION AS CONTRIBUTING MECHANISMS FOR THROMBOSIS IN ESSENTIAL THROMBOCYTHEMIA AND CORRELATION WITH THE JAK2 MUTATION STATUS P-MO-101
Elena - Tothova, Adriana Kafkova, Marek Sarisky, Beata Benova, Natalia Stecova, Monika Hlebaskova
DETECTION OF AUTOANTIBODIES AGAINST PLATELET GLYCOPROTEINS IN PATIENTS WITH ITP BY FLOW CYTOMETRY P-MO-102
Yang He, Ming Qing Zhu, Yi Ming Zhao, Chang Geng Ruan
ASSOCIATION OF PLATELET REACTIVITY WITH LIPID AND PAI-1 LEVELS IN A JAPANESE GENERAL POPULATION, THE SUITA STUDY P-MO-103
Sachika Kameda, Toshiyuki Sakata, Yoshihiro Kokubo, Mana Mitsuguro, Akira Okamoto, Michitaka Sano, Toshiyuki Miyata
WIDE TEMPERATURE RANGE TESTING WITH SONOCLOT PLATELET FUNCTION AND ROTEM EXTEM/FIBTEM/APTEM TESTS P-MO-104
Ulf Stellan Schott, Jens Brokopp, Attila Frigyesi, Jon Martinsson, Hans Friberg
COMPARISON STUDY BETWEEN TWO BLOOD COUNTER INSTRUMENTS: ADVIA 2120 AND LH 780 P-MO-105
Selime Ayaz, Gulsah Kacur Fidan
ASPIRIN RESISTANCE IN PATIENTS WITH SAPHENOUS VEIN CORONARY BYPASS GRAFT OCCLUSION P-MO-106
Selime Ayaz, Goksel Cagirci, Yilmaz Sevinc, Ozcan Ozdemir, Dursun Aras
TRANSPLACENTAL TRANSMISSION OF EDTA DEPENDENT PSEUDOTHROMBOCYTOPENIA IN A NEONATE P-MO-107
Ali Bay, Safak Tavil, Goksel Leblebisatan, Ercan Sivasli, Enes Coskun
A SIMPLE PORTABLE MICROSYSTEM TO MONITOR PLATELET AGGREGATION P-MO-108
Francine Rendu, Thibault Donnet, Daniel Fruman
DIFFERENTIAL PREVALENCE OF ANTI-HEPARIN PLATELET FACTOR 4 ANTIBODIES IN ELDERLY PATIENTS UNDERGOING ORTHOPAEDIC SURGERY AND ANTICOAGULATED WITH HEPARIN P-MO-109
Christopher Song, Josephine Cunanan, Debra Hoppensteadt, Hussein Kahn, Indermohan Thethi, Jawed Fareed
NEW MULTIPLATE AGGREGATION TEST TO SCREEN FOR GSα DYSFUNCTION: SCREENING OF PATIENTS WITH UNEXPLAINED MENTAL RETARDATION FOR GSα DYSFUNCTION P-MO-110
Irene MLW Korver-Keularts, Estela M. Rubio-Gozalbo, Connie TRM Schrander-Stumpel, Paul WM Verhezen, Dionne Maessen, Monique GM Willems, Paola EJ Meijden van der, Johan WM Heemskerk, Yvonne MC Henskens, Karly Hamulyak
Extrinsic Pathway of Coagulation
THE EXTENSIVE EPITOPE OVERLAP OF THE HUMANIZED MONOCLONAL ANTIBODY MAB 2021 WITH THE FXA BINDING SITE ON K2 EXPLAINS ITS NEUTRALIZING EFFECT ON TFPI P-MO-111
Jens Breinholt, Lennart Anders Svensson, Ida Hilden, Berit Olsen Krogh, Ole Hvilsted Olsen, Jesper Pass, Jes Thorn Clausen, Helle Heibroch Petersen, Albrecht Gruhler
EFFICIENT PROCEDURE FOR PURIFICATION OF HUMAN TISSUE FACTOR PATHWAY INHIBITOR (TFPI) EXPRESSED FROM A BABY HAMSTER KIDNEY (BHK) CELL LINE P-MO-112
Christina Jespersgaard, Jorn Meidahl Petersen, Ida Hilden
PROTEOMIC ANALYSIS OF ANGIOTENSIN II- INDUCED PROTEIN EXPRESSIONS IN U937 CELLS P-MO-113
Shilin He, Li Bangtao, Wen Zhibin, He Xiaofan
AN INFANT WITH PROLONGED CIRCUMCISION BLEEDING AND UNEXPLAINED COAGULOPATHY P-MO-114
Ali Bay, Ozlem Karaoglu, Goksel Leblebisatan, Enes Coskun, Ali Seckin Yalcin, Mehmet Keskin
EXPRESSION OF TF IN MONOCYTES AND PLASMA TF DURING ACUTE PHASE AND RECOVERY STAGE IN PATIENTS WITH MYOCARDIAL INFARCTION P-MO-115
Rui Wang, Shufu Zhang, Yitong Ma, De Chen, Jing Ma, Yimeng Zhou, Bingzhao Wen
ACUTE HAEMOSTATIC EFFECT OF A POLYCLONAL RABBIT ANTI-MOUSE TFPI ANTIBODY IN A MURINE JOINT BLEEDING MODEL P-MO-116
Kirstine Ovlisen, Mette Brunsgaard Hermit, Jes Thorn Clausen, Lars Christian Petersen, Mikael Tranholm, Brit Binow Sorensen, Ida Hilden
A POLYCLONAL ANTI-MOUSE TFPI ANTIBODY DOSE-DEPENDENTLY REDUCES BLOOD LOSS IN HAEMOPHILIA A MICE P-MO-117
Peter B. Johansen, Mette B. Hermit, Jes T. Clausen, Ida Hilden
SELECTION AND CHARACTERISATION OF A MONOCLONAL ANTIBODY AGAINST TISSUE FACTOR PATHWAY INHIBITOR (TFPI) BLOCKING THE INTERACTION BETWEEN TFPI KUNITZ 2 DOMAIN AND FACTOR XA P-MO-118
Jes Thorn Clausen, Berit Olsen Krogh, Andrew Neil Bowler, Christina Jespersgaard, Thomas Egebjerg, Birgitte Friedrichsen, Ida Hilden
THROMBINURIA AS A USEFUL MARKER FOR SCREENING AND MONITERING OF CRESENTIC GLOMERULONEPHRITIS P-MO-119
Yasunori Kitamoto, Kenji Arizono, Yoshio Taguma, Takahisa Imamura
A MONOCLONAL ANTI-TFPI-ANTIBODY, MAB 2021, REDUCES BLEEDING IN HAEMOPHILIC RABBITS AFTER INTRAVENOUS AND SUBCUTANEOUS ADMINISTRATION P-MO-120
Brian Lauritzen, Mette Brunsgaard Hermit, Kristoffer W. Balling, Henrik Agersoe, Brit Binow Sorensen, Ida Hilden
A MONOCLONAL ANTI-TFPI-ANTIBODY, MAB 2021, IS EFFICACIOUS AGAINST BLEEDING IN HAEMOPHILIC RABBITS FOR AT LEAST 7 DAYS P-MO-121
Brian Lauritzen, Lene Hansen, Henrik Agersoe, Kristoffer W. Balling, Mette Brunsgaard Hermit, Jes Thorn Clausen, Ida Hilden, Brit Binow Sorensen
PLATELET UPTAKE OF RECOMBINANT FACTOR VIIA P-MO-122
Agon Hyseni, Philip G. de Groot, Ton Lisman, Mark Roest
A MONOCLONAL ANTIBODY MAB 2021 BLOCKING TISSUE FACTOR PATHWAY INHIBITOR (TFPI) ENHANCES HAEMOSTASIS UNDER HAEMOPHILIA A LIKE CONDITIONS P-MO-123
Brit Binow Sorensen, Ida Hilden, Lars Chr. Petersen, Mette Brunsgaard Hermit, Helle Heibroch Petersen, Kristoffer W. Balling
PHARMACOLOGICAL EVALUATION OF FVIIA/FX MIXTURE (MC710) IN ANIMAL MODELS OF HEMOPHILIA P-MO-124
Yasushi Nakatomi, Teruhisa Nakashima, Manami Tsuji, Eisuke Takami, Hiroki Miyazaki, Emiko Kusumoto, Ai Takaki-Kakisaka, Asami Shindome, Kazuhiko Tomokiyo, Takayoshi Hamamoto, Tomohiro Nakagaki
DISCORDANT CLEARANCE PATHWAYS FOR FACTOR X AND ITS N-DEGLYCOSYLATED DERIVATIVE P-MO-125
Mohamad Kurdi, Ghislaine Cherel, Peter J. Lenting, Cecile V. Denis, Olivier D. Christophe
STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF NON-ANTICOAGULANT SULFATED POLYSACCHARIDES FOR THE TREATMENT OF HEMOPHILIA P-MO-127
Michael Dockal, Sabine Knappe, Susanne Till, Michael Palige, Christina Miki Szabo, Zhenqing Zhang, Klara Michalkova, Hartmut Ehrlich, Friedrich Scheiflinger
ENDOGENOUS BLOOD BORNE TISSUE FACTOR CONTRIBUTES TO CLOT FORMATION IN HAEMOPHILIA-LIKE WHOLE BLOOD ASSESSED BY KAOLIN-INITIATED THROMBOELASTOGRAPHY (TEG) ANALYSIS P-MO-128
Brit Binow Sorensen, Marie Louise Schougaard Christiansen, Mirella Ezban, Soeren Bjoern, Stefan Lethagen
Intrinsic Pathway of Coagulation
SIMULATION AND MESUREMENT OF THROMBIN PRODUCTION IN RESTING AND CONVULXIN-TREATED WHOLE BLOOD IN VITRO: XIIA BYPASS OF CORN TRYPSIN INHIBITOR P-MO-129
Scott L. Diamond, Manash Chatterjee
MILD HEMOPHILIA B IN A CASE OF SHEEHAN SYNDROME P-MO-130
Nasim Valizadeh, Neda Valizadeh
FUNCTIONAL CHARACTERIZATION OF IMMOBILIZED FACTOR VIII IN INTRA-THROMBUS FIBRIN NETWORK FORMATION UNDER WHOLE BLOOD FLOW CONDITIONS WITH HIGH SHEAR RATES P-MO-131
Masaaki Doi, Mitsuhiko Sugimoto, Hideto Matsui, Tomoko Matsumoto, Midori Shima
MOLECULAR PATHOLOGY OF HAEMOPHILIA B IN CHINA PATIENTS: IDENTIFICATION OF 20 NOVEL MUTATIONS P-MO-132
Jing Dai, Qiong Chen, Ting Ying Wu, Ling Ye Lu, Lan Qiu Ding, Li Hong Wang, Feng Xue Wang
METABOLIC REGULATION OF MOUSE LIVER F11 GENE TRANSCRIPTION AND ITS RELATION TO KLKB1 AND CYP4V3 CONTROL P-MO-133
Huma Safdar, Audery C.A. Cleuren, Ka Lei Cheung, Pieter H. Reitsma, Bart J.M. van Vlijmen
FACTOR IX ARG327ILE MUTATION RESULTING IMPAIRED AFFINITY TO FVIIIA AS WELL AS CATALYTIC EFFICIENCY LEADS TO SEVERE HAEMOPHILIA B P-MO-134
Jiawei Zhou, Jing Dai, Xuefeng Wang, Tingting Yu, yeling Lu, Qiulan Ding, Hongli Wang
AN EPIDEMIOLOGIC CLINICAL STUDY ON HEMOPHILIA IN THE PATIENTS FROM THE REGION OF OLTENIA, ROMANIA P-MO-135
Polixenia Stancu, Cristina Singer, Alina Botu, Simona Cosoveanu, Diana-Maria Trasca, Emil Tiberius Trasca
FACTOR VIII INHIBITORS IN HEMOPHILIA A PATIENTS WITH DIFFERENT TREATMENT MODALITIES P-MO-136
Ola Abdel-Halim Afifi, Salah Abdul-Azeem Argoon, Yousreyia Abdel-Rahman Ahmad, Nabila Mohamed Thabet, Reffat Fathi Abdul-All, Gamal Ghanem Mohamed, Ahmad Farrag Thabet
AVAILABILITY OF CYCLOSPORINE A IN COMBINATION WITH CORTICOSTEROIDS FOR ACQUIRED HAEMOPHILIA A - A REVIEW OF CLINICAL COURSE IN 13 PATIENTS P-MO-137
Seiji Saito, Teruhisa Fujii, Noboru Takata
POLYMORPHISM 4G/5G IN PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1 AS A FACTOR FOR EARLY RECURRENT PREGNANCY LOSS DEVELOPMENT P-MO-138
Petar D. Ivanov, Regina Komsa-Penkova, Emiliana Konova, Tsvetomira Tsvyatkovska, Ivan Ivanov, Katya Kovacheva, Maria Simeonova, Stoyan Tanchev
EXPRESSION OF RECOMBINANT HUMAN FACTOR IX PROTEIN IN MOUSE ERYTHROCYTES BY USING A TRANSGENIC RODENT MALARIA PARASITE, PLASMODIUM BEGHEI AS AN EXPRESSION VECTOR P-MO-139
Teruko Sugo, Hiroyuki Matsuoka, Makoto Hirai, Darrel Stafford, Paul Monahan
FACTOR VIII LIGHT CHAIN CONTAINS A BINDING SITE FOR FACTOR X P-MO-140
Masahiro Takeyama, Hironao Wakabayashi, Philip J. Fay
SUITABILITY OF INSECT CELLS FOR THE EXPRESSION OF HUMAN COAGULATION FACTOR VIII P-MO-141
Svetlana A. Shestopal, Daniel J. Makover, Timothy K. Lee, Andrey G. Sarafanov
INHIBITION OF FACTOR XI IMPROVES SEPSIS SURVIVAL IN MICE P-MO-142
Erik Ian Tucker, Melani Helm, Norah Verbout, Owen JT McCarty, Sawan Hurst, David Gailani, Andras Gruber
THE USE OF A VWF-CONTAINING PLASMA-DERIVED FVIII PRODUCT IN INHIBITOR PATIENTS LIKELY TO FAIL IMMUNE TOLERANCE INDUCTION P-MO-143
Margaret Heisel Kurth, J. Puetz, P. Kouides, J. Sanders, C. Sexauer, J. Berstein, R. Gruppo, M. Manco-Johnson, E. Neufeld, D. Quon, N. Rodriguez, B. WIcklund, L. Aledort
ANTI-FACTOR VIII INHIBITOR IN SEVERE HAEMOPHILA A CAUSED BY SER470ASN BINDS TO A2 AND C2 DOMAINS P-MO-144
Qiong Chen, Jiawei Zhou, Xuefeng Wang, Qiulan Ding, Jing Dai, Yeling Lu, Hongli Wang
GENETIC DIAGNOSIS OF TWO PEDIGREES WITH INHERITED COAGULATION FACTOR XII DEFICIENCY P-MO-145
Zhou Rong-Fu, Jian Ouyang, Lu Chen, Xiao-yan Shao, Jing-Yan Xu
Anticoagulant Pathway
GENERIC VERSIONS OF LOW MOLECULAR WEIGHT HEPARIN MAY NOT HAVE THE SAME SAFETY-EFFICACY PROFILE AS THE BRANDED LOW MOLECULAR WEIGHT HEPARINS IN ACUTE CORONARY SYNDROME P-MO-146
Debra A. Hoppensteadt, Walter Jeske, Evangelos Litinas, Omer Iqbal, Jeanine Walenga, Bruce Lewis, Hussein Kahn, Fareed Jawed
INTER-INDIVIDUAL DIFFERENCES IN BASELINE COAGULATION ACTIVITIES AND THEIR CLINICAL IMPLICATIONS FOR WARFARIN THERAPY P-MO-148
Harumi Takahashi, Yosuke Ichimura, Michael MT Lee, Mari Shiomi, Kiyoshi Mihara, Takashi Morita, Yuan-Tsong Chen, Hirotoshi Echizen
DEVELOPMENTAL EFFECTS ON THE GLYCOSYLATION OF ANTICOAGULANT PROTEIN C P-MO-149
Maria C. Van Walderveen, Leslie R. Berry, Anthony K.C. Chan
PHENOTYPIC AND GENOTYPIC CHARACTERIZATION OF PROTEIN C DEFICIENCY CASES FROM INDIA P-MO-150
Pai P. Navin, Ronit Mor-Cohen, Shrimati S. Shetty, Bipin P. Kulkarni, Kanjaksha Ghosh
CIRCULATING NUCLEOSOMES AS PROGNOSTIC MARKER AND TARGET OF PROTEIN C IN CHILDREN WITH MENINGOCOCCAL SEPSIS P-MO-151
Sacha Zeerleder, Femke Stephan, Marijke Emonts, Ester de Kleijn, Charles Esmon, Katalin Varadi, Erik Hack, Jan Hazelzet
PROTEIN Z LEVELS IN PREGNANT OMANI WOMEN: CORRELATION WITH PREGNANCY OUTCOMES P-MO-153
Anil Pathare, Vaidyanathan Gowri, Mariam Mathew, Karima AlFalahi, David Gravell, Ibrahim Zakwani
CHANGE OF BEHAVIOR IN C4B BINDING PROTEIN AND PROTEIN S IN THE PATIENT WITH INFLAMMATORY DISEASE P-MO-154
Makoto Ikejiri, Junji Nishioka, Yuko Sakamoto, Yuji Shimokariya, Katsura Noma, Yasunori Abe, Kaname Nakatani, Hideo Wada, Tatsuya Hayashi, Koji Suzuki, Tsutomu Nobori
WHAT IS THE ORIGIN OF FACTOR V LEIDEN MUTATION IN ARABS? THE FIRST MOLECULAR PROOF P-MO-155
Mehrez M. Jadaon, Ali A. Dashti, Hend L. Lewis
NEUTRALIZABLE PARENTERAL ANTICOAGULATION: EP217609 AND ITS SPECIFIC ANTIDOTE, AVIDIN, IN HEALTHY SUBJECTS. A NEW PARADIGM? P-MO-156
Eric Neuhart, Pierre Gueret, Chantal Krezel, Eliane Fuseau, Maurice Petitou
REVERSION OF VITAMIN K ANTAGONISTS (VKA) EFFECT IN PATIENTS WITH BLEEDING COMPLICATIONS: AN OBSERVATIONAL STUDY FOR MONITORING PCC USE P-MO-157
Marc C. Samama, Claudine Hecquard, Roland Jaussaud, Christian Guillaudin, Thibaut Desmettre, Flavie Lefebvre, Jean-Charles Crave, Pierre Clerson
COMPARISON OF THE PHARMACOKINETICS AND PHARMACODYNAMICS OF TAK-442, A NOVEL FACTOR XA INHIBITOR, BETWEEN JAPANESE ACUTE CORONARY SYNDROME PATIENTS AND HEALTHY JAPANESE MALES P-MO-158
Koki Nakamura, Hiroyuki Okamoto, Fran Stringer, Masashi Hirayama, Emi Nakata, Yuki Minamide, Masaki Kawamura, Hisao Ogawa
EVALUATION OF INTERETHNIC DIFFERENCES IN THE PHARMACOKINETICS AND PHARMACODYNAMICS OF TAK-442, A NOVEL FACTOR XA INHIBITOR, IN HEALTHY MALE JAPANESE AND EUROPEAN SUBJECTS P-MO-159
Hiroyuki Okamoto, Fran Stringer, Masashi Hirayama, Koki Nakamura, Emi Nakata, Yuki Minamide, Masaki Kawamura
Serine Protease Inhibitors
DEVELOPMENT OF A NEW IMMUNO-ACTIVITY ASSAY FOR QUANTIFICATION OF ALPHA-2-MACROGLOBULIN COMPLEXES P-MO-160
Helen M. Atkinson, Nagina Parmar, Leslie R. Berry, Anthony K.C. Chan
INCREASED MARGIN OF PATHOGEN SAFETY OF A HIGHLY-PURIFIED, PLASMA-DERIVED C1 ESTERASE INHIBITOR FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA P-MO-161
Albrecht Groener, Thomas Nowak, Birgit Popp, Wolfram Schaefer
NOVEL THROMBIN BINDING DNA APTAMER EXHIBITS HIGH INHIBITORY POTENTIAL FOR BLOOD COAGULATION P-MO-162
Elena Zavyalova, Roman Reshetnikov, Andrey Golovin, Nikolay Mudrik, Dmitriy Panteleev, Galina Pavlova, Alexey Kopylov
EFFICACY AND SAFETY OF EDOXABAN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE OR HIP ARTHROPLASTY: A POOLED ANALYSIS OF TWO PIVOTAL STUDIES VERSUS ENOXAPARIN P-MO-163
Takeshi Fuji, Ching-Jen Wang, Satoru Fujita, Shintaro Tachibana, Yohko Kawai, Yukihiro Koretsune, Takeshi Yamashita, Mashio Nakamura
CALCULATION OF A SENSITIVITY INDEX USING THE WHO RBT/90 THROMBOPLASTIN ELIMINATES THE VARIABILITY OF THROMBOPLASTIN REAGENTS FOR PLASMA SAMPLES SPIKED WITH RIVAROXABAN P-MO-164
Job Harenberg, Christina Giese, Christel Weiss, Svetlana Marx, Roland Kraemer
WHICH PATIENTS WOULD BE WILLING TO CHANGE ANTICOAGULATION WITH VITAMIN-K ANTAGONISTS TO A NEW ORAL ANTICOAGULANT P-MO-165
Job Harenberg, Nadja Abou-Ayash, Svetlana Marx, Vera Hoeing, Kathrin Schirk, Christel Weiss, Lutz Froelich
AN ANTIBODY SELECTIVE TO DABIGATRAN SAFELY NEUTRALIZES BOTH DABIGATRAN-INDUCED ANTICOAGULANT AND BLEEDING ACTIVITY IN IN VITRO AND IN VIVO MODELS P-MO-166
Joanne Van Ryn, Tobias Litzenburger, Alisa Waterman, Keith Canada, Norbert Hauel, Chris Sarko, Rachel Kroe-Barrett, Sanjaya Singh, John Park
COMPARISON OF DIRECT FACTOR XA INHIBITOR YM150 WITH OTHER ORAL FXA INHIBITORS ON PROTHROMBIN TIME CLOTTING TESTS USING COMMERCIALLY AVAILABLE THROMBOPLASTIN REAGENTS P-MO-167
Toshiyuki Funatsu, Yoshiyuki Iwatsuki, Seiji Kaku
EFFECTS OF YM150 AND ENOXAPARIN IN RABBIT MODELS OF VENOUS THROMBOSIS AND SURGICAL BLEEDING P-MO-168
Toshio Uemura, Seiji Kaku
THE ANTICOAGULANT EFFECT OF YM150 CAN BE REVERSED BY ADMINISTERING COAGULATION FACTORS IN VITRO AND IN VIVO P-MO-169
Seiji Kaku, Toshio Uemura, Ken-ichi Suzuki
COMPARISON OF YM150 WITH WARFARIN IN A MOUSE MODEL OF PULMONARY EMBOLISM P-MO-170
Yoshiyuki Iwatsuki, Mami Suzuki, Tomihisa Kawasaki
Structural Biology and Drug Design: Coagulation Factors and Inhibitors
DISSOCIATION OF THE HOMODIMER RFXIII MOLECULE UPON CALCIUM INDUCED ACTIVATION AND REASSOCIATION DUE TO ELIMINATION OF CALCIUM P-MO-171
Lene Hoerlyck, Gunhild Klarskov Kristiansen, Mette Dahl Andersen
CHARACTERIZATION OF TYROSINE SULFATION IN RFVIII (N8) EXPRESSED IN CHO AND HEK-293 CELLS P-MO-172
Per Franklin Nielsen, Brian Vandahl, Steffen Bak
ANALYSIS AND CHARACTERIZATION OF A GLYCOPEGYLATED RECOMBINANT HUMAN FACTOR VIII P-MO-173
Henrik Rahbek-Nielsen, Jytte Pedersen, Helle Hassan, Jensen Skyt Peter, Anne Kroll Kristensen, Niels Kristian Klausen
METHYL CHLORIDE AS AN IMPURITY IN GENERIC CLOPIDOGREL PREPARATIONS P-MO-174
Indermohan Thethi, Alain Duguet, Helene Belva-Besnet, Christine Conocar, Marc Daumas, Rakesh Wahi, Gundu Rao, Lekha Pathak, Jawed Fareed
DISTINCT STRUCTURE FOR MG(II)-PROTHROMBIN FRAGMENT 1 P-MO-175
Whyte G. Owen, Franklyn G. Prendergast, Joel Schrock, Jack Hedstrom
RESULTS OF A PATIENT SURVEY OF HEMOPHILIA PATIENTS WITH INHIBITORS IN THE US AND EU P-MO-176
Sangeeta Krishnan, Yan Xiong, Diane Ito
A DISCRETE CHOICE EXPERIMENT TO ELICIT PHYSICIAN PREFERENCES FOR MEDICATION ATTRIBUTES IN THE TREATMENT OF PATIENTS WITH SEVERE HEMOPHILIA A AND INHIBITORS TO FACTOR VIII P-MO-177
Sangeeta Krishnan, Heather Gelhorn, Elizabeth Merikle, Josephine Li-McLeod, Leonard A. Valentino
CAPTURING MEMBRANE BINDING OF COAGULATION FACTORS AT ATOMIC RESOLUTION USING A NOVEL MEMBRANE MIMETIC MODEL P-MO-178
Emad Tajkhorshid, Y. Zenmei Ohkubo
HEREDITARY THROMBOFILIA IN VENEZUELAN WOMEN WITH RECURRENT FETAL LOSS P-MO-179
Aixa J. Muller Soyano, Aixa Elena Soyano, Juan Aller, Anibal Pulido, Andres L. Soyano, Ana Ferreira, Gustavo Salazar, Gisela Mendez, Rafael Cortes
Exogenous Hemostatic Factors
USE OF RECOMBINANT FACTOR IX (BENEFIX) IN HIP REPLACEMENT IN A PATIENT WITH SEVERE HAEMOPHILIA B P-MO-180
Kai Severin, Michael Heyl, Markus Compes, H. Tilman Steinmetz, Stephan Schmitz
PROLONGED EFFECT OF N8-GP IN HAEMOPHILIA A DOGS SUPPORTS LESS FREQUENT DOSING P-MO-181
Henrik Agersoe, Henning Stennicke, Hermann Pelzer, Eva Norling Olsen, Tim Nichols, Mirella Ezban
THE USE OF RFVIIA AND APCC IN THERAPY OF BLEEDINGS OF DIFFERENT ORIGIN - THREE YEARS EXPERIENCE OF LODZ HEMOPHILIA TREATMENT CENTER P-MO-182
Jacek Trelinski, Michal Zamolski, Krzysztof Chojnowski
CONTINUOUS INFUSION FOR THE MANAGEMENT OF MAJOR POST-TRAUMATIC, LONG-LASTING MUSCULOSKELETAL BLEEDINGS IN HAEMOPHILIA A CHILDREN AND ADOLESCENTS P-MO-183
Brigitte A. Pautard Muchemble, Valerie Li Thiao Te, Christine Vinciguerra, Julie Notheaux-Micheli, Anne Lutun, Marie Anne Guersing, Bertrand Roussel, Claude Negrier
ADDITIONAL IMPACT OF MORNING HEMOSTATIC RISK FACTORS AND MORNING BLOOD PRESSURE SURGE ON STROKE RISK IN OLDER JAPANESE HYPERTENSIVE PATIENTS P-MO-184
Yuichiro Yano, Takefumi Matsuo, Satoshi Hoshide, Kazuo Eguchi, Kazuyuki Shimada, Kazuomi Kario
GLYCOPEGYLATED RFVIII (N8-GP) HAS PROLONGED HAEMOSTATIC EFFECT IN HAEMOPHILIA A MICE P-MO-185
Torben Elm, Mirella Ezban, Mikael Tranholm, Henning Stennicke, Heidi Holmberg
ADVATE HAEMOPHLIA A OUTOME DATABASE (AHEAD): A LONG-TERM REGISTRY FOCUSING ON JOINT HEALTH OUTCOMES AND QUALITY OF LIFE P-MO-186
Clara K. Song, Johannes Oldenburg, Gerald D. Spotts, Ingo Abraham, Manfred Pirck, Werner Engl, Armin J. Reininger
APCC (FEIBA) PROPHYLAXIS: LONG TERM EXPERIENCE (1998-2011) IN A SEVERE HAEMOPHILIA A PATIENT WITH FVIII INHIBITOR P-MO-187
Michele Schino, Pierosandro Sbrighi, Massimo Morfini
PLASMA DERIVED FACTOR VIII IN THE TREATMENT OF PATIENTS WITH HEMOPHILIA A: UPDATE OF A LONG-TERM PHARMACOVIGILANCE P-MO-188
Robert Klamroth, Rainer Zimmermann, Susanne Holzhauer, Marcus Stockschlaeder, Claudia Zacharias, Karin Kurnik
IMPACT OF THE 2500 U VIAL SIZE FOR APCC ON DOSE AND VIAL BURDEN IN A US SPECIALTY PHARMACY DATABASE P-MO-189
Sangeeta Krishnan, Yan Xiong
P.I.S.A. POST-MARKETING ITALIAN SURVEILLANCE STUDY ON ADVATE TREATMENT OF HAEMOPHILIA A PATIENTS IN ORDER TO EVALUATE ITS EFFICACY, SAFETY AND IMMUNOGENICITY P-MO-190
Michele Schino, Angiola Rocino, Elena Santagostino, MariaGabriella Mazzucconi
PRECLINICAL SAFETY PHARMACOLOGY OF BAXTER’S RECOMBINANT FACTOR IX P-MO-191
Barbara Dietrich, Susan Kubik, Hartmut Ehrlich, Friedrich Scheiflinger, Hans Peter Schwarz, Eva Maria Muchitsch
REPEATED APPLICATION OF BAXTER’S RECOMBINANT FACTOR IX IN RATS AND CYNOMOLGUS MONKEYS P-MO-192
Barbara Dietrich, Wilfried Auer, Kuno Wuersch, Martin Wolfsegger, Hartmut Ehrlich, Friedrich Scheiflinger, Hans Peter Schwarz, Eva Maria Muchitsch
IMMUNE TOLERANCE INDUCTION IN HEMOPHILIA A PATIENTS WITH INHIBITORS BY TREATMENT WITH RECOMBINANT FACTOR VIII (IN FACT): A RETROSPECTIVE NON-INTERVENTIONAL STUDY P-MO-193
Georges E. Rivard, Chantal Rothschild, Teresa Toll, Karin Achilles
A COMPARISON OF HEALTH-RELATED QUALITY OF LIFE AND JOINT HEALTH OUTCOMES BETWEEN HEMOPHILIA A PATIENTS WITH INHIBITORS AND NON-INHIBITOR PATIENTS P-MO-194
Diane Ito, Yan Xiong, Sangeeta Krishnan
Fibrinogen and Other Factors
COMPARISON OF BRANDED ENOXAPARIN (LOVENOX) AND A BIOSIMILAR VERSION OF ENOXAPARIN (FIBRINOX) P-MO-195
Walter Jeske, Elizabeth McGeehan, Omer Iqbal, Debra Hoppensteadt, Jeanine Walenga, Jawed Fareed
MOLECULAR MECHANISMS THAT CONTROL CLOT STRUCTURE: EXPLORING THE αC REGION WITH A HUMAN/CHICKEN HYBRID FIBRINOGEN P-MO-196
Susan T. Lord, Lifang Ping, Nathan E. Hudson, Michael R. Falvo
FACTOR X DEFICIENCY CAUSED BY DOUBLE NOVEL HETEROZYGOUS MUTATIONS ((IVS5+1G>A AND ASP368DEL) P-MO-197
Jiawei Zhou, Qiong Chen, Xuefeng Wang, Qiulan Ding, Hongli Wang
ABDOMINAL AORTIC CALCIFICATION IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE: PREVALENCE AND COAGULATION ABNORMALITY P-MO-198
Vladimir A. Zelinskiy, Vladimir V. Andreev
“SNAPSHOTS” OF FIBRIN POLYMERIZATION: ANALYSIS OF FORMALDEHYDE-FIXED PRODUCTS P-MO-200
Susan T. Lord, Lihong Huang
THE INTERIORS OF THE FIBERS IN A FIBRIN CLOT ARE ACCESSIBLE TO LARGE PROTEINS LIKE ACTIVATED FACTOR XIII P-MO-201
Susan T. Lord, Shelby L. Allen, Oleg V. Gorkun
RESTORATION OF IMPAIRED HEMOSTASIS BY PLATELETS AND COAGULATION FACTORS IN PATIENTS UNDERGOING CARDIOTHORACIC SURGERY P-MO-202
Marisa Ninivaggi, Marcus D. Lance, Gerhardus J. Kuiper, Saskia E. Schols, Marion A. Feijge, Marco Marcus, Hugo ten Cate, Johan W. Heemskerk
CHARACTERIZATION OF FIBRINOGEN DEPLETION AND RESPONSE TO REPLACEMENT THERAPY IN BLEEDING TRAUMA PATIENTS P-MO-203
Claire Rourke, Nicola S. Curry, Sirat Khan, Simon Stanworth, Karim Brohi
DISCREPANCY BETWEEN ACTIVITY AND ANTIGEN LEVELS OF FACTOR(F) XIII AFTER ADMINISTRATION OF FXIII CONCENTRATES IN HEMORRHAGIC ACQUIRED FXIII DEFICIENCY DUE TO ITS AUTOANTIBODY P-MO-204
Fumihiro Ishida, Kentaro Okubo, Toshiro Ito, Nobuo Okumura, Masayoshi Souri, Akitada Ichinose
IDENTIFICATION OF FIBRIN CLOT-BOUND PLASMA PROTEINS P-MO-205
Simone Talens, Frank W.G. Leebeek, Jeroen A.A. Demmers, Dick C. Rijken
ANALYSIS AND CHARACTERIZATION OF GLYCOPEGYLATED RECOMBINANT HUMAN FIX P-MO-206
Lisbeth C. Palm, Karen Hansen, Anders Dybdal Nielsen, Finn Stausholm Nielsen, Anette Skammelsen Schmidt
Laboratory Tests: Coagulation Factors and Inhibitors
ABSENCE OF LOW-DOSE TISSUE FACTOR INDUCED-THROMBIN GENERATION IN SOME SEPTIC SHOCK PATIENTS P-MO-207
Jean-Christophe Raymond Gris, Eva Cochery-Nouvellon, Erik Mercier, Marie Bozon, Geraldine Lissalde-Lavigne, Christian Bengler, Guillaume Louart, Jean-Yves Lefrant
DETERMINING THE ACTIVITY OF RIVAROXABAN TREATMENT: THE NEW PROTHROMBIN TIME REAGENT TECHNOCLOT PT PLUS P-MO-208
Lieselotte Wagner, Jutta Mager, Viktoria Kaufmann, Nikolaus Binder
THE EVALUATION OF THE ISI AND MNPT USING FRESH PATIENT SAMPLES AND AK-CALIBRANT: A COMPARISON P-MO-209
Lieselotte Wagner, Viktoria Kaufmann, Jutta Mager, Nikolaus Binder
EVALUATION OF ASSAY PERFORMANCE MONITORING XA INHIBITORS WITH TECHNOCHROM ANTI-XA (AT+) AND TECHNOCHROM ANTI-XA P-MO-210
Lieselotte Wagner, Sabine Geiter, Stephan Stranz, Viktoria Kaufmann, Jutta Mager, Markus Graf
ABNORMAL APTT SECOND DERIVATIVE CLOT CURVES ON THE ACL TOP ANALYSER AND THEIR DIAGNOSTIC UTILITY P-MO-211
Simon J. Davidson, Cristina Valenciano, Stephen Fox, Farah Kamani, Louise Tillyer
FACTOR XIII LEVELS IN CHILDREN WITH CYANOTIC AND ACYANOTIC CONGENITAL HEART DEFECTS: THE IMPACT OF CARDIOPULMONARY BYPASS P-MO-212
Leo A. Bockeria, Natalia N. Samsonova, Ivan A. Yurlov, Ludmila G. Klimovitch, Elena F. Kozar, Iya Tsagareli, Nikolay N. Eliseev, Eva HN. Olsen, Sergey B. Zaets
THE STATUS OF CARRIER AND PRENATAL DIAGNOSIS OF HAEMOPHILIA IN CHINA P-MO-213
Jing Dai, Ling Ye Lu, Lan Qiu Ding, Li Hong Wang, Feng Xue Wang
HAEMOLYSIS DURING SAMPLE COLLECTION CAUSES VARIABLE BUT SOMETIMES CLINICALLY IMPORTANT ERRORS P-MO-214
Anita Woolley, Kevin Horner, Steve Kitchen
EFFECT OF MATRINE ON THE EXPRESSION OF TISSUE FACTOR INDUCED BY LIPOPOLYSACCHARIDE IN MONOCYTES P-MO-215
Zhibin Wen, Xudong Tang, Xiaofan He, Shinlin He
A NEW APTT REAGENT WITH SYNTHETIC PHOSPHOLIPIDS P-MO-216
Virginia Montanini, Maite Munoz, Albert Huisman, Ana Chiva
HIGH ANTI-FACTOR V (AFV) ACTIVITY AND NO-SPONTANEOUS BLEEDING: A CASE REPORT P-MO-217
Silvia Grosso, Marcelo Ingratti, Graciela Alfonso, Analia Sanchez Luceros, Susana Meschengieser, Alicia Blanco, Maria Lazzari
UPREGULATION OF INFLAMMATORY MEDIATORS IN END STAGE RENAL DISEASE AS MEASURED VIA BIOCHIP ARRAY TECHNOLOGY P-MO-218
Vinod Bansal, Rachel Davis, Evangelos Litinas, Debra Hoppensteadt, Jawed Fareed
THE INHIBITORY EFFECT OF SERUM ALBUMINS ON THE HYDROLYSIS OF ZGGR-AMC BY THROMBIN AND α2M-THROMBIN AND ITS CONSEQUENCES FOR FLUOROGENIC THROMBIN GENERATION METHODS P-MO-219
Erik De Smedt, Rob Wagenvoord, C. H. Hemker
EVALUATION OF THE Q HEMOSTASIS ANALYSER (GRIFOLS) FOR ROUTINE TESTS OF HAEMOSTASIS P-MO-220
Anita Woolley, Steve Kitchen
COAGULATION TESTING: INFLUENCE OF BLOOD COLLECTION TUBE AND PRE-ANALYTICAL STORAGE TEMPERATURE P-MO-221
Marie-Claire F. Kleinegris, M.C.F. Kleinegris, R. Loeffen, F.J.M. van der Meer, P.H. Reitsma, S.T.B.G. Loubele, H.M.H. Spronk, H. ten Cate
COMPARISON OF SYSMEX CS AND CA SERIES ANALYSERS FOR ROUTINE TESTS OF HAEMOSTASIS P-MO-222
Julie M. Smith, Jackie Deeming, Kevin Horner, Anne Sermon, Jackie Storr, Anita Woolley, Steve Kitchen
SCALING UP Q HEMOSTASIS ANALYZER TO HIGH THROUGHPUT LABORATORIES P-MO-223
Josep Pages, Ramon Cases, Susanna Torres
IMPORTANCE OF THROMBIN GENERATION ASSAY IN MONITORING OF HEMOSTASIS IN PATIENTS WITH HEMOPHILIA P-MO-224
Yilmaz Ay, Can Balkan, Deniz Yilmaz, Basri Bilenoglu, Kaan Kavakli
DECREASED PROCOAGULANT PHOSPHOLIPIDS IN PATIENTS WITH VITAMIN K ANTAGONISTS P-MO-225
Aurelie Rousseau, Barry Woodhams, Bernard Lenormand, Marc Vasse
ATYPICAL VARIANTS OF THE F8 INTRON 22 INVERSION IDENTIFIED USING INVERSE SHIFTING-PCR P-MO-226
Felicity Catherine Edwards, Jacky Cutler, Steve Austin, Savita Rangarajan, Mike Mitchell
COMPARISON OF INHIBITION OF THROMBIN GENERATION BY DIFFERENT CLASSES OF ANTICOAGULANTS P-MO-227
Yiming Xu, KehDih Lai, Barry Antonacci, Madhu Chintala
POLYBRENE CAN NEUTRALISE ENOXAPARIN IN PLASMA BEING TESTED FOR THROMBIN GENERATION, HOWEVER THIS EFFECT IS CONCENTRATION DEPENDENT P-MO-228
Jignesh P. Patel, Lara N. Roberts, Raj K. Patel, Michael S. Marsh, Bruce Green, John G. Davies, Roopen Arya
ACCURACY AND RELIABILITY OF INTERNATIONAL NORMALIZED RATIO (INR) IN MONITORING OF WARFARIN ON QUICK-PT (INR) AND OWREN-TT (INR) REAGENTS P-MO-229
Masahiro Okuda, Tasuku Sakayori, Sumiyoshi Naito, Mika Yoshida, Noriyoshi Kato, Nobuhiko Takahashi, Masahiro Ieko
PASTEURIZATION EFFECTIVELY INACTIVATES CLOTTING ACTIVITIES DURING MANUFACTURING OF TWO LIQUID READY TO USE DIFFERENT INTRAVENOUS IMMUNOGLOBULIN (IVIG) PRODUCTS P-MO-230
Marta Jose, Marzo Nuria, Lopez Laura, Lopez Maite, Ristol Pere, Jorquera I. Juan
THROMBIN GENERATION (TG) ASSAYS IN HAEMOPHILIACS WITH INHIBITORS TREATED WITH BY-PASSING AGENTS: THE UTILITY OF ADDING CORN TRYPSIN INHIBITOR (CTI) P-MO-231
Veena Chantarangkul, Maria Elisa Mancuso, Laura Lemma, Marigrazia Clerici, Elena Santagostino, Armando Tripodi
COMPARISON BTWEEN ACT+ AND ACT-LR RESULTS USING THE HEMOCHRON SIGNATURE ELITE P-MO-232
Tarek Owaidah, Merlito De Torres
COAGULATION TESTING BEFORE EPIDURAL ANALGESIA AT DELIVERY: COST-ANALYSIS P-MO-233
Eugenia Biguzzi, Franca Franchi, Buthaina Ibrahim, Federica Rossi, Maria Luisa Maspero, Oronzo Morabito, Daniela Asti, Paolo Bucciarelli
CORRECTION OF INR DISCREPANCY BETWEEN LABORATORIES USING VARIOUS PT SYSTEMS P-MO-234
Felix JM Van Der Meer, Anton M. Van den Besselaar, Anton P. Van Zanten, Helen M. Brandjes, Mark G. Elisen, Dennis C. Poland, August Sturk, Anja Leyte, Ad Castel
EVALUATION AND PERFORMANCE CHARACTERISTICS OF THE Q HEMOSTASIS ANALYZER P-MO-235
Pierre A. Toulon, Florence Fischer, Anny Appert-Flory, Didier Jambou
A LOW MAGNESIUM EVACUATED BLOOD COLLECTION TUBE MINIMIZES INR DISCREPANCIES AMONGST DISPARATE PROTHROMBIN TIME SYSTEMS P-MO-236
Keith Moskowitz, Evelina Witteveen, Karen Byron, Amy Mouser, David Warunek, A.M.H.P. van den Besselaar
ANTITHROMBIN-INDEPENDENT IMPAIRED THROMBIN INACTIVATION IS NOT A FREQUENT FINDING AMONG THROMBOPHILIC PATIENTS P-MO-237
Heiko Ruehl, Jens Mueller, Ursula Harbrecht, Johannes Oldenburg, Bernd Poetzsch
Experimental Models: Coagulation Factors and Inhibitors
PROLONGED HAEMOSTATIC EFFECT OF N8-GP ON JOINT BLEEDS IN HAEMOPHILIA A MICE P-MO-238
Kirstine Ovlisen, Mirella Ezban, Mikael Tranholm
EXPERIMENTAL USE OF RECOMBINANT FACTOR XIII (RFXIII) IN CRITICAL CONDITIONS: COMPARISON OF EFFECTIVENESS IN DIFFERENT ANIMAL MODELS P-MO-239
Sergey B. Zaets, Da-Zhong Xu, Qi Lu, Eleonora Feketova, Tamara Berezina, Inga Malinina, Edwin Deitch, Eva Olsen
THE EFFECT OF COMMON BETA2-RECEPTOR HAPLOTYPES ON CATECHOLAMINE LEVELS AND HEMOSTASIS AFTER STANDING UP P-MO-240
Olav R. De Peuter, Joost C. Meijers, Bas Van den Bogaard, Yu-Sok Kim, Marianna C. Schaap, Rienk Nieuwland, Wouter E. Kok, Harry R. Buller, Pieter W. Kamphuisen
DEVELOPMENT OF AN EX VIVO MODEL OF OCCLUSIVE THROMBUS FORMATION P-MO-241
Ishan A. Patel, Garth Tormoen, Hrebesh Subhash, Erik I. Tucker, Andras Gruber, Owen JT McCarty
EFFICACY OF BAXTER’S RECOMBINANT FACTOR VIIA IN ANIMAL MODELS OF HEMOPHILIA P-MO-242
Alexandra Schiviz, John Philip Lawo, Marlene Resch, Peter Leidenmuehler, Bettina Bischetsrieder, Hartmut Ehrlich, Friedrich Scheiflinger, Hans-Peter Schwarz, Werner Hoellriegl, Eva-Maria Muchitsch
EFFICACY OF BAXTER’S RECOMBINANT FACTOR IX IN MOUSE MODELS OF HEMOPHILIA B P-MO-243
Werner Hoellriegl, Alexandra Schiviz, Barbara Eder, John Philip Lawo, Martin Wolfsegger, Hartmut Ehrlich, Friedrich Scheiflinger, Hans-Peter Schwarz, Eva-Maria Muchitsch
PHARMACOKINETICS OF BAXTER’S RECOMBINANT FIX IN FACTOR IX KO MICE, RATS AND CYNOMOLGUS MONKEYS P-MO-244
Gerald Hoebarth, Susan Kubik, John Philip Lawo, Alfred Weber, Herbert Gritsch, Alexandra Schiviz, Hartmut Ehrlich, Friedrich Scheiflinger, Hans-Peter Schwarz, Eva-Maria Muchitsch
PHARMACOKINETICS OF BAXTER’S RECOMBINANT FVIIA IN FACTOR VIII KO MICE, RATS AND CYNOMOLGUS MONKEYS P-MO-245
Gerald Hoebarth, Susan Kubik, Martin Wolfsegger, John Philip Lawo, Alfred Weber, Herbert Gritsch, Alexandra Schiviz, Hartmut Ehrlich, Friedrich Scheiflinger, Hans-Peter Schwarz, Eva-Maria Muchitsch
REVERSAL AGENTS FOR EDOXABAN, A FACTOR XA INHIBITOR: EFFECTS OF FACTOR VIIA, ANTI-INHIBITOR COAGULANT COMPLEX, PROTHROMBIN COMPLEX CONCENTRATE, FRESH PLASMA, AND VITAMIN K P-MO-246
Yoshiyuki Morishima, Yuko Honda, Chikako Kamisato, Taketoshi Furugohri, Toshiro Shibano
IMPAIRED CARBOXYLATION OF OSTEOCALCIN BY WARFARIN, BUT NOT BY EDOXABAN, AN ORAL DIRECT FACTOR XA INHIBITOR, IN RATS P-MO-247
Yoshiyuki Morishima, Chikako Kamisato, Yuko Honda, Taketoshi Furugohri, Toshiro Shibano
CHARACTERIZATION OF A NOVEL VITAMIN K EPOXIDE REDUCTASE INHIBITOR P-MO-248
Yoshiyuki Morishima, Toshiyuki Sato, Naoki Tsuji, Mina Delawary, Yuko Honda, Chikako Kamisato, Toshiro Shibano
PROGRESSION OF THE HYPERCOAGULABLE STATE IN AGEING BMAL1 DEFICIENT MICE P-MO-249
Bianca Hemmeryckx, Cor E. Van Hove, Paul Fransen, Jan Emmerechts, Alexandre Kauskot, Hidde Bult, Henri Roger Lijnen, Marc Hoylaerts
Plasminogen Activator Inhibitors
EFFECT OF INSULIN ON THE PRODUCTION OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 IN HEPG2 CELLS: INDUCTION THROUGH 3’-UNTRANSLATED REGION P-MO-250
Satoshi Fujii, Ryu Miyagawa, Takefumi Asakura, Tomomi Nakamura, Hiromi Okada, Soichiro Iwaki, Burton E. Sobel
EFFECT OF FIBRINOGEN AND FACTOR XIII ON CLOT FORMATION AND THROMBIN GENERATION IN GLANZMANN THROMBASTHENIA BLOOD P-MO-251
Boris Shenkman, Tami Livnat, Mudi Misgav, Ivan Budnik, Uri Martinowitz
PLASMINOGEN ACTIVATOR INHIBITOR -1 4G/5G POLYMORPHISM AND RISK OF ACUTE ONSET ISCHEMIC STROKE IN YOUNG ASIAN INDIANS P-MO-252
Mohd S. Akhter, Arijit Biswas, Ravi Ranjan, Amit Sharma, Sunil Kumar, Madhuri Behari, Renu Saxena
AGE- AND GENDER-RELATED DIFFERENCES IN PAI-1 ANTIGEN LEVELS IN A JAPANESE GENERAL POPULATION, THE SUITA STUDY P-MO-253
Okamoto Akira, Toshiyuki Sakata, Yoshihiro Kokubo, Michitaka Sano, Toshiyuki Miyata
PAI-1 DEFICIENCY IN HUMANS AND MICE P-MO-254
Takayuki Iwaki, Takao Kobayashi, Kazuo Umemura, Tetsumei Urano, Tetsuhito Kojima, Naohiro Kanayama
XANTHOANGELOLS ISOLATED FROM ANGELICA KEISKEI INHIBIT INFLAMMATORY-INDUCED PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) PRODUCTION P-MO-255
Naoki Ohkura, Yoshitaka Nakakuki, Masahiko Taniguchi, Shiho Kanai, Katsunori Ohnishi, Toshiyuki Sakata, Tomoyoshi Nohira, Juzo Matsuda, Kimiye Baba, Gen-ichi Atsumi
INCREASED FIBRINOLYTIC POTENTIAL IN PATIENTS WITH TYPE 1 DIABETES P-MO-256
Anna Agren, Gun Jorneskog, Per-Eric Lins, Graciela Elgue, Hakan Wallen, Bjorn Wiman
AUGMENTATION OF CIRCADIAN PAI-1 EXPRESSION IN A KETOGENIC DIET-FED PPARα-NULL MICE : THE POSSIBLE INVOLVEMENT OF PPARγ ACTIVATION IN THE INDUCTION P-MO-257
Shuichi Horie, Daisuke Uchida, Naoki Ohkura, Katsutaka Oishi
Fibrinogen and Fibrin
EFFECTS OF MONOMERIC C-REACTIVE PROTEIN ON CLOT DYNAMICS AND FIBRIN STRUCTURE FROM ENDOTHELIAL CELLS: A POSSIBLE MECHANISM OF THE INCREASED THROMBOTIC RISK P-MO-258
Jianbo Wu, Tammy L. Strawn, William P. Fay
FIBRINOGEN MINTO: CONGENITAL HYPOFIBRINOGENAEMIA DUE TO HETEROZYGOSITY FOR A NOVEL MUTATION IN THE FIBRINOGEN GAMMA CHAIN CORRESPONDING TO A γ346GLY TO VAL SUBSTITUTION P-MO-259
Diane Zebeljan, Lye Lin Ho, Penelope Motum, Stephen Lang, Stephen Brennan, Sarah Just
A NOVEL MECHANISM FOR HYPOFIBRINOLYSIS IN DIABETES: THE ROLE OF COMPLEMENT C3 P-MO-260
Katharina Hess, Verena Schroeder, Saad Alzahrani, Mathew Mathai, Gareth Howell, Kerrie Smith, Angela M. Carter, Nikolaus Marx, Peter J. Grant, Ramzi Ajjan
MATURITY ONSET DIABETES OF THE YOUNG IS CHARACTERISED BY LESS THROMBOTIC FIBRIN NETWORK STRUCTURE COMPARED WITH PHENOTYPICALLY SIMILAR TYPE 2 DIABETES SUBJECTS P-MO-261
Ramzi A. Ajjan, Matthew J. Bottomley, Gaya Thanabalasingham, Saad H. Alzahrani, Katharina Hess, Katharine R. Owen
THE PREDICTIVE ABILITY OF D-DIMER FOR THE EFFECT OF THROMBOLYTIC THERAPY AT DEEP VEIN THROMBOSIS P-MO-262
Satoshi Ota, Norikazu Yamada, Yoshito Ogihara, Akihiro Tsuji, Ken Ishikura, Mashio Nakamura, Masaaki Ito
EFFECTS OF BβARG448LYS POLYMORPHISM ON FIBRIN CLOT STRUCTURE/FIBRINOLYSIS AND CARDIOVASCULAR COMPLICATIONS IN SUBJECTS WITH TYPE 2 DIABETES P-MO-263
Katie Amy Greenhalgh, Saad Alzahrani, J. Price, M. Strachan, P. Baxter, Kristina Standeven, Z. Kurdee, Peter Grant, Ramzi Ajjan, Robert SA Ariens
A HIGH DOSE OF ASPIRIN IS REQUIRED FOR POSITIVE INFLUENCE ON PLASMA FIBRIN NETWORK IN PATIENTS WITH TYPE 1 DIABETES P-MO-264
Sara Tehrani, Aleksandra Antovic, Fariborz Mobarrez, Koteiba Mageed, Per-Eric Lins, Ulf Adamson, Hakan Wallen, Gun Jorneskog
PULMONARY COAGULATION IS INCREASED DEPENDENT ON MAST CELLS IN A MURINE ASTHMA MODEL USING INTRANASAL INOCULATION OF HOUSE DUST MITE EXTRACT P-MO-265
Johannes Daan De Boer, C. Van t Veer, TJ Hommes, AF De Vos, JJTH Roelofs, JS Van der Zee, T. Van der Poll
COMPLEMENT C3 IS SUBSTRATE FOR PLASMIN AND IMPAIRS TPA-MEDIATED PLASMIN GENERATION RESULTING IN IMPAIRED FIBRINOLYSIS P-MO-266
Victoria R. Richardson, Kristina F. Standeven, Peter J. Grant, Angela M. Carter
IN VIVO N-HOMOCYSTEINYLATION OF FIBRINOGEN AND ITS ROLE IN THROMBOSIS P-MO-267
Amy L. Cilia La Corte, Majid Ali, Rafal Glowacki, Hieronim Jakubowski, Victoria Ridger, Richard Pease, Julian Scott, Robert A. Ariens, Helen Philippou
THE ANTIFIBRINOLYTIC FUNCTION OF FACTOR XIII IS EXCLUSIVELY EXPRESSED THROUGH α2ANTIPLASMIN CROSS-LINKING P-MO-268
Nicola J. Mutch, Steven R. Fraser, Nuala A. Booth
FIBRIN CLOT FORMATION IS A REVERSIBLE PROCESS P-MO-269
Irina N. Chernysh, John W. Weisel, Chandrasekaran Nagaswami, Prashant K. Purohit
POSSIBILITY OF FIBRIN MONOMER AS A EARLY MARKER FOR DISSEMINATED INTRAVASCULAR COAGULATION P-MO-270
Hyoeun Shim, Seongsoo Jang, Borae G. Park, Chan-Jeoung Park, Hyun-Sook Chi, Sang-Bum Hong
Laboratory Tests: Fibrinolysis and Proteolysis
MEASUREMENT OF IMPAIRMENT OF SPONTANEOUS THROMBOLYTIC ACTIVITY IN HABITUAL SMOKERS BY THE GLOBAL THROMBOSIS TEST P-MO-271
Akira Suehiro, Ichiro Wakabayashi, Tsutomu Yamashita, Junichiro Yamamoto
FISH INGREDIENT TAURINE MIGHT RAISE ENDOGENOUS THROMBOLYTIC ACTIVITY IN HEALTHY MIDDLE-AGED JAPANESE, ASSESSED BY A GLOBAL THROMBOSIS TEST (GTT) P-MO-273
Yoshinobu Ijiri, Hideo Ikarugi, Yukinori Tamura, Mayumi Ura, Mai Morishita, Mari Mori, Hiromitsu Ishii, Yukio Yamori, Junichiro Yamamoto
HYPERFIBRINOLYSIS - TIME REQUIRED TO REACH THE DIAGNOSIS USING STANDARD THROMBOELASTOMETRY ASSAYS P-MO-276
Ole Halfdan Larsen, Christian Fenger-Eriksen, Kirsten Christiansen, Jorgen Ingerslev, Benny Sorensen
HIGHLY SENSITIVE ELISA METHOD FOR THE DETERMINATION OF α2-PLASMIN INHIBITOR ANTIGEN LEVEL IN PLASMA AND OTHER BODY FLUIDS P-MO-277
Eva Katona, Adrienn Orosz, Andrea Csapo, Laszlo Muszbek
DEVELOPMENT OF AN IMMUNOASSAY FOR THROMBOMODULIN ON STACIA SYSTEM P-MO-278
Shuhei Matsushita, Tomoko Ono
Deep Vein Thrombosis and Pulmonary Embolism
TWO TEST-SYSTEMS FOR QUANTIFICATION OF SOLUBLE FIBRIN AND D-DIMER APPROBATION IN CLINICS P-MO-279
Eduard Vitalievich Lugovskoy, Serhiy Vasilievich Komisarenko, Irina Nikolaevna Kolesnikova, Tetyana Anatoliivna Koshel, Ievgen Oleksandrovich Koliesnik, Nataliya Eduardovna Lugovskaya, Lesya Petrivna Urvant, Olena Petrivna Kostyuchenko
CAUSAL RELATIONSHIP BETWEEN HYPERFIBRINOGENEMIA, THROMBOSIS, AND RESISTANCE TO THROMBOLYSIS P-MO-280
Kellie Rae Machlus, Jessica Cardenas, Frank Church, Alisa S. Wolberg
STRESS-INDUCED HYPERGLYCEMIA AND VENOUS THROMBOEMBOLISM FOLLOWING TOTAL HIP OR TOTAL KNEE ARTHROPLASTY: ANALYSIS FROM THE RECORD TRIALS P-MO-281
Danny Michael Cohn, Jeroen Hermanides, J. Hans DeVries, Pieter-Willem Kamphuisen, Sylvia Kuhls, Martin Homering, Joost B.L. Hoekstra, Anthonie W.A. Lensing, Harry R. Buller
'RISING LEUKOCYTE COUNT ' COULD MAKE A GOOD MARKER FOR VENOUS THROMBOEMBOLISM! P-MO-282
Raghavendra R. Allareddy
RESIDUAL VEIN OBSTRUCTION TO PREDICT THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS WITH DEEP VEIN THROMBOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS P-MO-283
Marc Carrier, Marc A. Rodger, Phil S. Wells, M. Righini, Gregoire Le Gal
VENOUS THROMBOEMBOLIC EVENTS AT A SPECIALIST HEART AND LUNG CENTRE P-MO-285
M. Louise Tillyer
HIGH LEVELS OF GLUCOSE AT TIME OF DIAGNOSING VENOUS THROMBOSIS: A CASE-CONTROL STUDY P-MO-286
Vladimir Tichelaar, Willem M. Lijfering, Jan C. ter Maaten, Hanneke C. Kluin-Nelemans, Karina Meijer
EVALUATION OF DIAGNOSTIC PROCEDURES FOR DIAGNOSIS OF HEPARIN-INDUCED DELAYED-TYPE HYPERSENSITIVITY REACTIONS (DTH) P-MO-287
Marc Schindewolf, Katja Hardt, Manfred Wolter, Roland Kaufmann, Birgit Kahle, Wolf-Henning Boehncke, Edelgard Lindhoff-Last, Ralf J. Ludwig
DEEP VEIN THROMBOSIS AFTER TOTAL KNEE OR HIP ARTHROPLASTY IS ASSOCIATED WITH INCREASED CALF MUSCLE DEOXYGENATION BEFORE SURGERY P-MO-288
Takashi Yamaki, Atsumori Hamahata, Daisuke Fujisawa, Hisato Konoeda, Kazuyuki Kubo, Taro Kono, Mitohiro Nozaki, Hiroyuki Sakurai
INCREASING OF ISCHEMIC STROKE IN RESIDENTS WITH DVT AFTER MID NIIGATA PREFECTURE EARTHQUAKE P-MO-289
Kazuhiko Hanzawa, Maiko Ikura, Takeshi Okamoto, Kohichi Sato, Kyoko Shinada, Takashi Nakajima
HYPERTENSION IS A RISK FACTOR FOR DVT IN JAPANESE QUAKE RESIDENTS P-MO-290
Kazuhiko Hanzawa, Maiko Ikura, Takeshi Okamoto, Kohichi Sato, Kyoko Shinada, Takashi Nakajima
RELEVANCE OF THROMBOPHILIA IN DEEP VEIN THROMBOSIS FOLLOWING A MAJOR EARTHQUAKE P-MO-291
Mana Mitsuguro, Toshiyuki Sakata, Akira Okamoto, Kazuhiko Hanzawa, Kyoko Shinada, Takashi Nakajima, Sachika Kameda, Michitaka Sano, Toshiyuki Miyata
QUALITY AND SAFETY LABORATORY MONITORING OF INDIRECT ANTICOAGULANTS THERAPY P-MO-292
Nadezda A. Vorobyeva, Alyona I. Vorobyeva, Ludmila A. Isaeva, Alexsandra S. Rogozina, Petr A. Lavrinov
HEREDITARY PROTEIN C DEFICIENCY CAUSED BY COMPOUND HETEROZYGOUS MUTANTS IN TWO UNRELATED CHINESE FAMILIES P-MO-293
Yingting Wu, Xuefeng Wang, Hongli Wang, Qiulan Ding, Jing Dai, Yeling Lu
LOW INCIDENCE OF POSTOPERATIVE DEEP VEIN THROMBOSIS IN PATIENTS UNDERGOING COLORECTAL CANCER SURGERY SEEN IN TAIWAN P-MO-294
Ching-Yeh Lin, Ming Ching Shen, Hung Chang Chen, Ting Ming Huang, Tsang Chi Lin, Jau Jie You, Shyuann Yuh Lin, Han Ni Hsieh
THROMBIN GENERATION IS INCREASED IN AFRICAN-CARIBBEANS COMPARED TO CAUCASIANS WITH DEEP VEIN THROMBOSIS P-MO-295
Lara N. Roberts, Raj K. Patel, Roopen Arya
PROGNOSTIC VALUE OF THE GENEVA PREDICTION RULE IN PATIENTS WITH PULMONARY EMBOLISM P-MO-296
Laurent Bertoletti, Gregoire Le Gal, Drahomir Aujesky, Olivier Sanchez, Pierre-Marie Roy, Franck Verschuren, Henri Bounameaux, Arnaud Perrier, Marc Righini
PROGNOSTIC VALUE OF THE GENEVA PREDICTION RULE IN PATIENTS IN WHOM PULMONARY EMBOLISM IS RULED OUT P-MO-297
Laurent Bertoletti, Gregoire Le Gal, Drahomir Aujesky, Olivier Sanchez, Pierre-Marie Roy, Franck Verschuren, Henri Bounameaux, Arnaud Perrier, Marc Righini
HEMATOCRIT AND THE RISK OF RECURRENT VENOUS THROMBOSIS: A PROSPECTIVE COHORT STUDY P-MO-298
Lisbeth Eischer, Verena Tscholl, Georg Heinze, Ludwig Traby, Paul Alexander Kyrle, Sabine Eichinger
PAST PROVOKING VENOUS THROMBOSIS RISK SITUATIONS ON THE RISK OF A RECURRENT THROMBOTIC EVENT: A COHORT STUDY P-MO-299
Daniel Dias Ribeiro, Willem Lijfering, Sandhi Barreto, Izabella Silva, Mariana Chalup, Frits Rosendaal, Suely Rezende
IS DEEP-VEIN THROMBOSIS ALWAYS THE ORIGIN OF PULMONARY EMBOLISM? IMAGING OF VEINS WITH A TOTAL-BODY DIRECT THROMBUS MRI TECHNIQUE P-MO-300
Kirsten van Langevelde, A. Sramek, P. W.J. Vincken, C.J. van Rooden, F. R. Rosendaal, S. C. Cannegieter
HOMOZYGOUS FACTOR V LEIDEN AND COMPOUND HETEROZYGOSITY FOR FACTOR V LEIDEN AND PROTHROMBIN MUTATION P-MO-301
Ymir Saemundsson, Signy Vala Sveinsdottir, Henrik Svantesson, Peter J. Svensson
SOCIOECONOMIC FACTORS AND CONCOMITANT DISEASES ARE RELATED TO THE RISK FOR VENOUS THROMBOEMBOLISM DURING 13 YEARS OF PROSPECTIVE FOLLOW-UP P-MO-302
Nazim Isma, Peter J. Svensson, Bengt Lindblad, Juan Merlo, Henrik Ohlsson, Anders Gottsater
SAFETY AND EFFICACY OF FONDAPARINUX FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM (VTE) IN JAPANESE PATIENTS UNDERGOING COLORECTAL CANCER SURGERY P-MO-303
Taishi Hata, Masayoshi Yasui, Kohei Murata, Masaki Okuyama, Masayuki Ohue, Masataka Ikeda, Shigeyuki Ueshima, Kotaro Kitani, Junichi Hasegawa, Hiroshi Tamagawa, Makoto Fujii, Atsushi Ohkawa, Takeshi Kato, Shunji Morita, Takayuki Fukuzaki, Tsunekazu Mizushima, Mitsugu Sekimoto, Riichiro Nezu, Yuichiro Doki, Masaki Mori
DOES RESIDUAL VEIN OBSTRUCTION PREDICT RECURRENT THROMBOEMBOLISM AFTER DEEP VEIN THROMBOSIS? A PATIENT-LEVEL META-ANALYSIS P-MO-304
Marco P. Donadini, Walter Ageno, Benilde Cosmi, Daniela Poli, Paolo Prandoni, Sergio Siragusa, Laura Young, Francesco Dentali, Monica Caprioli, James Douketis
ACTIVATION OF COAGULATION BY A THALIDOMIDE-BASED REGIMEN P-MO-305
Yu Isozumi, Aya Matsumoto, Asuka Hoshi, Jihwa Chung, Takatoshi Koyama
BENCHMARK OF THE INTERNATIONAL NORMALIZED RATIO DURING VITAMIN K TREATMENT IN VENOUS THROMBOEMBOLISM: A SYSTEMATIC REVIEW P-MO-306
Petra MG Erkens, Hugo ten Cate, Martin H. Prins
THROMBOSIS RISK IN MEDICAL INPATIENTS: ASSESSMENT OF TWO THROMBOSIS RISK SCORES P-MO-307
Neil Adrian Zakai, Peter W. Callas, Allen B. Repp, Mary Cushman
THE MANAGEMENT OF SUB-SEGMENTAL PULMONARY EMBOLISM: A CROSS-SECTIONAL SURVEY OF CANADIAN THROMBOSIS PHYSICIANS P-MO-308
Marc Carrier, Gregoire Le Gal, Susan Kahn, Michael Kovacs, Philip Wells, David Anderson, Marc Rodger
DEVELOPMENT AND APPLICATION OF AN AUTOMATED THROMBIN GENERATION ASSAY WHICH IS SENSITIVE TO DEFECTS OF PROTEIN C PATHWAY P-MO-309
Laura Green, Andrew S. Lawrie, Ian J. Mackie, Kim Ryland, Hannah Cohen, Ri Liesner, Samuel J. Machin
EVALUATION OF A NEW D-DIMER TEST IN COMBINATION WITH PRETEST CLINICAL PROBABILITY SCORE FOR DIAGNOSIS OF PULMONARY EMBOLISM AND DEEP VENOUS THROMBOSIS P-MO-310
Tarek M. Owaidah, Nahla Al.Ghasham, Khalid Magrabi
BLEEDING-THE MOST FREQUENT UNEXPECTED EFFECT OF THE THERAPY WITH ORAL ANTICOAGULANT DRUGS P-MO-311
Deniza Donco Stambolieva, Tanja Timova, Jani Angelovski, Meri Sorova, Laura Gorcaj, Lence Maseva, Mirjana Trenceva, Ivanka Nikoloska
ANTICOAGULANT PROTOCOL FOR TREATING CEREBRAL VEIN THROMBOSIS: A PROSPECTIVE SINGLE-CENTER STUDY P-MO-312
Maria Teresa Sartori, Sofia Barbar, Paolo Zampieri, Marina Munari, Carla Carollo, Chiara Briani, Gianluigi Ricchieri, Laura Pasetto, Graziella Saggiorato, Paolo Prandoni
INCREASED INCIDENCE OF PULMONARY EMBOLISM IN PATIENTS WITH SEVERE ASTHMA P-MO-313
Christof J. Majoor, Aelko H. Zwinderman, Harry B. Buller, Pieter W. Kamphuisen
PROGNOSTIC MARKERS FOR RESIDUAL PERFUSION DEFECTS IN PATIENTS WITH ACUTE PULMONARY EMBOLISM P-MO-314
Roger EG Schutgens, Mariette Agterof, Roger Schutgens, Fred Verzijlbergen, Monique van Buul, Repke Snijder, Rene Eijkemans, Douwe Biesma
ASSESSMENT OF THROMBIN GENERATION IN PRIMARY THROMBOPHILIA AND ACQUIRED RISK FACTORS FOR VENOUS THROMBOEMBOLISM P-MO-316
Antonin Hlusi, Ludek Slavik, Jana Ulehlova, Jana Prochazkova, Vera Krcova
PROC GLOBAL ASSAY IN PATIENTS WITH VENOUS THROMBOEMBOLISM AND PREGNANCY COMPLICATIONS P-MO-317
Pablo Alberto Martinez, Maria Luciana Roumeque, Romina Valeria Suarez, Solange Alejandra Rodriguez
EFFICACY OF RIVAROXABAN FOR PREVENTION OF VENOUS THROMBOEMBOLISM AFTER KNEE ARTHROSCOPY: A RANDOMIZED DOUBLE-BLIND TRIAL (ERIKA STUDY) P-MO-318
Giuseppe Camporese, Enrico Bernardi, Franco Noventa
EMERGENCY DEPARTMENT ACCESS RATE FOR VENOUS THROMBOEMBOLISM, CARDIOVASCULAR AND PULMONARY DISEASES IN RELATIONSHIP WITH THE COARSE AND FINE PARTICULATE MATTER AIR POLLUTION P-MO-319
Nicola Martinelli, Davide Cigolini, Marco Sandri, Domenico Girelli, Giorgio Ricci, Giampaolo Rocca, Oliviero Olivieri
ANTICOAGULANT UTILIZATION IN CANCER ASSOCIATED THROMBOSIS (CAT) PATIENTS P-MO-320
Elham Rahme, Guillaume Feugere, Elodie Ramos, Myriam Antoun
AIR POLLUTION-INDUCED PROCOAGULANT CHANGES ARE TRIGGERED BY CIRCULATING MICROVESICLES P-MO-321
Jan Emmerechts, Lotte Jacobs, Soetkin Van kerckhoven, Serena Loyen, Chantal Mathieu, Frans Fierens, Ben Nemery, Tim Nawrot, Marc Hoylaerts
A COMMON STANDARD IS INAPPROPRIATE FOR DETERMINING THE POTENCY OF SEMULOPARIN AND BEMIPARIN P-MO-322
Walter Jeske, Debra Hoppensteadt, Angel Gray, Jeanine Walenga, Josephine Cunanan, Lauren Meyer, Jawed Fareed, Alain Bayol, Helene Rigal, Christian Viskov
CYSTATIN C IS ASSOCIATED WITH RISK OF VENOUS THROMBOEMBOLISM IN SUBJECTS WITH NORMAL KIDNEY FUNCTION - THE TROMSO STUDY P-MO-323
Ellen E. Brodin, Sigrid Braekkan, Anders Vik, Jan Brox, John-Bjarne Hansen
EMOTIONAL STATES AND FUTURE RISK OF VENOUS THROMBOEMBOLISM: THE TROMSO STUDY P-MO-324
Kristin F. Enga, Sigrid K. Braekkan, Ida J. Hansen-Krone, John-Bjarne Hansen
INPATIENT RISKS OF VENOUS THROMBOEMBOLISM AND BLEEDING FOLLOWING HIP AND KNEE REPLACEMENT SURGERY P-MO-325
Elham Rahme, Kaberi Dasgupta, Susan R. Kahn, Sasha Bernatsky, Greg K. Berry, Alain Cirkovic, Yves Laflamme, Ronald A. Dimentberg, Mark Burman, Youssef Habel, Celine Khodr
OUTPATIENT RISKS OF VENOUS THROMBOEMBOLISM AND BLEEDING FOLLOWING HIP AND KNEE REPLACEMENT SURGERY P-MO-326
Elham Rahme, Kaberi Dasgupta, Susan R. Kahn, Sasha Bernatsky, Greg K. Berry, Mark Burman, Alain Cirkovic, Yves Laflamme, Ronald A. Dimentberg, Youssef Habel, Celine Khodr
EPIDEMIOLOGY OF VENOUS THROMBOEMBOLISM IN TRAUMA PATIENTS WITH LOWER EXTREMITY INJURIES P-MO-327
Kerry Hitos, Patrick Chu, John P. Fletcher
CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND THE RISK OF PE AND DVT P-MO-328
Linda E. Flinterman, Astrid Hylckama Vlieg, Suzanne C. Cannegieter, Frits R. Rosendaal
INFLUENCE OF PUBLIC AWARENESS OF SYMPTOMS OF DEEP VEIN THROMBOSIS AND BURDEN OF THE DISEASE ON THE RATE OF CONFIRMED THROMBOTIC EVENTS P-MO-329
Malgorzata Dybowska, Witold Z. Tomkowski, Renata Gralec, Janusz Burakowski, Adam Jozwik, Pawel Kuca
SEASONAL RATE OF DEEP VENOUS THROMBOSIS P-MO-330
Pawel Kuca, Malgorzata Dybowska, Renata Gralec, Janusz Burakowski, Adam Jozwik, Witold Z. Tomkowski
Genetic Determinants and Epidemiology
INTERACTION BETWEEN HYPERHOMOCYSTEINEMIA AND SEVERAL DNA POLYMORPHISMS INVOLVED IN ENDOTHELIAL DYSFUNCTION IN VENOUS THROMBOEMBOLISM P-MO-331
Veronika Shmeleva, Sergei Kapustin, Anastasia Polyakova, Mikhail Blinov
PROTHROMBIN G20210A MUTATION IS ASSOCIATED WITH HIGHER DILUTE RUSSELL VIPER VENOM TIME, WHICH HAS MODERATE POWER TO PREDICT CARRIER STATUS P-MO-332
Kristi Johnson Smock, George M. Rodgers, Brian H. Shirts
ROLE OF GENE ENVIRONMENTAL INTERACTIONS IN DEVELOPMENT OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE IN NORTH WEST RUSSIA P-MO-334
Veronika Shmeleva, Sergei Kapustin, Mikhail Blinov, Ludmila Papayan
SUPERFICIAL VEIN THROMBOSIS AS A PRECURSOR FOR VENOUS THROMBOSIS IN THE MEGA STUDY P-MO-335
Kirsten van Langevelde, Willem M. Lijfering, Frits R. Rosendaal
R147W MUTATION OF PROTEIN C GENE IS COMMON IN THAI POPULATION P-MO-336
Ampaiwan Chuansumrit, Werasak Sasanakul, Duangrurdee Wattanasirichaigoon, Nongnuch Sirachainan, Natjava Yudhasompop, Arjit Tiraganjana, Praguywan Kadegasem
A NOVEL PROTHROMBIN GENE MUTATION LEADS TO AN AT-RESISTANT THROMBIN IN A FAMILY WITH INHERITED THROMBOPHILIA P-MO-337
Yuhri Miyawaki, Atsuo Suzuki, Yuhta Fujimori, Junko Fujita, Asuka Maki, Akira Takagi, Takashi Murate, Michio Sakai, Kohji Okamoto, Tadashi Matsushita, Tetsuhito Kojima
STUDY ON THE DEFICIENCY OF ANTICOAGULANT PROTEINS IN PATIENTS OF THROMBOTIC EVENTS WITH NO EVIDENT ACQUIRED FACTORS: CLINICAL PREVALENCE, RISKS, AND GENETIC ANALYSIS P-MO-338
Changcheng Zheng, Jingsheng Wu, Kaiyang Ding, Jie Li, Xin Liu, Xiaoyan Cai, Weibo Zhu
PON2 SER311CYS POLYMORPHISM IS A PREDICTOR OF TOTAL AND CARDIOVASCULAR MORTALITY IN PATIENTS WITH ANGIOGRAPHICALLY CONFIRMED CORONARY ARTERY DISEASE P-MO-339
Nicola Martinelli, Domenico Girelli, Elisa Grison, Letizia Consoli, Roberta Micaglio, Elisabetta Trabetti, Giovanni Malerba, Simonetta Friso, Francesca Pizzolo, Pier Franco Pignatti, Roberto Corrocher, Olivieri Oliviero
RISK OF VENOUS THROMBOEMBOLISM ASSOCIATED WITH DIFFERENT PLASMA LEVELS OF ANTITHROMBIN, PROTEIN C AND PROTEIN S P-MO-340
Ida Martinelli, Paolo Bucciarelli, Francesca Gianniello, Serena M. Passamonti, Franca Franchi, Eugenia Biguzzi, Pier Mannuccio Mannucci
STUDY ON THE PATHOGENESIS OF PROC P275S MUTATION IN PROTEIN C DEFICIENCY AND THE ROLE OF ITS CORRESPONDING LOOP P-MO-341
Tingting Yu, Jing Dai, Jian Wang, Xuefeng Wang, Qihua Fu
PHYSICAL ACTIVITY AND RISK OF FIRST VENOUS THROMBOSIS: A SUBGROUP ANALYSIS WITHIN THE MEGA CASE-CONTROL STUDY P-MO-342
Willem M. Lijfering, Frits Rosendaal, Suzanne Cannegieter
OVER FIFTY PERCENT OF DUTCH VTE FAMILIES WITH PROTEIN C DEFICIENCY SHARE A FOUNDER R272C MUTATION P-MO-343
Jorine S. Koenderman, Rogier M. Bertina, Pieter H. Reitsma, Marieke CH de Visser
MULTIVARIATE ANALYSIS OF GENETIC, BEHAVIOURAL AND SOCIO-PSYCHOLOGICAL DETERMINANTS OF VITAMIN K-ANTAGONIST DOSE P-MO-344
Jane Skov, Else-Marie Bladbjerg, Morten Arendt Rasmussen, Johannes Sidelmann, Anja Leppin, Joergen Jespersen
Antiphospholipid Syndrome
LATE ONSET WARFARIN INDUCED SKIN NECROSIS IN A YOUNG FEMALE WITH ANTIPHOSPHOLIPID ANTIBODY SYNDROME P-MO-345
Nasim Valizadeh, Mir Amir Aghdashi, Sona Nori Vahed, Kamran Keyvan Pazhuh, Fathollah Moradi
PLATELET ACTIVATION AND PARADOXICAL INHIBITION OF ADP INDUCED AGGREGATION BY ANTIPHOSPHOLIPID ANTIBODIES IN VITRO P-MO-346
Kenji Oku, Tatsuya Atsumi, Olga Amengual, Yuuichirou Fujieda, Kotaro Otomo, Masaru Kato, Shin Furukawa, Hirohiko Kitakawa, Shinsuke Yasuda, Tetsuya Horita, Yuuji Hori, Tetsuhiro Nishikawa, Kazuyoshi Nihei, Masahiro Ieko, Takao Koike
ARTERIAL THROMBOSIS IN ANTIPHOSPHOLIPID SYNDROME P-MO-347
Nuria Bermejo, M.J. Garcia Blanco, C. Martin Aguilera, M.L Bengochea, F. Carnicero, J. Bergua
HAEMOSTATIC CHANGES IN CORONARY ARTERY DISEASE PATIENTS WITH HYPERHOMOCYSTEINEMIA AND ANTI-BETA2 GLYCOPROTEIN-I AND/OR ANTI-PROTHROMBIN ANTIBODIES P-MO-348
Veronika Shmeleva, Olga Smirnova, Vera Kobilyanskaya, Ludmila Papayan
FIBRINOLYSIS IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES P-MO-349
Karen A. Breen, Kiran Parmar, Beverley J. Hunt
COMPLEMENT ACTIVATION IN PATIENTS WITH ISOLATED ANTIPHOSPHOLIPID ANTIBODIES (APL) AND PRIMARY ANTIPHOSPHOLIPID SYNDROME (PAPS) P-MO-350
Karen A. Breen, Paul Seed, Kiran Parmar, Beverley J. Hunt
USEFULNESS OF THROMBOELASTOGRAPHY IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES OR PRIMARY ANTIPHOSPHOLIPID SYNDROME P-MO-351
Karen A. Breen, Beverley J. Hunt
MESENTERIC VASCULAR THROMBOEMBOLISM IN ASSOCIATION WITH ANTIPHOSPHOLIPID ANTIBODIES: A CASE SERIES P-MO-352
Karen A. Breen, Beverley J. Hunt
THE PROBLEM OF INTER-ASSAY VARIABILITY IN ANTIPHOSPHOLIPID ANTIBODY ASSAYS PERSISTS P-MO-353
Katrien M.J. Devreese
AUTOANTIBODIES AGAINST PROTHROMBIN AND PROTHROMBIN-PHOSPHATIDYLSERIN COMPLEX: A DIAGNOSTIC TOOL FOR THE ANTIPHOSPHOLIPID SYNDROME? P-MO-354
Katrien M.J. Devreese, Marc F. Hoylaerts
THE RISK OF MISSING LUPUS ANTICOAGULANT: VALIDATION OF ISTH GUIDELINES 2009 P-MO-355
Jun Teruya, Ozlem Bilen, Barry Myones
FOLLOW-UP OF 148 PATIENT WITH ANTIPHOSPHOLIPID SYNDROME (APS) DURING A 18-YEAR PERIOD P-MO-356
Tatiana M. Reshetnyak, Inna B. Shtivelband, Natatia V. Seredavkina, Elena N. Aleksandrova, Lubov V. Kondratyeva, Evgenii L. Nassonov
RENAL TRANSPLANTATION IN A PATIENT WITH CATASTROPHIC APLS AND HIT AND DOUBLE TRANSPLANTATION (LIVER AND RENAL) IN A PATIENT WITH TTP P-MO-357
Dorit Blickstein, Eytan Mor, Ruth Rahamimov, Aida Inbal
Pregnancy, Hormones, Women’s Issues
MONITORING ANTI-XA ACTIVITY OF TINZAPARIN AND BEMIPARIN [LOW MOLECULAR WEIGHT HEPARINS (LMWHS)]AT THERAPEUTIC DOSAGES DURING PREGNANCY P-MO-358
Amparo Santamaria, Adriana Sierra, Laura Hernandez, Marina Carrasco, Montse Borrell, Dolors Llobet, Jordi Fontcuberta
INCREASED LEVELS OF TISSUE FACTOR ACTIVITY ON SYNCYTIOTROPHOBLAST MICROVESICLES RELEASED INTO THE MATERNAL CIRCULATION DURING PRE-ECLAMPSIA P-MO-359
Chris Gardiner, Dionne S. Tannetta, Paul Harrison, Christopher WG Redman, Ian L. Sargent
A “NEW” THROMBOPHILIA MARKER IN THE PROTEIN C PATHWAY - A LIKELY CAUSE FOR UNEXPLAINED RECURRENT PREGNANCY LOSS IN YOUNG MALAYSIAN WOMEN! P-MO-360
Thiruchelvam Ayadurai, Faraizah Abdul Karim, Sekaran Muniandy
PREGNANCY IS A HIGH RISK FACTOR FOR HEPARIN-INDUCED ALLERGIC SKIN REACTIONS - RESULTS OF A PROSPECTIVE STUDY P-MO-361
Marc Schindewolf, Corinna Gobst, Hartmut Kroll, Andreas Recke, Frank Louwen, Manfred Wolter, Roland Kaufmann, Wolf-Henning Boehncke, Edelgard Lindhoff-Last, Ralf J. Ludwig
STUDY OF VARIABILITY IN THE MANAGEMENT OF THROMBOEMBOLIC DISEASE (TD) IN WOMEN IN SPAIN: NATIONAL MULTICENTER STUDY P-MO-362
Amparo Santamaria, Dolors Tassies, Oscar Martinez, F.Javier Rodriguez-Martorell, R. Lecumberri, M. Casellas, M.Jose Gutierrez-Pimentel, IM Ramirez
INCIDENCE OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH CUSHING’S SYNDROME: A MULTICENTER COHORT STUDY P-MO-363
Danka J. Stuijver, Bregje van Zaane, Richard A. Feelders, Jan Debeij, Suzanne C. Cannegieter, Ad R. Hermus, Gerrit van den Berg, Alberto M. Pereira, Wouter W. de Herder, Margreet A. Wagenmakers, Michiel N. Kerstens, Pierre M. Zelissen, Eric Fliers, Nicolaas Schaper, Madeleine L. Drent, Olaf M. Dekkers, Victor E. Gerdes
THROMBOPHILIC STATUS OF WOMEN WITH COMPLICATED OBSTETRIC HISTORY P-MO-364
Nadezda A. Vorobyeva, Diana R. Gamyrkina, Yana A. Dremova Ya
POSTPARTUM LIFE-THREATENING THROMBOEMBOLIC COMPLICATIONS IN A PATIENT WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA: A ‘RESCUER’ ROLE FOR ECULIZUMAB? P-MO-365
Kristin Jochmans, Frederik Vandenbroucke, Marc De Waele, Fabienne Trullemans
OCCURRENCE OF OBSTETRIC AND THROMBOEMBOLIC COMPLICATIONS IN FAMILY MEMBERS OF WOMEN WITH COMMON INHERITED THROMBOPHILIAS AND PREVIOUS OBSTETRIC COMPLICATIONS P-MO-366
Elvira Grandone, Michela Villani, Donatella Colaizzo, Giovanni Tiscia, Elena Chinni, Filomena Cappucci, Patrizia Vergura, Gennaro Vecchione, Lucia Fischetti, Maurizio Margaglione
THE THROMBIN GENERATION PROFILES OF WOMEN ON PROPHYLACTIC ENOXAPARIN DURING PREGNANCY AND THE PUERPERIUM P-MO-367
Jignesh P. Patel, Raj K. Patel, Michael S. Marsh, Bruce Green, John Graham Davies, Roopen Ayra
WOMEN’S VIEWS AND ADHERENCE TO ENOXAPARIN THERAPY DURING PREGNANCY AND THE PUERPERIUM P-MO-368
Jignesh P. Patel, Vivian Auyeung, Raj K. Patel, Michael S. Marsh, Bruce Green, Roopen Arya, John Graham Davies
PREGNANCY COMPLICATIONS AND ANTIPHOSPHOLIPID ANTIBODIES P-MO-369
Katia M. Taouli, Riad Benhabib, Nabila Baba Ahmed, Sara Ayad
THE RISK OF RECURRENT VENOUS THROMBOSIS ASSOCIATED WITH ORAL CONTRACEPTIVE USE P-MO-370
Astrid van Hylckama Vlieg, Linda E. Flinterman, Suzanna C. Cannegieter, Frits R. Rosendaal
CAN ANTICOAGULANT THERAPY IMPROVE THE OUTCOME OF PREGNANCY IN THROMBOPHILIC WOMEN? P-MO-371
Mirjana K. Kovac, Zeljko Mikovic, Gorana Mitic, Valentina Djordjevic, Ivana Jaglicic, Vesna Mandic, Dragica Radojkovic
RESULTS OF THROMBOPHILIA SCREENING IN ORAL CONTRACEPTIVE USERS WITH VENOUS THROMBOTIC COMPLICATIONS IN NORTH WEST RUSSIA P-MO-372
Veronika Shmeleva, Natalia Saltikova, Ludmila Papayan, Natalia Aganezova
RISK OF PPH IN WOMEN USING THERAPEUTIC DOSAGE OF LMWH DURING PREGNANCY AND PUERPERIUM P-MO-373
H. Marieke Knol, Lejan Schultinge, Jan Jaap H.M. Erwich, Nic J.G.M. Veeger, Hanneke C. Kluin-Nelemans, Karina Meijer
RISK OF RECURRENCE AFTER CONTRACEPTION-RELATED VENOUS THROMBOSIS: COHORT STUDY P-MO-374
Emmanuelle Le Moigne, Aurelien Delluc, Emmanuel Novak, Dominique Mottier, Gregoire Le Gal
Cancer and Thrombosis
CIRCULATING BLASTS, PLATELET COUNT AND D-DIMER IN ACUTE LEKEMIA : IS THERE ANY CORRELATION? P-MO-375
Amaylia Oehadian, Anggun Mekar, Rachmat Sumantri, Nadjwa Zamalek
SPLANCHNIC VENOUS THROMBOEMBOLISM IN AMBULATORY CANCER PATIENTS RECEIVING CHEMOTHERAPY P-MO-376
Rita Carlotta Santoro, Simona Prejano', Piergiorgio Iannaccaro
CLINICOHAEMATOLOGICAL RESPONSE AND RESISTANCE/INTOLERANCE TO HYDROXYCARBAMIDE IN ESSENTIAL THROMBOCYTHAEMIA P-MO-377
Rita Carlotta Santoro, Simona Prejano', Piergiorgio Iannaccaro
PROTEIN C PATHWAY AND ANTITHROMBIN IN THROMBOSIS-RELATED GASTROINTESTINAL DISORDERS P-MO-378
Selime Ayaz, Huseyin Alkim, Canan Alkim, Nurgul Sasmaz
HYPERHOMOCYSTEINEMIA AS PREDICTOR OF THROMBOTIC COMPLICATIONS IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE DISEASES AND MULTIPLE MYELOMA P-MO-379
Veronika Shmeleva, Ludmila Papayan, Kudrat Abdulkadyrov, Stanislav Bessmeltsev, Ekaterina Chait, Tatyana Zamotina
INCIDENTAL PULMONARY EMBOLISM IN CANCER PATIENTS IS ASSOCIATED WITH SIGNIFICANT MORBIDITY AND MORTALITY. A COMPREHENSIVE CANCER CENTER EXPERIENCE P-MO-380
Hikmat N. Abdel-Razeq, Asem H. Mansour, Yousef M. Ismael
THE RISK OF STROKE AND MYOCARDIAL INFARCTION IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS. A STUDY OF THE IMPORTANCE OF PLATELET AGGREGATION P-MO-381
Viola Maria I. Popov, Ana Maria Vladareanu, Horia Bumbea, Eugenia Kovacs, Tudor Savopol, Adrian Tase, Minodora Onisai, Mihaela Camelia Stancu, Anca Maria Ilea, Camelia Marioara Dobrea, Stanciu Marian
RECOMBINANT THROMBOMODULIN MAY PLAY A PREVENTIVE ROLE FOR VENO-OCCLUSIVE DISEASE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION P-MO-382
Shosaku Nomura, Shinya Fujita, Ryotaro Ozasa, Takahisa Nakanishi, Michihiko Miyaji, Shinichiro Mori, Tomoki Ito, Kazuyoshi Ishii
CURRENT USE OF PROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) IN COLORECTAL CANCER SURGERY PATIENTS: THE SCALA STUDY P-MO-383
Walter Ageno, Charles M. Samama, Fred A. Anderson
LONG-TERM USE OF CURATIVE DOSES OF TINZAPARIN VERSUS VITAMIN K ANTAGONISTS IN THE TREATMENT OF VENOUS THROMBOEMBOLISM (VTE): META-ANALYSIS OF 5 RANDOMIZED TRIALS P-MO-384
Silvy Laporte, Laurent Bertoletti, Patrick Mismetti
IDENTIFICATION OF GLYCOPROTEIN IB (GPIB), LRP1 AND ANNEXIN II MRNA IN DIFFERENT HUMAN AND MOUSE TUMOR CELL LINES P-MO-385
Yanina P. Powazniak, Ana C. Kempfer, Julio C. Calderazzo Pereyra, Daniel F. Alonso, Maria A. Lazzari, Analia Sanchez-Luceros
CANCER-CELL EPCR CONTRIBUTES TO CELL-SURVIVAL, TUMOR-PROGRESSION AND PROMOTES HYPERCOAGULABILITY P-MO-386
E. Ducros, S. Mirshahi, P. Mirshahi, A. M. Faussat, F. Dagonnet, D. Azzazene, S. Camilleri-Brouet, E. Mery, A. Therwath, E. Pujade-Lauraine, J. Soria, M. Mirshahi
EXPRESSION OF ENDOTHELIAL PROTEIN C RECEPTOR BY HUMAN HEMATOLOGIC MALIGNANCIES: IMPLICATION IN CANCER-ASSOCIATED HYPERCOAGULABILITY P-MO-387
E. Ducros, S. Mirshahi, A. M. Faussat, P. Mirshahi, S. Dimicoli, R. Tang, N. Benabbou, J. Pardo, F. Fava, A. Therwath, J. P. Marie, J. Soria, M. Mirshahi
Pediatric Thrombosis
BILATERAL CAROTID ARTERY THROMBOSIS IN A NEWBORN P-MO-389
Monika Hannelore Girisch, Michael Alber, Gesa Wiegand, Michael Hofbeck
TESTING FOR HERITABLE THROMBOPHILIA IN CHILDREN AT STARSHIP CHILDREN’S HOSPITAL: AN AUDIT OF REQUESTS BETWEEN 2004 AND 2009 P-MO-390
Peter Bradbeer, Nyree Cole, Lochie Teague
INFLUENCE OF GENETIC THROMBOPHILIC DISORDERS IN EXTRAHEPATIC PORTAL VEIN THROMBOSIS IN CHILDREN AND ADOLESCENTS P-MO-391
Matteo Luciani, Andrea Pietrobattista, Juan G. Abraldes, Manila Candusso, Simona Pancotti, Massimo Soldati, Lidia Monti, Giuliano Torre, Valerio Nobili
NORMALIZED COAGULATION MARKERS AND ANTICOAGULATION PROTEINS IN CHILDREN WITH SEVERE β-THALASSEMIA DISEASE AFTER STEM CELL TRANSPLANTATION P-MO-392
Nongnuch Sirachainan, Jaruwan Thongsad, Samart Pakakasama, Suradej Hongeng, Ampaiwan Chaunsamrit, Praguywan Kadegasem, Arjit Tirakanjana, Napaporn Archararit, Somtawin Sirireung
THROMBIN AND PLASMIN GENERATION IN CHILDREN FOLLOWING PERINATAL ARTERIAL ISCHEMIC STROKE P-MO-393
Jennifer Armstrong-Wells, Mindy Simpson, Elizabeth Villalobos-Menuey, Timothy Bernard, Neil Goldenberg, Marilyn Manco-Johnson
ATYPIC HEPARIN THROMBOCYTOPENIA: ABOUT A PAEDIATRIC CASE P-MO-394
Dominique Desprez, Julien Exinger, Annie Heidt, Monique Gladin, Pauline Vernay, Francois Depasse, Laurent Mauvieux, Lelia Grunebaum, Harry Magnani
A COMPARISON OF CAT AND A MANUAL SUB-SAMPLING THROMBIN GENERATION ASSAYS IN HEALTHY CHILDREN P-MO-395
Robyn G. Summerhayes, Paul Monagle, Vera Ignjatovic
THE INFLUENCE OF PLASMA ALPHA 2-MACROGLOBULIN LEVELS AND COMPLEXION TO THROMBIN DURING THROMBIN GENERATION IN HEALTHY CHILDREN P-MO-396
Robyn G. Summerhayes, Paul Monagle, Vera Ignjatovic
AGE-RELATED DIFFERENCES IN HEPARIN COFACTOR ANTIGEN AND ACTIVITY IN HEALTHY CHILDREN: EVIDENCE FOR STRUCTURAL DIFFERENCES IN HEPARIN COFACTOR II IN NEONATES P-MO-397
Robyn G. Summerhayes, Paul Monagle, Vera Ignjatovic
PROGNOSTIC FACTORS FOR PERSISTENT VENOUS OCCLUSION IN CHILDREN WITH VENOUS THROMBOEMBOLISM P-MO-398
Courtney A. Lyle, Amy E. Lovejoy, Neil A. Goldenberg
RISK FACTORS FOR ELEVATED INR VALUES DURING WARFARIN THERAPY AT A PEDIATRIC HOSPITAL P-MO-399
Lisa Bomgaars, Meng Ung, Brady Moffett
A THAI BOY WITH SEVERE PROTEIN C DEFICIENCY; CLINICAL PRESENTATIONS, GENETIC MUTATION ANALYSIS AND TREATMENT OUTCOMES P-MO-400
Bunchoo Pongtanakul, Kleebsabai Sanpakit, Jassada Buaboonnam, Nongnuch Sirachainan
TRENDS OF THE COAGULATION INHIBITOR PROTEINS: PROTEIN C, PROTEIN S AND ANTITHROMBIN (AT) IN CHILDREN FOLLOWING LIVER TRANSPLANT P-MO-401
Patricia Massicotte, Mary Bauman, Aisha Bruce, Jessica Tan, Ketan Kulkarni, Jason Yap, Norm Kneteman
EVALUATION OF UPPER VENOUS THROMBOSIS AND ITS ASSOCIATION WITH CHYLOTHORAX IN POST SURGICAL CHILDREN WITH CONGENITAL HEART DISEASE P-MO-402
Patricia Massicotte, Satvinder Kaur, Mary Bauman, Luis Quinonez, Aisha Bruce
Microparticles
NOVEL METHODOLOGY IN THE CHARACTERIZATION OF PLATELET-DERIVED MICROVESICLES P-MO-403
Pia R-M Siljander, Maria T. Aatonen, Mikaela Gronholm
DETECTION OF 100 NM BEADS WITH OPTICAL PROPERTIES CLOSE TO MICROPARTICLES AND EXOSOMES USING A REGULAR FLOW CYTOMETER P-MO-404
Edwin van der Pol, A. Sturk, T. G. van Leeuwen, R. Nieuwland
SIZE DISTRIBUTION AND CONCENTRATION OF MICROPARTICLES AND EXOSOMES DETERMINED BY ADVANCED OPTICAL AND NON-OPTICAL DETECTION METHODS P-MO-405
Edwin van der Pol, C. Gardiner, P. Harrison, A. E. Grootemaat, A. Sturk, T. G. van Leeuwen, R. Nieuwland
PLATELET-DERIVED MICROPARTICLES AND TISSUE FACTOR ACTIVITY ARE ENHANCED IN BEHCET’S DISEASE P-MO-406
Elena G. Arias-Salgado, I. Fernandez-Bello, M. Martin-Salces, M.T. Alvarez-Roman, A. Moreno-Rubio, A. Chicon-Arias, V. Jimenez-Yuste, A. R.de la Rua, J. Lopez-Longo, I. Rivas-Pollmar, N. Butta-Coll
INCREASED NUMBERS OF MICROPARTICLES AND INCREASED MICROPARTICLE SPECIFIC THROMBIN GENERATION IN PATIENTS WITH MYELOPROLIFERATIVE DISEASE P-MO-407
Muriel van Schilfgaarde, Marijke C. Trappenburg, Michiel C. van Aalderen, Pascal J. Molenaar, Hugo ten Cate, Anja Leyte, Wim E. Terpstra
PLACENTA-SPECIFIC RNA IS PRESENT IN VESICLES ISOLATED FROM MATERNAL BLOOD P-MO-408
Guus Sturk, Anita Boing, Elke de Grouw, Chi Hau, Wessel Ganzevoort, Carrie Ris-Stalpers, Rienk Nieuwland
PLATELET MICROPARTICLES PARTICIPATE TO IMMUNE COMPLEXE FORMATION IN RHEUMATOID ARTHRITIS P-MO-409
Nathalie Cloutier, Ruslan Shnayder, William Robinson, Richard Farndale, David M. Lee, Eric Boilard
TISSUE-FACTOR BEARING MICROPARTICLES ARE INCREASED IN NON-HODGKIN’S LYMPHOMA, AND MAINLY DERIVED FROM B-LYMPHOCYTES P-MO-410
Brandon James McMahon, Hau C. Kwaan, Ivy Weiss, James Marvin
ACTIVATED FACTOR X-BASED ASSAY FOR THE DETECTION OF PROCOAGULANT PHOSPHOLIPID ACTIVITY IN PATIENTS WITH CANCER AND/OR VENOUS THROMBOEMBOLISM P-MO-411
Claudia Maria Radu, Luca Spiezia, Elena Campello, Sabrina Gavasso, Sara Carraro, Valeria Ferri, Barry Woodhams, Paolo Simioni
MICROPARTICLE ANALYSIS BY FLOWCYTOMETRY DEPENDS ON WELL DEFINED PRE-ANALYTICAL CONDITIONS P-MO-412
Muriel van Schilfgaarde, Saskia V. Oussoren, Anja Leyte
ELEVATION OF TOTAL CELL-DERIVED MICROPARTICLE IN THE PATEINT WITH ESSENTIAL HYPERTENSION P-MO-413
Pornlada Nuchnoi, Duangdao Nantakomol, Chartchalerm Isarankura-Na-Ayudhya, Virapong Prachayasittikul
Clinical Trials and Registries
LOW ALLERGENICITY OF FONDAPARINUX - RESULTS OF A PROSPECTIVE INVESTIGATION P-MO-414
Marc Schindewolf, Julia Scheuermann, Hartmut Kroll, Jurate Garbaraviciene, Carola Hecking, Ingo Marzi, Manfred Wolter, Roland Kaufmann, Wolf-Henning Boehncke, Edelgard Lindhoff-Last, Ralf J. Ludwig
INCIDENCE AND CAUSES OF HEPARIN-INDUCED SKIN LESIONS - RESULTS OF A PROSPECTIVE INVESTIGATION P-MO-415
Marc Schindewolf, Svantje Schwaner, Manfred Wolter, Hartmut Kroll, Andreas Recke, Roland Kaufmann, Wolf-Henning Boehncke, Edelgard Lindhoff-Last, Ralf J. Ludwig
THE EFFECT OF POLYMORPHISMS OF CYP2C9 AND VKORC1 ON STABILITY OF THE INR WHEN SUPPLEMENTED WITH VITAMIN K1 P-MO-416
Edward P.A. Gebuis, Frits R. Rosendaal, Erik van Meegen, Felix J.M. van der Meer
VENOUS THROMBOEMBOLISM (VTE) AFTER SURGERY FOR BENIGN PROSTATIC HYPERPLASIA (BHP). A SYSTEMATIC REVIEW ON THROMBOPROPHYLAXIS P-MO-417
David Bergqvist
SAFETY OF LOW MOLECULAR WEIGHT HEPARINS IN SWEDEN AS REFLECTED BY ADVERSE EVENTS REPORTED TO NATIONAL AUTHORITIES P-MO-418
David Bergqvist, Nils Feltelius
ORAL FACTOR XA INHIBITORS VERSUS ENOXAPARIN FOR THROMBOPROPHYLAXIS AFTER JOINT REPLACEMENT SURGERY: A META-ANALYSIS P-MO-419
Simon Mantha
HEMOSTASIS IN THE PRIMARY MULTIPLE MYELOMA PATIENTS P-MO-420
Evdokiya S. Urnova, Larissa P. Mendeleeva, Olga S. Pokrovskaya, Elena I. Sinauridze, Anna N. Balandina, Elena N. Lipets, Irina V. Gribkova, Sergey A. Vasiliev, Valery G. Savchenko
NATURAL HISTORY OF PATIENTS DEVELOPING THROMBOCYTOPENIA WHILE RECEIVING ANTICOAGULANT THERAPY FOR VENOUS THROMBOEMBOLISM P-MO-422
Adriana Visona, Pierpaolo Di Micco, Nicolas Falvo, Justo Ruiz, Jose M. Pedrajas, Mariano Valdes, Manuel Monreal, and the RIETE Investigators
DESIRUDIN-REACTIVE IGG ANTIBODIES IN THE DESIR-ABLE THROMBOSIS PREVENTION CLINICAL TRIAL: LOW PREVALENCE OF ANTIGENICITY IN DESIRUDIN-TREATED SUBJECTS P-MO-423
Robert G. Hamilton, Jerrold H. Levy
Intravascular Devices and Thrombosis
VENOUS THROMBOSIS AS A COMPLICATION OF PACEMAKER IMPLANTATION - IN OWN OBSERVATIONS P-MO-424
Teresa Barbara Domagala, Jacek Lelakowski, Anna Rydlewska, Justyna Piekarz, Rafal Januszek, Grzegorz Karkowski, Katarzyna Kotula-Horowitz, Jacek Musial
DESIGN OF THE CATHETER DIRECTED THROMBOLYSIS AND ANTICOAGULATION THERAPY VS ANTICOAGULATION ALONE; THE DUTCH CAVA-STUDY; MULTICENTER RANDOMIZED CONTROLLED TRIAL P-MO-425
Rob H.W. Strijkers, Arina J. ten Cate - Hoek, Martin H. Prins, Hugo ten Cate, Cees H.A. Wittens
POLYURETHANE IMMOBILIZED WITH A COVALENT ANTITHROMBIN-HEPARIN COMPLEX FOR REDUCING THROMBOSIS ON BLOOD CONTACTING DEVICES P-MO-426
Kyla N. Sask, Leslie R. Berry, Anthony KC Chan, John L. Brash
ROLE OF LOW MOLECULAR WEIGHT HEPARINS IN PROPHYLAXIS OF THROMBOEMBOLIC EVENTS IN ONCOLOGICAL PATIENTS RECEIVING ANTITUMOR THERAPIES P-MO-427
Oksana Vasilievna Somonova, Albina Vasilievna Madzhuga, Anna Lyvovna Elizarova
REASONS FOR FAILURE TO REMOVE INFERIOR VENA CAVA FILTERS (IVCF): 2 YEAR RETROSPECTIVE STUDY IN A TERTIARY CARE AND TRAUMA CENTRE P-MO-428
Erica Ann Peterson, Paul Richard Yenson, Dave Liu, Andy Lee, Agnes Yuet Ying Lee
IN VITRO AND IN VIVO COMPARISON OF VKORC1 MUTATIONS P-MO-429
Katrin Jeannette Czogalla, Matthias Watzka, Philipp Westhofen, Ann-Christin Wendeln, Johannes Oldenburg
LOW SULFATED HEPARIN (ODSH) INTERFERES WITH ANTI-PF4/HEPARIN ANTIBODY INDUCED PLATELET ACTIVATION BY DISRUPTING PF4/HEPARIN COMPLEXES P-MO-430
Krystin Krauel, Christine Hackbarth, Birgitt Fuerll, Andreas Greinacher
THE EVALUATION OF BLOOD COAGULATION AND FIBRINOLYTIC FACTORS IN HEMODIALYSIS P-MO-431
Elizaveta Alexandrovna Vlasova, Irina Anatol'evna Vasilenko, Maria Sergeevna Surovikina, Vera Vladimirovna Samoylenko, Vladimir Procop'evich Suslov
DISORDERS OF MORPHOLOGY AND FUNCTION OF LIVING PLATELETS IN PATIENTS TREATED WITH HEMODIALYSIS P-MO-432
Elizaveta Vlasova, Irina Vasilenko, Vladimir Suslov
TWO CASES OF THROMBOTIC COMPLICATIONS IN INFANTS ON ECMO: HETEROZYGOUS FACTOR V LEIDEN AND COCCIDIODOMYCOSIS P-MO-433
Fong W. Lam, Ozlem Bilen, Trung C. Nguyen, Jun Teruya
Health Service and Outcomes
THE IMPACT OF ANTICOAGULANT MONITORING AND CONTROL ON RECURRENT VENOUS THROMBOEMBOLISM AND BLEEDING IN ROUTINE CLINICAL PRACTICE P-MO-434
Neil S. Roskell, Sorrel E. Wolowacz, Ryan Ziemiecki, Arlene M. Gallagher, Martin Feuring, Mandy Fraessdorf, Bastian Hass
INTERPLAY BETWEEN DIET AND VITAMIN K-ANTAGONISTS: DISCLOSED BY VISUALIZATION OF A MULTIVARIATE MODEL P-MO-435
Jane Skov, Else-Marie Bladbjerg, Morten Arendt Rasmussen, Johannes Sidelmann, Marianne Vamosi, Joergen Jespersen
A COLLABORATIVE STUDY OF OUTCOMES FROM ROOT CAUSE ANALYSIS OF HOSPITAL-ASSOCIATED THROMBOSIS P-MO-436
Lara N. Roberts, Kim Carter, Huw Rowswell, Christopher James, Lorraine Albon, Tim Nokes, Raj K. Patel, Roopen Arya
COST-EFFECTIVENESS OF APIXABAN PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM (VTE) IN TOTAL KNEE AND HIP REPLACEMENT (TKR/THR) P-MO-438
Dale Rublee, Teresa Simon, Kristen Migliaccio-Walle, Elizabeth Merikle, Jamie Caro, Nick Marchant, Pieter Drost
PROTAMINE DRUG UTILIZATION EVALUATION TO DETERMINE POSSIBLE FUTURE ROLES FOR THE HEPATGONIST REVERSAL AGENT PMX-60056 P-MO-439
Charles Mahan
REDUCTION IN HOSPITAL ACQUIRED VTE BY IMPROVED COMPLIANCE WITH VTE RISK ASSESSMENT P-MO-440
Jamie M. Maddox, Anthony P. Roberts
USE OF NATIONAL PATIENT SAFETY AGENCY / BRITISH SOCIETY OF HAEMATOLOGY SAFETY INDICATORS FOR ORAL ANTICOAGULANTS IN HOSPITALISED PATIENTS P-MO-441
Jamie M. Maddox
REDUCTION OF EMERGENCY DEPARTMENT (ED) UTILIZATION FOR COMPLICATIONS OF WARFARIN THERAPY USING ORGANIZED ANTICOAGULATION CLINICS IN AN ACADEMIC MEDICAL INSTITUTION P-MO-442
Patrick Michael Klem, Tiffany Brown, William Pace, Gina Woodhouse, Kathryn Hassell, Christiana Thienelt, Shardul Poydal, Julie Cantlon, Gregory Misky, William LeBlanc, Kristen Nordenholz, Carolee Whitehill
von Willebrand Factor
INTERACTION BETWEEN A1, A2 AND A3 DOMAINS REGULATES THE BINDING OF VWF TO PLATELET GPIBα IN SOLUTION P-MO-443
Miguel A. Cruz, Matthew Auton, Katie E. Sowa
INCREASED VON WILLEBRAND FACTOR LEVELS IN LATER LIFE ARE ASSOCIATED WITH EVIDENCE OF BOTH ENHANCED BIOSYNTHESIS AND REDUCED CLEARANCE P-MO-444
Silvia Albanez, Julie Grabell, Erin Burnett, Kate Sponagle, Paula D. James, David Lillicrap
STABILIZATION OF FVIII BY VWF FRAGMENTS P-MO-445
Andrew Yee, Beth M. McGee, David Ginsburg
EPITOPE MAPPING OF HUMAN VWF A3 RECOGNIZED BY MONOCLONAL ANTIBODY SZ-123 USING MALDI MASS SPECTROMETRY P-MO-446
Miao Jiang, Yiming Zhao, Yang He, Fei Shen, Changgeng Ruan
VON WILLEBRAND FACTOR PLASMA LEVELS IN PATIENTS WITH ESSENTIAL THROMBOCYTHAEMIA P-MO-447
Ksenia Bykowska, Ewa Czajkowska, Magdalena Letowska, Bozena Sokolowska, Krzysztof Warzocha, Edyta Odnoczko, Jerzy Windyga
PHARMACOKINETIC (PK) EVALUATION OF A NEWLY INTRODUCED VON WILLEBRAND FACTOR (VWF) CONCENTRATE AT TWO LONDON HAEMOPHILIA CENTRES P-MO-448
Natasha M. Wiles, Anne Wareing, Bella Madan, Steven K. Austin
AFFINITY AND KINETICS OF VWF PROPEPTIDE BINDING TO MATURE VWF P-MO-449
Sriram Neelamegham, Sri R. Madabhushi, Chengwei Shang, Kannayakanahalli M. Dayananda, Thomas E. Ryan
THE INTERACTION OF VON WILLEBRAND FACTOR WITH ANGIOPOIETINS-1 & 2 P-MO-450
Thomas McKinnon, Agata Nowak, Kushani Ediriwickrema, Mike Laffan
THE DISCOVERY AND CHARACTERIZATION OF A SECOND GENERATION VON WILLEBRAND FACTOR (VWF) A-1 DOMAIN INHIBITORY APTAMER P-MO-451
Robert G. Schaub, P. Shannon Pendergrast, Kathleen E. McGinness, Xianbin Tian
IN VITRO AND IN VIVO CHARACTERIZATION OF VON WILLEBRAND FACTOR COLLAGEN BINDING VARIANTS USING A MOUSE MODEL SYSTEM P-MO-452
Yasuaki Shida, Christine Ann Brown, Jeff Mewburn, Kate Sponagle, Carol Anne Hegadorn, David Lillicrap
von Willebrand Disease
ESTABLISHMENT OF A VON WILLEBRAND FACTOR RISTOCETIN CO-FACTOR ACTIVITY ELISA AND ITS APPLICATION IN THE DIAGNOSIS AND CLASSIFICATION OF VWD P-MO-453
Yiming Zhao, Ying Gu, Jianfeng Yang, Changgeng Ruan
MUTATION SPECTRUM AND CHARACTERIZATION OF TWO NOVEL LARGE DELETIONS CAUSING SEVERE TYPE 3 VON WILLEBRAND DISEASE P-MO-454
Firdos Ahmad, Reinhard Schneppenheim, Florian Oyen, Tobias Obser, Meganathan Kannan, Renu Saxena
-1 TO +4 VS. 0 TO +3?: COMPARING SCORING SYSTEMS FOR BLEEDING SYMPTOMS IN THE CONDENSED MCMDM-1 VWD AND THE PEDIATRIC BLEEDING QUESTIONNAIRES P-MO-455
Paula D. James, Tina T. Biss, Dewi S. Clark, Julie Grabell, Jim Riddel, Mariana Silva, Dilys Rapson, Margaret L. Rand
EFFECT OF FIBRINOLYSIS ON BLEEDING PHENOTYPE IN MODERATE AND SEVERE P-MO-456
Eva M. De Wee, Kevin Klaij, Jeroen Eikenboom, Johanna van der Bom, Manon Degenaar-Dujardin, Karin Fijnvandraat, Arja Goede-Bolder, Britta Laros-van Gorkom, Eveline Mauser-Bunschoten, Karina Meijer, Gerard Goverde, Peter-Willem van der Linden, Dingeman Rijken, Frank Leebeek
WILATE® 500 AND WILATE® 1000 - ADVANCED CONTENT OF VWF AND FVIII: A COMPARISON OF ACTIVE INGREDIENTS AND EXCIPIENTS DRUG RATIOS P-MO-457
Gerhard Gruber, Monika Stadler, Manfred Karlovits, Josef Weinberger, Juergen Roland Roemisch
DETERMINANTS OF BLEEDING PHENOTYPE IN PATIENTS WITH MODERATE OR SEVERE VON WILLEBRAND DISEASE P-MO-458
Eva M. De Wee, Eveline Mauser-Bunschoten, Anske van der Bom, Manon Degenaar-Dujardin, Jeroen Eikenboom, Arja de Goede-Bolder, Britta Laros-van Gorkom, Karina Meijer, Karly Hamulyak, Marten Nijziel, Karin Fijnvandraat, Frank Leebeek
UNUSUAL FINDING IN LABORATORY TESTS IN A PREGNANT PATIENT WITH VON WILLEBRAND DISEASE TYPE 2B P-MO-459
Adriana I. Woods, Analia Sanchez-Luceros, Maria Fabiana Alberto, Ana Catalina Kempfer, Alicia Noemi Blanco, Maria Angela Lazzari
THE P.CYS1060TYR MUTATION IS RESPONSIBLE FOR VON WILLEBRAND DISEASE TYPE 2N P-MO-460
Bas J.T. van Haren, Selene C.M. Schoormans, Tom G.J. Hofste, Britta A.P. Laros-van Gorkom, Paul P.T. Brons, Lies H. Hoefsloot, Waander L. van Heerde
COLLAGEN BINDING ASSAY AND GENOTYPIC ANALYSIS HAVE AN ADDITIONAL VALUE IN THE SUBCLASSIFICATION OF VON WILLEBRAND DISEASE TYPE 2M P-MO-461
Bas J.T. van Haren, Selene C.M. Schoormans, Tom G.J. Hofste, Britta A.P. Laros-van Gorkom, Paul P.T. Brons, Lies H. Hoefsloot, Waander L. van Heerde
ASSESSMENT OF THE BURDEN OF VON WILLEBRAND DISEASE IN A US COMMERCIAL POPULATION P-MO-462
Diane Ito, Yan Xiong, Josephine Li-McLeod
DEVELOPMENT OF A HEALTH-RELATED QUALITY OF LIFE INSTRUMENT FOR VON WILLEBRAND DISEASE P-MO-463
Diane Ito, Kathy Lasch, Kristina Fitzgerald, Andrea Zeytoonjian, Steve Hwang, Josephine Li-McLeod
DIAGNOSIS OF TYPE 2N VON WILLEBRAND DISEASE IN A JAPANESE PATIENT BY PHARMACOKINETICS, FACTOR VIII BINDING ASSAY AND GENE ANALYSIS P-MO-464
Yushi Chikasawa, Kagehiro Amano, Keiko Shinozawa, Tomoko Matsumoto, Hiroshi Inaba, Midori Shima, Katsuyuki Fukutake
A GLY1609ARG MISSENSE MUTATION IN THE VWF GENE IN A KOREAN PATIENT WITH VON WILLBRAND DISEASE TYPE 2A P-MO-465
Duck Jin Hong, Seung Jun Choi, Jonghyeon Choi, Sue Jung Kim, Hee-Jin Kim, Kyung-A Lee, Jaewoo Song, Jong-Rak Choi, Jong-Ha Yoo
A FAMILY WITH TYPE 2M VWD WITH NORMAL VWF:RCO BUT REDUCED VWF:CB DUE TO A M1761K MUTATION IN THE A3 DOMAIN P-MO-466
David M. Keeling, James Beavis, Rhiannon Marr, Kampta Sukhu, Patricia Bignell
Acquired von Willebrand Syndrome
TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) AND THE EFFECTS ON VON WILLEBRAND FACTOR (VWF) AND ADAMNTS-13 CONCENTRATIONS P-MO-467
Simon J. Davidson, Jayenthan Karunanantham, Kaltun Farah, Sarah Barker, Simon W. Davies, Moat Neil
MITRAL VALVE PROSTHESIS LEAK AND ACQUIRED VON WILLEBRAND SYNDROME (AVWS) P-MO-468
Almudena Perez-Rodriguez, Joana Costa Pinto, Esther Loures, Angela Rodriguez-Trillo, Jose Joaquin Cuenca, Javier Batlle, Maria Fernanda Lopez-Fernandez
VWF & PROPEPTIDE ASSAY (GTI DIAGNOSTICS) EVALUATION IN ACQUIRED VON WILLEBRAND SYNDROME P-MO-469
Claudine Caron, Jacqueline Tapon-Bretaudiere, Sylvia Bellucci, Philippe Cauchie, Isabelle Martin Toutain, Brigitte Pan Petesch, Catherine Ternisien, Jenny Goudemand
A RARE CASE OF ACQUIRED VON WILLEBRAND SYNDROME IN THE SETTING OF NEW DIAGNOSIS POLYMYOSITIS P-MO-470
Adrienne Lee, Gary D. Sinclair, Karen Valentine, Man-Chiu Poon
EXCESS PROTEOLYSIS OF VON WILLEBRAND FACTOR IN AORTIC STENOSIS DOES NOT ENHANCE THE RISK OF BLEEDING AFTER AORTIC VALVE REPLACEMENT P-MO-471
Sophie Susen, Andre Vincentelli, Thierry Le Tourneau, Claudine Caron, Annie Borel-Derlon, Massimo Massetti, Jeanne-Yvonne Borg, Helene Eltchaninoff, Fabrice Bauer, Eric Van Belle, Jenny Goudemand, Brigitte Jude
THERAPEUTIC ALGORITHM FOR PATIENTS WITH ACQUIRED VON WILLEBRAND SYNDROME AND MONOCLONAL GAMMOPATHY P-MO-472
Peter Staritz, Peter Lages, Manuela Krause, Rainer Zimmermann, Angela Huth-Kuehne
ACQUIRED LOSS OF THE LARGEST VON WILLEBRAND FACTOR MULTIMERS IN SEVERE TETRALOGY OF FALLOT: A CASE REPORT P-MO-473
Sofia Barbar, Alessandra Casonato, Emiliano De Bon, Elena Pontara, Antonella Bertomoro
A NEGATIVE FEEDBACK MECHANISM OF REGULATING VWF PROTEOLYSIS BY ADAMTS-13 P-MO-474
Trung Chanh Nguyen, Chalmette Ball, Miguel A. Cruz, Xiaowen Liang, Zhou Zhou, Jing-fei Dong
ACQUIRED VON WILLEBRAND DISEASE (AVWD) SECONDARY TO ACUTE MYELOPATHY P-MO-475
Erica Okazaki, Audrey Kruse Zeinad Valim, Paula Ribeiro Villaca, Patricia Lima Junqueira, Dalton de Alencar Fischer Chamone, Elbio Antonio DAmico
ADAMTS13
UPREGULATION OF VON WILLEBRAND FACTOR, VON WILLEBRAND FACTOR PROPEPTIDE AND ADAMTS-13 IN END STAGE RENAL DISEASE P-MO-476
Vinod Bansal, Rachel Davis, Evangelos Litinas, Debra Hoppensteadt, Indermohan Thethi, Jawed Fareed
DETERMINATION OF ADAMTS13 AND ITS CLINICAL SIGNIFICANCE RELATED TO ENDOTOXEMIA IN PATIENTS WITH HEPATIC FAILURE P-MO-477
Hiroaki Takaya, Masahito Uemura, Masao Fujimoto, Tomomi Matsuyama, Chie Morioka, Masatoshi Ishikawa, Tatsuhiro Tsujimoto, Hideto Kawaratani, Shinya Takeyama, Masanori Matsumoto, Yoshihiro Fujimura, Hiroshi Fukui
CILOSTAZOL DOWN-REGULATES THE HEIGHT OF MURAL PLATELET THROMBI FORMED UNDER A HIGH SHEAR RATE FLOW IN THE ABSENCE OF ADAMTS13 ACTIVITY P-MO-478
Hideo Yagi, Naoko Yamaguchi, Yasuaki Shida, Masanori Matsumoto, Mitsuhiko Sugimoto, Kazuo Tsubaki, Yoshihiro Fujimura
ISOELECTRIC FOCUSING ANALYSIS WITH A LARGE-PORE AGAROSE-ACRYLAMIDE COMPOSITE GEL IDENTIFIED TWO FORMS OF ADAMTS13, UNBOUND AND BOUND TO VON WILLEBRAND FACTOR, IN PLASMA MILIEU P-MO-479
Yuji Hori, Ayami Isonishi, Kenji Soejima, Masanori Matsumoto, Midori Shima, Yoshihiro Fujimura
ESTIMATION OF THE NUMBER OF INDIVIDUALS WITH A CONGENITAL ADAMTS13 DEFICIENCY IN JAPAN P-MO-480
Koichi Kokame, Yoshihiro Kokubo, Toshiyuki Miyata
POTENTIAL ROLE OF ADAMTS13 ASSOCIATED WITH POST ERCP PANCREATITIS P-MO-481
Chie Morioka, Masahito Uemura, Hiroaki Takaya, Masayoshi Sawai, Motoyuki Yoshida, Akira Mitoro, Jyunichi Yamao, Masanori Matsumoto, Yoshihiro Fujimura, Hiroshi Fukui
THE ADAMTS13 ACTIVITY REFLECTS THE CUMULATIVE SURVIVAL OF PATIENTS WITH LIVER CIRRHOSIS P-MO-482
Masahito Uemura, Yoshihiro Fujimura, Masanori Matsumoto, Hiromichi Ishizashi, Tomomi Matsuyama, Seiji Kato, Yuji Hori, Chie Morioka, Hiroaki Takaya, Masao Fujimoto, Tatsuhiro Tsujimoto, Hideto Kawaratani, Hiroshi Fukui
VWF AND ADAMTS13 LEVELS AND THE RISK OF MYOCARDIAL INFARCTION AND ISCHAEMIC STROKE IN YOUNG WOMEN: RESULTS FROM THE RATIO CASE-CONTROL STUDY P-MO-483
Bob Siegerink, Helena M. Andersson, Brenda M. Luken, James TB Crawley, Ale Algra, David A. Lane, Frits R. Rosendaal
EVALUATION OF A NEW ADAMTS13 ELISA BASED ACTIVITY ASSAY AND COMPARISON TO AN IN-HOUSE COLLAGEN BINDING ASSAY P-MO-484
Wahbi Hammouda, Jacqueline Ongteco, Nellie Ku
CHARACTERIZATION OF TWO CASES OF CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA ASSOCIATED WITH PREGNANCY P-MO-485
Xia Bai, Jian Su, Minghua Jiang, Changgeng Ruan
DISCREPANCIES BETWEEN DIFFERENT TYPES OF ADAMTS13 ASSAYS IN PATIENTS WITH THROMBOTIC MICROANGIOPATHIES P-MO-486
Ian J. Mackie, Katy Langley, Andrew Chitolie, Ri Leisner, Marie Scully, Sam Machin, Flora Peyvandi
NOVEL ADAMTS13 MUTATIONS IN CONGENITAL THROMOTIC THROMBOCYTOPENIC PURPURA P-MO-487
Ziqiang Yu, Yunwen Bu, Jian Su, Qingya Cui, Xia Bai, Changgeng Ruan
Hemophilia
PROFILING OF F8 GENE MUTATIONS IN 262 CHINESE HAEMOPHILIA A PATIENTS P-MO-488
Yeling Lu, Xuefeng Wang, Qiulan Ding, Jing Dai, Hongli Wang, Xiaodong Xi
SPORADIC HAEMOPHILIA A PEDIGREE WITH MOSAICISM OF THE F8 GENE MUTATION IN THE INDEX'S MATERNAL GRANDMOTHER P-MO-489
Yeling Lu, Xuefeng Wang, Qiulan Ding, Jing Dai, Hongli Wang, Xiaodong Xi
IMPROVEMENTS OF HEMOPHILIA CARES IN 30 YEARS SEEN IN TAIWAN P-MO-490
Ming Ching Shen, Wei Tsay, Young Li Yang, Shyuann Yuh Lin, Ching Yeh Lin, Po Kuang Chen, In Ling Chang, Ta Sen Wei, Chin Ming Jeng, Chao Yu Hsu, Ruei Pung Lin, Cheng Hsiung Chang
CHARACTERIZATION AND VALIDATION OF A NOVEL PANEL OF 6 SHORT TANDEM REPEATS FOR CARRIER AND PRENATAL DIAGNOSIS OF HAEMOPHILIA A P-MO-491
Qiulan Ding, Yeling Lu, Jing Dai, Xioadong Xi, Xuefeng Wang, Hongli Wang
F8 LOCUS ITSELF SEEMS TO EXPLAIN ALL CASES OF HEMOPHILIA A PATIENTS WITHOUT MUTATIONS IN THE F8 CDNA P-MO-492
Osman El-Maarri, Behnaz Pezeshkpoor, Natascha Vidocich, Nicole Nuesgen, Indrajit Nanda, Thomas Haaf, Ulrich Budde, Johannes Oldenburg, Osman El-Maarri
CARRIER AND PRENATAL DIAGNOSIS IN A HAEMOPHILIA A FAMILY WITH LARGE F8 GENE DELETION BY FLUORESCENT QUANTITATION PCR METHOD P-MO-493
Yeling Lu, Xuefeng Wang, Qiulan Ding, Jing Dai, Xiaodong Xi, Hongli Wang
INCREASED PREVALENCE OF HYPERTENSION IN HAEMOPHILIA PATIENTS P-MO-494
Roger EG Schutgens, Dietje Fransen van de Putte, Kathelijn Fischer, Mike Makris, Campbell Tait, Pratima Chowdary, Peter Collins, Karina Meijer, Goris Roosendaal, Eveline Mauser-Bunschoten
INCREASED QRISK2 CARDIOVASCULAR DISEASE RISK SCORE IN HAEMOPHILIA PATIENTS P-MO-495
Roger EG Schutgens, Dietje Fransen van de Putte, Kathelijn Fischer, Mike Makris, Campbell Tait, Pratima Chowdary, Peter Collins, Karina Meijer, Goris Roosendaal, Eveline Mauser-Bunschoten
DECREASED OCCURRENCE OF CARDIOVASCULAR DISEASE IN HAEMOPHILIA PATIENTS P-MO-496
Roger EG Schutgens, Dietje Fransen van de Putte, Kathelijn Fischer, Astrid Pulles, Goris Roosendaal, Eveline Mauser-Bunschoten
MALIGNANCIES IN HAEMOPHILIA PATIENTS P-MO-497
Roger EG Schutgens, Dietje Fransen van de Putte, Kathelijn Fischer, Astrid Pulles, Goris Roosendaal, Eveline Mauser-Bunschoten
THE PROVISION OF GENETIC TESTING FOR BLEEDING DISORDERS IN THE UK - AN OVERVIEW AND AUDIT OF UKHCDO GENETIC NETWORK LABORATORIES P-MO-498
Marian Hill, Jacky Cutler, Mike Mitchell
A COST-EFFECTIVE PROVINCIAL REDISTRIBUTION SYSTEM TO PREVENT WASTAGE OF CLOTTING FACTOR CONCENTRATES P-MO-499
Jerome Teitel, Sarah Crymble, Monique Anderson, Antonette Travas, Georgina Floros
DISTINCT X-CHROMOSOMAL REARRANGEMENTS WITH F8-INTRON22 INVERSION IN THREE UNRELATED JAPANESE SEVERE HEMOPHILIA A PATIENTS WITH HIGH TITER INHIBITOR P-MO-500
Junko Fujita, Atsuo Suzuki, Yuhri Miyawaki, Asuka Maki, Yuhta Fujimori, Akira Takagi, Takashi Murate, Tadashi Matsushita, Nobuaki Suzuki, Hidehiko Saito, Tetsuhito Kojima
HELICOBACTER PYLORI INFECTION IN PATIENTS WITH HEREDITARY HEMORRHAGIC DISORDERS: A COMPARISON OF STOOL ANTIGEN TEST AND SEROLOGY TESTS P-MO-501
Dolatkhah Roya, Khoshbaten Manouchehr, Asvadi Kermani Iraj, Bonyadi Mohammad Reza, Ghojazadeh Morteza, Sanaat Zohreh
SAFETY AND EFFICACY OF RALTEGRAVIR IN PATIENTS WITH HAEMOPHILIA AND ANTI-HIV MULTIDRUG RESISTANCE P-MO-502
Alessandro Gringeri, Lucia Mangiafico, Myrvete Muca-Perja, Silvia Riva, Francesco Fusco, Debora Mago
MUTATION ANALYSIS OF HEMOPHILIA A IN THE JAPANESE POPULATION: INCREASED PREVALENCE OF TYR473CYS CAUSED BY FOUNDER EFFECT P-MO-503
Hiroshi Inaba, Keiko Shinozawa, Takashi Suzuki, Manabu Otaki, Ikuo Seita, Kyoichi Ogata, Mihoko Yotsumoto, Takashi Muramatsu, Yushi Chikasawa, Takeshi Hagiwara, Yasuyuki Yamamoto, Kagehiro Amano, Katsuyuki Fukutake
PSEUDOTUMOR SURGERY IN HAEMOPHILIA A PATIENTS: COMPARATIVE RESULTS BETWEEN INHIBITOR AND NON-INHIBITOR PATIENTS P-MO-504
Caviglia Horacio, Alejandra Baques, Ana Laura Douglas Price, Daniela Neme, Guillermo Arbesu, Raul Perez Bianco
IMAGING EVALUATION OF ARTHROPATHY AT THE BEGINNING OF PROPHYLAXIC THERAPHY FOR SEVERE HEMOPHILIA CHILDREN P-MO-505
Kaoru Kitsukawa, Hideyuki Takedani, Midori Shima, Masashi Taki
IDENTIFICATION AND CHARACTERIZATION OF AN ANCIENT HAEMOPHILIA A FOUNDER MUTATION P-MO-506
Sylvia Elisabeth Reitter, Arndt von Haeseler, Birgit Horvath, Raute Sunder-Plassmann, Vera Tiedje, Ingrid Pabinger-Fasching, Christine Mannhalter
THE EFFECT OF CRYOPRECIPITATE ON THE SEROPREVALENCE OF VARICELLA ZOSTER VIRUS IN PATIENTS WITH SEVERE HEMOPHILIA P-MO-507
Thomas W. van der Vaart, Marc van der Valk, Jan TM van der Meer, Caroline Valk, Hans L. Zaaijer, Pieter Willem Kamphuisen
WIDE VARIATION IN FACTOR VIII PLASMA LEVELS IN MILD AND MODERATE HEMOPHILIA A PATIENTS WITH THE SAME MISSENSE MUTATION IS PRESENTLY UNEXPLAINED P-MO-508
Corien Eckhardt, Alice S. van Velzen, Marjolein Peters, Elena Santagostino, Kathelijne Peerlinck, Jan Astermark, Johannes Oldenburg, Charles R.M. Hay, Pieter-Willem Kamphuisen, Johanna G. van der Bom, Karin Fijnvandraat
Hemophilia Therapy
EFFECTIVE PATHOGEN REDUCTION OF A PLASMA-DERIVED FACTOR VIII CONCENTRATE THROUGH MULTIPLE DEDICATED MEASURES P-MO-509
Albrecht Groener, Thomas Nowak, Birgit Popp, Wolfram Schaefer
POST MARKETING SURVEILLANCE OF BLOOD PRODUCTS IN JAPAN P-MO-510
Teruyo Arato, Kaori Nomura, Madoka Hiraki, Jun Matsumoto, Atsushi Yoshimura, Toyotaka Iguchi, Masanari Takayama
CURRENT SITUATION OF CLINICAL TRIALS OF BLOOD COAGULATION FACTORS FOR HAEMOPHILIA PATIENTS IN JAPAN P-MO-511
Atsushi Yoshimura, Masayuki Nagasaki, Jun Matsumoto, Madoka Hiraki, Yasuhiro Kishioka, Masanari Takayama, Teruyo Arato
THE COMBINED TREATMENT OF APCC AND TRANEXAMIC ACID IN PATIENTS WITH HAEMOPHILIA A WITH INHIBITORS AND IN PATIENTS WITH ACQUIRED HAEMOPHILIA A - A TWO-CENTRE EXPERIENCE P-MO-512
Hoa Thi Tuyet Tran, Margareta Holmstrom, Paal Andre Holme
SUCCESSFUL TREATMENT OF PROSTATE CANCER IN A CASE OF SEVERE HAEMOPHILIA A PATIENT P-MO-513
Sandra Lejniece, Gunta Kluce, Armands Balins, Peteris Tomins, Aivars Lejnieks
IMPROVED KINETICS OF RIX-FP, A RECOMBINANT FUSION PROTEIN LINKING COAGULATION FACTOR IX WITH ALBUMIN, IN CYNOMOLGUS MONKEYS AND HEMOPHILIA B DOGS P-MO-514
Marc W. Nolte, Timothy Nichols, Sabine Zollner, Jochen Mueller-Cohrs, Ingo Pragst, Gerhard Dickneite
FINE (FEIBA INHIBITOR ENTRY) POST-AUTHORIZATION SAFETY SURVEILLANCE (PASS) : CAPTURING LONG-TERM EXPERIENCE IN JAPANESE INHIBITOR SUBJECTS UNDER ROUTINE CLINICAL MANAGEMENT P-MO-515
Satoshi Higasa, Kagehiro Amano, Hideji Hanabusa, Shinji Muto, Tadashi Matsushita, Midori Shima, Teruhisa Fujii, Michio Sakai, Study Group FINE
CLINICAL AND LABORATORY DATA OF SAFETY, EFFICACY OF A RECOMBINANT FACTOR VIII CONCENTRATE IN PATIENTS WITH SEVERE HAEMOPHILIA A IN A PRIVATE PRACTICE CCC P-MO-516
Katalin KoehlerVajta, Gerhard Froesner, Reinhard Zachoval
GASTROINTESTINAL BLEEDING FROM UPPER GASTROINTESTINAL TRACT IN PATIENTS WITH HEMOPHILIA P-MO-517
Sergey Shutov, S. R. Karagyulyan, V. Y. Zorenko, A. V. Grzhimolovsky, K. I. Danishyan, E. E. Karpov, T. Y. Polyanskay, G. M. Galstyan
FINAL PHARMACOKINETIC, EFFICACY AND SAFETY DATA OF THE FIRST STUDY WITH A RECOMBINANT FACTOR VIII FROM A HUMAN CELL LINE P-MO-518
Sigurd Knaub, Nadezhda Zozulya, Olga Plyushch, Martina Jansen
ANTI-FIBRINOLYTIC EFFECTS OF RECOMBINANT FACTOR VIIA IN PLASMA FROM PATIENTS WITH HEMOPHILIA A WITH INHIBITORS P-MO-519
Kamran Bakhtiari, Maria Elisa Mancuso, Karly Hamulyak, Elena Santagostino, Roger E.G. Schutgens, Pieter W. Kamphuisen, Joost C.M. Meijers
Inherited Coagulation Disorders (Except for von Willebrand Disease)
ATHEROSCLEROSIS IN PATIENTS WITH CONGENITAL BLEEDING DISORDERS P-MO-520
Marjan Zwiers, Joop D. Lefrandt, Andries J. Smit, Rijk O.B. Gans, Rozemarijn Vliegenthart, Angelique V.M. Brands-Nijenhuis, Hanneke (J) C. Kluin-Nelemans, Karina Meijer
SURVIVAL AMONG 5118 PATIENTS WITH BLEEDING DISORDERS COMPARED TO MATCHED CONTROLS IN SWEDEN: RESULTS FROM A COHORT REGISTER STUDY P-MO-521
Karin M. Henriksson, Jan Astermark, Jan-Ake Nilsson, Fariba Baghaei, Margareta Holmstrom, Erik Berntorp
A PLASMA-DERIVED FXIII CONCENTRATE WITH A VERY HIGH MARGIN OF VIRUS SAFETY FOR THE TREATMENT OF CONGENITAL FXIII DEFICIENCY P-MO-522
Albrecht Groener, Thomas Nowak, Birgit Popp, Wolfram Schaefer
A FIRST TAIWANESE PATIENT OF SEVERE PREKALLIKREIN DEFICIENCY WITH NOVEL MUTATIONS SEEN IN TAIWAN P-MO-523
Jiaan-Der Wang, Ming Ching Shen, Kuo Shu Hua, Chuan Cheng Wang, Ching Ye Lin, Bo Do Lin, Su Feng Kuo, Jen Shiou Lin, Shyuann Yuh Lin, Kuan Ju Lai, Cheng Shyong Chang, Chih-Yuan Chong
POINT MUTATIONS REGARDED AS MISSENSE MUTATIONS CAUSE SPLICING DEFECTS IN THE FACTOR XI GENE P-MO-524
Michal Zucker, Nurit Rosenberg, Hava Peretz, David Green, Frederic Bauduer, Ariella Zivelin, Uri Seligsohn
PREVENTION OF BLEEDING AND HAEMORRHAGIC COMPLICATIONS IN PERIOPERATIVE PERIOD IN PATIENTS WITH INHERITED FACTOR VII DEFICIENCY P-MO-525
Adam Wiszniewski, Ksenia Bykowska, Piotr Szopinski, Alfred Jerzy Meissner
NOVEL L13Q MUTATION OF ENDOGLIN GENE IN HEREDITARY HEMORRHAGIC TELANGIECTASIA CAUSED IMPAIRED COTRANSLATIONAL PROCESSING AND CELL-SURFACE EXPRESSION P-MO-526
Atsuo Suzuki, Yuhri Miyawaki, Junko Fujita, Asuka Maki, Yuta Fujimori, Akira Takagi, Takashi Murate, Masaaki Teranishi, Tadashi Matsushita, Hidehiko Saito, Tetsuhito Kojima
A NOVEL HEREDITARY BLEEDING DISORDER CHARACTERIZED BY LOW THROMBIN GENERATION CAUSED BY FACTOR V INHIBITION P-MO-527
Yesim Dargaud, Theo Lindhout, Rob J. Wagenvoord, Elisabetta Castoldi, Tilman Hackeng, Christine M. Trzeciak, Coenraad H. Hemker
MOLECULAR CHARACTERIZATION OF A NEW COMBINED FACTOR V AND FACTOR VII DEFICIENCY AND REVIEW OF THE LITERATURE P-MO-528
Michael Daskalakis, Julia Driesen, Anna Pavlova, Johannes Oldenburg, Meike Burger, Ulrich Geisen, Juergen Heinz
FIRST REPORT OF A PATIENT WITH SEVERE FACTOR X DEFICIENCY RESULTING FROM TWO HOMOZYGOUS FACTOR X MUTATIONS AND LOW BLEEDING TENDENCY P-MO-529
Michael Daskalakis, Winnie Schroeder, Juliane Najm, Ute Felbor, Barbara Zieger, Meike Burger, Juergen Heinz, Ulrich Geisen
Acquired Coagulation Disorders
PATIENTS WITH SEVERE AORTIC VALVE STENOSIS AND IMPAIRED PLATELET FUNCTION BENEFIT FROM PRE-OPERATIVE DESMOPRESSIN INFUSION P-MO-530
Barbara Steinlechner, Michael Spannagl, Peter Quehenberger, Petra Zeidler, Bernd Jilma
SUCCESSFUL RITUXIMAB-TREATMENT OF TWO PATIENTS WITH ACQUIRED HEMORRHAPHILIA 13 (HEMORRHAGIC ACQUIRED FACTOR 13 DEFICIENCY DUE TO ITS AUTOANTIBODIES) P-MO-531
Yasuhiro Nagate, Satoru Kosugi, Soichi Nakata, Takeshi Kotake, Toru Kida, Hironori Take, Masayoshi Souri, Shuichi Katagiri, Akitada Ichinose
CORRELATION BETWEEN PLATELET ACTIVATION MARKERS AND HMGB1 IN DIC PATIENTS WITH HEMATOLOGIC MALIGNANCY P-MO-532
Shinya Fujita, Ryotaro Ozasa, Takahisa Nakanishi, Michihiko Miyaji, Shinichiro Mori, Kazuyoshi Ishii, Tomoki Ito, Shosaku Nomura
WARFARIN TREATED PATIENTS HAVE INCREASED MORTALITY FOLLOWING CHRONIC SUBDURAL HEMATOMA P-MO-534
Israel Gavish, Lion Levi, Anatoly Rikier, Daniel Kirshner, Ali Hatib, Menashe Zaaroor, Benjamin Brenner
DELAYED DIAGNOSIS OF ACQUIRED HAEMOPHILIA A IN SUBJECTS WITH BLEEDING SYMPTOMS P-MO-535
Gabriella Gamba, Nadia Montani, Alice Trinchero, Fabio Lodo, Nicola Ghidelli
ACQUIRED HAEMOPHILIA A (AHA) IN THREE PATIENTS ON ANTICOAGULANT THERAPY AND PROFUSE BLEEDING: DIAGNOSTIC AND THERAPEUTIC PROBLEMS P-MO-536
Gabriella Gamba, Nadia Montani, Alice Trinchero, Fabio Lodo, Nicola Ghidelli
A CASE OF ACQUIRED HEMOPHILIA WITH SPURIOUSLY ELEVATED ALP MAY BE ASSOCIATED WITH DRUGS P-MO-537
Yutaka Komiyama, Tomoki Ito, Shosaku Nomura, Yukie Sato, Yoshika Masamichi, Masaki Hiroya, Hakuo Takahashi
THE SURVEY OF SUPPORTIVE THERAPY FOR COAGULATION DISORDER DURING L-ASPARAGINASE(L-ASP) THERAPY IN JAPAN P-MO-538
Chitose Ogawa, Atsushi Manabe, Akira Ohara, Akira Ishiguro
DIVERSITY OF UNDERLYING DISORDERS AND VARIETY OF FIRST VISIT CLINICS FOR PATIENTS WITH ACQUIRED HEMOPHILIA: RESULTS FROM SHIZUOKA REGISTRY P-MO-539
Chiho Otani, Sadahiro Tamashima, Michiaki Koike, Jun Taguchi, Kensuke Naito, Nobuharu Kosugi, Kentarou Misawa, Toshihide Tanaka, Juichi Tanabe, Hiroshi Mouri
RECOMBINANT FACTOR VIIA (RFVIIA) USE FOR SURGERY IN ACQUIRED HEMOPHILIA (AH): ANALYSIS FROM THE HEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY (HTRS) REGISTRY P-MO-540
Alice Ma, Craig M. Kessler, Robert Z. Gut, David L. Cooper
Innovative Therapies for Hemorrhagic Disorders
RFVIIA ADMINISTERED AS CONTINUOUS INFUSION DURING SURGERY IN PATIENTS WITH CONGENITAL SEVERE FVII DEFICIENCY P-MO-541
Hoa Thi Tuyet Tran, Geir Tjonnfjord, Albert Paus, Paal Andre Holme
SUCCESSFUL TREATMENT OF HEMOTHORAX AND INTRACRANIAL HEMORRHAGE IN A TAIWANESE HEMOPHILIAC WITH INHIBITORS BY ACTIVATED RECOMBINANT FACTOR VII AND POSITIVE PRESSURE VENTILATION P-MO-542
Chia-Yau Chang, Ming-Ching Shen, Chung-Che Wu, Chen-Hua Tsai, Jia-Ruey Tsai, Shi-Yi Lin, Ing-Jy Tseng
DEVELOPMENT AND USE OF A SURGICAL DATABASE TO STANDARDIZE CARE, ASSESS EFFICACY AND OUTCOMES IN BLEEDING DISORDER PATIENTS: REPORT OF 1184 PROCEDURES FROM A SINGLE CENTER P-MO-543
Charles Nakar, Craig Haddix, Nina Meschino, Jeanne Sagar, Elaine Menshouse, Ivonne Fuentes, Anne Greist, Amy Shapiro
PARTIAL PROHEMOSTATIC EFFECT OF TRANSFUSION OF FIBRINOGEN CONCENTRATE REPLACING FRESH FROZEN PLASMA IN MASSIVE HEMORRHAGE P-MO-544
Marcus D. Lance, M. Ninivaggi, M.A.E. Marcus, K. Hamulyak, E.C.M. van Pampus, H. ten Cate, J.W.M. Heemskerk
TREATING ANTICOAGULATION RESISTANCE IN THROMBOTIC HYPODYSFIBRINOGENAEMIA P-MO-545
Catherine J. Rea, Julia Mitchell, Beverley J. Hunt
IMPROVEMENT OF SPATIAL FIBRIN FORMATION BY THE ANTI-TFPI APTAMER BAX499: CHANGING CLOT SIZE BY TARGETING EXTRINSIC PATHWAY INITIATION P-MO-546
Leonid A. Parunov, Olga A. Fadeeva, Ann N. Balandina, Natalia P. Soshitova, Konstantin G. Kopylov, Maria A. Kumskova, James C. Gilbert, Robert G. Schaub, Kathleen E. McGinness, Fazoil I. Ataullakhanov, Michael A. Panteleev
LONGATE, A LONG-ACTING LIPOSOMAL FORMULATION OF PLASMA-DERIVED FACTOR VIII - RESULTS OF AN OPEN LABEL PHASE IIIB CLINICAL TRIAL IN ADULT HEMOPHILIA A PATIENTS P-MO-547
Moshe Baru, Jack Spira, Olga Plyushch, Tatiana Andreeva, Vladimir Zorenko, Nadezhda Zozulya, Irena VelichkoI, Rivka Yatuv
HAEMOSTASTIC POTENTIAL OF COAGULATION FACTOR CONCENTRATES VS ALLOGENEIC BLOOD PRODUCTS FOLLOWING CARDIAC SURGERY P-MO-548
Mariann Tang, Per Wierup, Jacob Greisen, Joergen Ingerslev, Benny Soerensen
USE OF PROTHROMBIN COMPLEX CONCENTRATE IN PATIENTS WITH ACUTE OR CHRONIC LIVER DISEASE - A SINGLE CENTRE RETROSPECTIVE AUDIT P-MO-549
Anja B. Drebes, Andrew Burroughs, Alex Gatt, Susan Mallett, Edward G.D. Tuddenham, Pratima Chowdary
AN ANALOGUE OF FACTOR VIIA IMPROVES WOUND HEALING IN HEMOPHILIA B MICE P-MO-550
Maureane Hoffman, Jacqueline Brock, Mirella Ezban, Dougald M. Monroe
NEUTRALIZING ANTIBODIES AGAINST ADENO-ASSOCIATED VIRUS EXAMINED PROSPECTIVELY IN PEDIATRIC PATIENTS WITH HEMOPHILIA P-MO-551
Paul E. Monahan, Chengwen Li, Nattee Narkbunnam, R. Jude Samulski, Genlin Hu, Aravind Asokan, Marilyn J. Manco-Johnson, Joint Outcome Study Investigators
BONE MARROW TRANSPLANTATION CURES HEMOPHILIA A P-MO-552
Antonia Follenzi, Sanj Raut, Simone Merlin, Rita Sarkar, Sanjeev Gupta
THROMBIN ACTIVATION OF PAR-1 ON BOECS RESULTS IN RELEASE OF CYTOKINES THAT LIKELY CONTRIBUTE TO THE IMMUNE RESPONSE IN A CANINE HEMOPHILIA GENE TRANSFER STRATEGY P-MO-553
Christine A. Hough, Colleen Notley, Nathalie LeBlanc, Margareth C. Ozelo, Christine Brown, Carol Hegadorn, Andrea Labelle, David Lillicrap
INTRA-ARTICULAR INJECTION OF AUTOLOGOUS MESENCHYMAL STEM CELLS AMELIORATES HEMOPHILIC ARTHROPATHY IN FACTOR VIII-DEFICIENT MICE P-MO-554
Yuji Kashiwakura, Tsukasa Ohmori, Jun Mimuro, Atsushi Yasumoto, Akira Ishiwata, Asuka Sakata, Seiji Madoiwa, Makoto Inoue, Mamoru Hasegawa, Natsumi Watanabe, Kohei Tatsumi, Kazuo Ohashi, Teruo Okano, Yoichi Sakata
Atherosclerosis
SILENCING THE F11R GENE CONFIRMS THE CRITICAL ROLE OF THE F11 RECEPTOR (F11R/JAM-A) IN PLATELET ADHESION TO INFLAMED ENDOTHELIUM AND IN ATHEROSCLEROSIS P-MO-555
Bani Mekisha Azari, Jonathan D. Marmur, Moro O. Salifu, Yigal H. Ehrlich, Elizabeth Kornecki, Anna Babinska
THE LONG PENTRAXIN 3 (PTX3), A BIOMARKER OF INFLAMMATION, PREDICTS LONG-TERM MORTALITY IN PATIENTS HOSPITALIZED WITH SUSPECTED ACUTE CORONARY SYNDROME P-MO-556
Trygve Brugger-Andersen, Volker Poenitz, Frederic Kontny, Harry Staines, Oistein Mjelva, Heidi Grundt, Dennis WT Nilsen
ACTIVATED PROTEIN C THERAPY PREVENTS AGAINST COMPLEX ATHEROSCLEROSIS PROGRESSION IN MICE WITH GENETICALLY IMPAIRED ANTICOAGULANT RESPONSE P-MO-557
Julian I. Borissoff, Sarah T.B.G. Loubele, Sylvia Heeneman, Peter Leenders, Rene van Oerle, Oliver Soehnlein, Karly Hamulyak, Erik A. Biessen, Hartmut Weiler, Charles T. Esmon, Tilman M. Hackeng, Mat J.A.P. Daemen, Henri M.H. Spronk, Hugo ten Cate
VITAMIN K-ANTAGONISTS INDUCE A VULNERABLE ATHEROSCLEROTIC PLAQUE PHENOTYPE P-MO-558
Leon J. Schurgers, Martijn Chatrou, Jagat Narula, Leonard Hofstra, Cees Vermeer, Chris P. Reutelingsperger
SECRETION OF SALUSIN-β FROM HUMAN MONOCYTE-DERIVED CELLS AND DEVELOPMENT OF AN ENZYME-LINKED IMMUNOSORBENT ASSAY FOR MEASUREMENT OF SALUSIN-β IN HUMAN PLASMA P-MO-559
Kazumi Fujimoto, Kengo Sato, Masayoshi Shichiri, Takatoshi Koyama
THE FACTOR VII-ACTIVATING PROTEASE (FSAP) ENHANCES THE ACTIVITY OF TRANSFORMING GROWTH FACTOR-β (TGF-β) FAMILY MEMBERS P-MO-560
Elfie Roedel, Frank Ploeger, Elisabeth Schwarz, Sandip Kanse
MMP-9 SERUM LEVELS ARE ASSOCIATED WITH CAROTID ATHEROSCLEROSIS PROGRESSION P-MO-562
Walter S. Speidl, Matthias Hoke, Jasmin Amighi, Wolfgang Mlekusch, Alexander Niessner, Gerald Maurer, Renate Koppensteiner, Erich Minar, Johann Wojta, Martin Schillinger
PLASMATIC LEUKOCYTE-DERIVED MICROPARTICLES : NEW BIOMARKER FOR PREDICTION OF PLAQUE UNSTABILITY IN ASYMPTOMATIC PATIENTS WITH HIGH-GRADE CAROTID STENOSIS P-MO-563
Gabrielle Sarlon-Bartoli, Youssef Bennis, Laurent Arnaud, Michel-Alain Bartoli, Julien Mancini, Romaric Lacroix, Audree Boudes, Marie-Dominique Piercecchi, Emmanuelle Sarlon, Benjamin Thevenin, Aurelie Leroyer, Christian Squarcioni, Francois Nicoli, Pierre-Edouard Magnan, Francoise Dignat-George, Florence Sabatier
CD39 IN ATHEROSCLEROTIC LESION CONTRIBUTES TO THE VASCULAR PLEIOTROPIC EFFECTS OF STATIN P-MO-564
Tsunenari Soeda, Hiroyuki Kawata, Ji-Hee Sung, Satoshi Somekawa, Masanori Matsumoto, Yoshihiro Fujimura, Shiro Uemura, Yoshihiko Saito
Endothelial Cells
SIGNIFICANCE OF ENDOTHELIAL CELL-DERIVED MICROPARTICLES IN TYPE 2 DIABETES MELLITUS P-MO-565
Oleksii M. Korzh, Elena A. Pavlova, Sergiy V. Krasnokutskiy
VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)-ENHANCED VASCULAR PERMEABILITY VIA VEGF RECEPTOR-2 SELECTIVELY FORM FENESTRAE ULTRASTRUCTURE IN ENDOTHELIUM P-MO-566
Yukiko Matsunaga, Yasuo Yamazaki, Hidenori Suzuki, Takashi Morita
THE PREDICTIVE VALUE OF THE LONG PENTRAXIN 3 (PTX3) FOR HEART FAILURE DEVELOPMENT IN ACUTE CHEST PAIN PATIENTS P-MO-567
Trygve Brugger-Andersen, Volker Ponitz, Frederic Kontny, Harry Staines, Oistein Mjelva, Heidi Grundt, Dennis Nilsen
THE EFFECT OF RADICAL SCAVENGER TO NO RELEASE IN MICROVESSELS P-MO-568
Tsutomu Yamashita, Kumi Sakamoto, Hiroshi Yamanishi, Junichiro Yamamoto
THE EFFECT OF RADICAL SCAVENGER TO LEUKOCYTE ROLLING IN MICROVESSELS P-MO-569
Kumi Sakamoto, Tsutomu Yamashita, Hiroshi Yamanishi, Junichiro Yamamoto
ALTERATIONS OF MARKERS OF INFLAMMATION AND ENDOTHELIAL CELL DAMAGE AFTER CAROTID ENDOARTERECTOMY P-MO-570
Masako Yamazaki, Yoshikazu Okada, Akitsugu Kawashima, Koji Yamaguchi, Taku Yoneyama, Shinichiro Uchiyama
VON WILLEBRAND FACTOR (VWF) ANTIGEN AND VWF PRO-PEPTIDE AS BIOMARKERS OF ACUTE LUNG INJURY IN H1N1 P-MO-571
Simon J. Davidson, Anne Riddell, Louise Tillyer, Simon J. Finney, Jeremy J. Cordingley, Mark J. Griffiths
THE VITAMIN K-DEPENDENT ANTI-COAGULANT FACTOR, PROTEIN S, REGULATES ANGIOGENESIS IN VITRO AND IN VIVO P-MO-572
Sylvain Fraineau, Michel Philippe, Julie Talbot, Sandip M. Kanse, Arnaud Monvoisin, Omar Benzakour
PROTEIN KINASE C ISOFORMS IN THE DIVERGENT ENDOTHELIAL SIGNALLING EXERTED BY THROMBIN- AND ACTIVATED PROTEIN C-DEPENDENT ACTIVATION OF PAR-1 P-MO-573
Yao Yu, James TB Crawley, Justin C. Mason, David A. Lane
UREMIC TOXINS ENHANCE ENDOTHELIAL TISSUE FACTOR PRODUCTION P-MO-574
Bertrand Gondouin, Claire Cerini, Laetitia Dou, Noemie Jourde Chiche, Raymond Calaf, Ariane Duval Sabatier, Laurent Arnaud, Stephane Poitevin, Stephane Burtey, Francoise Dignat George, Philippe Brunet
CIRCULATING ENDOTHELIAL CELLS AND ITS POTENTIAL AS A MARKER OF THE VASCULAR CONDITION P-MO-575
Manuel Cesar Campos, Claudia Torres, Mafalda Fonseca, Ana Santos, Marlene Santos, Marta Goncalves, Sonia Fonseca, Luis Queiroz, Catarina Lau, Marika Antunes, Anjos Teixeira, Rui Matos, Sara Morais, Margarida Lima
Inflammatory Cells and Cytokines
THE EFFECT OF PLATELET DERIVED MICROPARTICLES ON GENES IN CELLS OF WHOLE BLOOD AND THP-1 CELLS P-MO-576
Bjarne Osterud, Trine Lund, Hege Devold
THROMBOMODULIN TREATMENT OF DENDRITIC CELLS ALTERS GENE EXPRESSION P-MO-577
John Morser, Masaaki Toda, Daniel Boveda Ruiz, Paloma Gil Bernabe, Corina N. D'Alessandro-Gabazza, Yasushi Miyake, Esteban C. Gabazza
RELATIONSHIP BETWEEN ENDOTHELIAL HAEMOSTATIC MARKERS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE P-MO-578
Oleksii M. Korzh, Elizaveta Lavrova, Elena Pavlova
PLASMIN-CLEAVED CHEMERIN, CHEM158K, IS THE DOMINANT CHEMERIN ISOFORM IN INFLAMMATORY CEREBROSPINAL FLUIDS P-MO-579
Lei Zhao, Yasuto Yamaguchi, Shadi Sharif, Xiaoyan Du, Lawrence D. Recht, John M. Morser, Lawrence L.K. Leung
EXOGENOUS GLUCOCORTICOIDS ATTENUATES HYPERCOAGULABLE STATE AND SYSTEMIC INFLAMMATION IN EXPERIMENTAL HEATSTROKE P-MO-580
Chia-Chyuan Liu, Yi-Szu Wen, Wen-Yueh Ho, Kuen-Lin Leu, Tsai-Hsiu Yang
HIGH PLASMA LEVELS OF S-ADENOSYLHOMOCYSTEINE HAVE INCREASED THE RISK OF HEATSTROKE IN A RAT MODEL P-MO-581
Tsai-Hsiu Yang, Chau-Chen Yang, Mei-Lin Tsai, Mei-Ying Wang, Chia-Chyuan Liu
TWO-SITE PHOSPHORYLATION OF A TRNA SYNTHETASE LINKS CDK5-MTOR-S6K TRIO TO CONTROL OF INFLAMMATORY GENE EXPRESSION P-MO-582
Abul Arif, Paul Fox
UROKINASE RECEPTOR (CD87) IS DECREASED AT THE SURFACE OF MONOCYTES OF PATIENTS TREATED BY STATINS AND CORRELATES WITH PLATELET MICROPARTICLES P-MO-583
Marc Vasse, Dany Bigot, Sylviane Leclerc, Bernard Lenormand
EVIDENCE THAT THE THIOL ISOMERASE-BINDING PEPTIDE, MASTOPARAN, INHIBITS SHEAR-INDUCED TGF-β1 ACTIVATION P-MO-584
Teresa Brophy, Jasimuddin Ahamed, Barry S. Coller
Angiogenesis and Lymphangiogenesis
PLATELETS TRANSPORT THE TUMOR SECRETOME DURING CANCER PROGRESSION AND METASTASIS P-MO-586
Bethany A. Kerr, Weiyi Feng, Maria Madajka, N. Patrick McCabe, Tatiana V. Byzova
PROANGIOGENIC ACTIVITY OF RECOMBINANT THROMBOMODULIN PROTEINS P-MO-587
Guey-Yueh Shi, Yu-Ming Cheng, Bi-Ing Chang, Cheng-Hsiang Kuo, Hua-Lin Wu
CONDITIONAL ABLATION OF ALPHA6 INTEGRIN SUBUNIT IN MOUSE ENDOTHELIUM REDUCES ANGIOGENESIS P-MO-588
Claire Bouvard, Adele De Arcangelis, Blandine Dizier, Isabelle Galy-Fauroux, Anne-Marie Fischer, Elisabeth Georges-Labouesse, Dominique Helley
THE ROLE OF THROMBOMODULIN AND LEWIS Y ANTIGEN ON VASCULAR ENDOTHELIAL TUBE FORMATION P-MO-589
Cheng-Hsiang Kuo, Po-Ku Chen, Hua-Lin Wu, Guey-Yueh Shi
THE CARCINOEMBRYONIC ANTIGEN (CEA) INDUCES ANGIOGENESIS VIA INTEGRIN B3- DEPENDENT ACTIVATION OF ENDOTHELIAL CELLS P-MO-590
Gerald W. Prager, Kira H. Bramswig, Marina Poettler, Fritz Wrba, Christoph C. Zielinksi
PRESERVATION OF RENAL MICROVASCULATURE IN VASCULAR ENDOTHELIAL ENDOTHELIN-1 KNOCK OUT (VEETKO) MICE AFTER KIDNEY FIBROSIS P-MO-591
Nur Arfian, Noriaki Emoto, Keiko Yagi, Kazuhiko Nakayama, Vita Y. Anggraeni, Hirowati Ali, Dyah S. Mayasari, Eko Purnomo, Dwi A. Nugrahaningsih, Budi A. Hartopo
EVALUATION THE ANTIANGIOGENIC EFFECT OF A NOVEL ENDOGENOUS ANTIANGIOGENIC FACTOR P-MO-592
Ching-Hu Chung
ANALYSIS OF THE CELLULAR RESPONSE AND THE PROTEASE ACTIVITIES IN THE PROCESS OF RECOVERY FROM SCRATCH WOUNDING USING A PERFUSION CELL CULTURE SYSTEM P-MO-593
Moyuru Hayashi, Motoyuki Shimonaka
INTRAMYOCARDIAL INJECTION OF ANGF-1 IMPROVES CARDIAC FUNCTION AFTER MYOCARDIAL INFARCTION IN PIGS P-MO-594
Kuan-Chieh Wang, Hsieh C.H. Patrick, Shi Guey-Yueh, Lee Fang-Tzu, Chu Ting-Yu, Shih Ya-Yun, Wu Hua-Lin
INHIBITORY EFFECTS OF THAN42 ON ANGIOGENESIS INDUCED BY VASCULAR ENDOTHELIAL GROWTH FACTOR P-MO-595
Chih-Yuan Tan, Tur-Fu Huang
BP5250 INHIBITS THE VASCULAR ENDOTHELIAL GROWTH FACTOR INDUCED ANGIOGENESIS AND HIF-1α EXPRESSION ON ENDOTHELIAL CELLS P-MO-596
Kuan-Ting Lin, Tur-Fu Huang
SIGNIFICANCE OF HRT FAMILY OF TRANSCRIPTION FACTORS IN POSTNATAL ANGIOGENESIS P-MO-597
Hisaki Hayashi, Masahide Sakabe, Tomoko Ioka, Takashi Morioka, Genki Sato, Ken Inada, Osamu Nakagawa
THE ANTHOCYANIN DELPHINIDIN-3-GLUCOSIDE, CONTAINED IN WILD BLUEBERRIES, PROTECTS ENDOTHELIAL CELLS FROM PROANGIOGENIC AND PROTHROMBOTIC STIMULI P-MO-598
Marina Marchetti, Gaia Bonacina, Erika Diani, Alfonso Vignoli, Patrizia Riso, Marisa Porrini, Anna Falanga
TARGETING TUMOR VASCULATURE WITH SIRNA AGAINST BETA 1 INTEGRIN SUBUNIT AND MMP-7 P-MO-599
Jolanta M. Niewiarowska, Tomasz - Wysocki, Magdalena - Wiktorska, Izabela - Sacewicz-Hofman, Olga - Stasikowska, Czeslaw S. Cierniewski
Structural Biology and Drug Design: Innovation and Technology
NEW GENERATION OF ANTITHROMBOTIC COMPOUNDS WITH DUAL - THROMBIN INHIBITORY AND GPIIB/IIIA RECEPTOR ANTAGONISTIC ACTIVITY P-MO-600
Janez Ilas, Danijel Kikelj
TARGETING OF THE TENASE COMPLEX BY RATIONAL DESIGN OF FACTOR VIII-MEMBRANE INTERACTION INHIBITORS P-MO-601
Gerry A.F. Nicolaes, Mahesh Kulharia, Olivier Sperandio, Jan Voorberg, Simone Wielders, Bruno O. Villoutreix
DISCOVERY OF BIOLOGICALLY ACTIVE MOLECULES THAT INHIBIT THE FUNCTIONS OF ANTICOAGULANT ACTIVATED PROTEIN C P-MO-602
Gerry A.F. Nicolaes, Karin C.A.A. Wildhagen, Olivier Sperandio, Roy Schrijver, Bruno O. Villoutreix
THE PERFORMANCES OF MULTI-WAVELENGTH COAGULOMETER ON HEMOLYZED, ICTERIC, AND LIPEMIC SAMPLES. A COMPARATIVE STUDY WITH A MECHANICAL COAGULOMETER P-MO-603
Rahajuningsih Dharma Setiabudy, Agus Kosasih, Lyana Setiawan
PREVENTION OF VENOUS THROMBUS FORMATION IN RABBITS AFTER SINGLE ORAL AND INTRAVENOUS DOSES OF DERMATAN SULPHATE EXTRACTED FROM BOVINE HIDE PROCESSING WASTE P-MO-604
Simone Angelique Osborne, Paul Masci, Sharon Qianyun Du, Robyn Daniel, Wei Chen, Peter Stockwell, Kerri Tyrrell, Gregory Harper, Kirthi Desilva, Robert Seymour
IDENTIFICATION OF FACTOR IX LIGHT CHAIN VARIANTS WITH INCREASED ACTIVITY; V86 SATURATION MUTAGENESIS AND ANALYSIS OF A D85X-V86A-T87X FOCUSED LIBRARY P-MO-605
Chandra Patel, Uwe Gritzan, Xiaqiao Jiang, Ulrich Haupts, Jesper Haaning, John E. Murphy, Alan R. Brooks
CREATION OF TNFR1-SELECTIVE MUTANT TNF WITH ANTAGONISTIC ACTIVITY P-MO-606
Haruhiko Kamada, Yasuhiro Abe, Kazuya Nagano, Yasuo Tsutsumi, Shin-ichi Tsunoda
TISSUE FACTOR TRIGGERED WHOLE BLOOD THROMBOELASTOMETRY AND THROMBIN GENERATION ASSAY IDENTIFY INTER-INDIVIDUAL VARIABILITY OF ANTICOAGULANT RESPONSE TO TREATMENT WITH LMWH P-MO-607
Grigoris Thomas Gerotziafas, Mourad Chaari, Mouna Sassi, Galea Vassiliki, Chrysoula Papageorgiou, Hatmi Mohamed, Elalamy Ismail, Meyer Michel Samama
1-6 ANHYDRO RING OF ENOXAPARIN IS ESSENTIAL FOR THE DOWN-REGULATION OF FACTOR VIIA GENERATION DURING CLOTTING OF HUMAN PLASMA P-MO-608
Grigoris Thomas Gerotziafas, Tahar Chakroun, Andre Uzan, Meyer Michel Samama, Ismail Elalamy
COMPARISON OF METHODS FOR THROMBOEMBOLIC RISK ASSESSMENT WITH CLINICAL PERCEPTIONS AND AWARENESS IN REAL LIFE MEDICAL PATIENTS. COMPASS-MED STUDY P-MO-609
Grigoris Thomas Gerotziafas, Asterios Katsamouis, Athanasios Lioupis, Dimitris Kiskinis, John Tsolakis, Evagelos Tsimogiannis, Anastasios Koukos, Alex Spyropoulos, Vassiliki Galea, Isabelle Debrix, Hela Bacouche, Ismail Elalamy
LOVENOX AND ITS GENERICS EXERT DIFFERENT DEGREE OF INHIBITION OF THROMBIN GENERATION IN PLATELET RICH PLASMA. AN ADDITIONAL CRITERION FOR THE EVALUATION OF LMWH BIOSIMILARITY P-MO-610
Grigoris Thomas Gerotziafas, Mouna Sassi, Vassiliki Galea, Jawed Fareed, Jeanine Walenga, Ismail Elalamy
IN VITRO INHIBITORY EFFECT OF TINZAPARIN AND ENOXAPARIN ON THROMBIN GENERATION TRIGGERED BY OVARIAN ADENOCARCINOMA CELLS IGROV1 P-MO-611
Vassiliki Galea, Mouna Sassi, Grigoris T. Gerotziafas, Elisabeth Mbemba, Mohamed Hatmi, Jean Francois Bernaudin, Ismail Elalamy
LOW MOLECULAR WEIGHT HEPARINS TINZAPARIN AND ENOXAPARIN EQUALLY INHIBITED IN VITRO THROMBIN GENERATION TRIGGERED BY PROSTATE CANCER CELL LINE PC3 P-MO-612
Vassiliki Galea, Grigoris T. Gerotziafas, Mohamed Hatmi, Ismail Elalamy
Late Breaking Clinical Trials
HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)-RETROSPECTIVE ANALYSIS OF DATA ON INCIDENCE AND OUTCOMES (HIT-RADIO STUDY) P-LB-001
David J. Kuter, E. Gerstenberger, Barbara A. Konkle, L. Uhl, S. F. Assmann, T. L. Ortel
EFFECTS OF TANSHINONEIIA ON INFLAMMATORY CYTOKINES AND GMP-140 IN THE PATIENT WITH KAWASAKI DISEASES P-LB-002
Qing Zhang
MULTI-CENTER TRIAL OF DESIRUDIN FOR THE PROPHYLAXIS OF THROMBOSIS: AN ALTERNATIVE TO HEPARIN-BASED ANTICOAGULATION-RESULTS FROM THE DESIRABLE TRIAL P-LB-004
Jerrold H. Levy, Sergio D. Bergese, Amir Jaffer, Harold S. Minkowitz, Michael A. Kurz, David C. Sane
RIVAROXABAN VERSUS ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS: ANALYSIS OF FACTORS CONTRIBUTING TO BENEFIT AND RISK IN MAGELLAN P-LB-006
Alexander Thomas Cohen, Theodore Erich Spiro, Harry Roger Buller, Lloyd Haskell, Dayi Hu, Russell Hull, Alexandre Mebazaa, Geno Merli, Sebastian Schellong, Alex Spyropoulos, Victor Tapson
XAMOS: A NON-INTERVENTIONAL STUDY OF RIVAROXABAN IN THE PROPHYLAXIS OF VENOUS THROMBOEMBOLISM AFTER HIP OR KNEE SURGERY P-LB-007
Alexander G.G. Turpie, Waheed Jamal, Andre Schmidt, Michael Lassen, Lorenzo Mantovani, Reinhold Kreutz, Sylvia Haas
THE ROLE OF HLA-ANTIGENS AS PREDISPOSING AND/OR PROTECTIVE FACTORS IN PATIENTS WITH IDIOPATHIC THROMBOTIC THROMBOCYTOPENIC PURPURA P-LB-008
Marie-Luise John, Inge Scharrer
PROTEIN S ALTERS DIFFERENTIATION, MATURATION AND ANTIGEN PRESENTATION OF MURINE DENDRITIC CELLS IN VITRO P-LB-011
Yuki Matsushima, Masaaki Toda, Yasushi Miyake, Atsushi Yasukawa, Corina N. Gabazza, Takehiro Takagi, Masahiro Naito, Daniel Boveda Ruiz, Paloma Gil Bernabe, Osamu Taguchi, John Morser, Esteban C. Gabazza
MOLECULAR BASIS OF HEREDITARY FACTOR VII DEFICIENCY IN SEVEN UNRELATED TUNISIAN PATIENTS P-LB-012
Hejer Elmahmoudi, Rim Sassi, Asma Jlizi, Kaouther Zahra, Belkis Meddeb, Amel Elgaaied Ben Ammar, Emna Gouider
RE-CANALIZATION OF CHRONIC DEEP VEIN THROMBOSIS WITH COMBINATION OF HERBAL MEDICINES DESCRIBED IN AYURVEDA P-LB-013
Abhay Narayan Kulkarni
Scientific Program
